The antiviral role of cytokines by Lidbury, Brett
The Antiviral Role of Cytokines. 
By 
Brett Andrew Lidbury. 
22/03/1993 . . 
A thesis submitted for the degree of Doctor of Philosophy of the Australian 
National University. 
Statement. 
All the work presented m this thesis was performed by me except fo r the 
following; 
Reactive nitrogen intermediate (RNI) assays were performed by Melissa Awbum; 
IL 1 assays were done by Sarah Osvath; 
The univalent Fab' fragments of Mab 32 were prepared by Louise Furphy. 
The L-arginine inhibitors and two of the cyclooxygenase/lipoxygenase inhibitors were 
made in Dr. Bill Cowden's laboratory. 
The work described has not been submitted previously for a degree at this or any 
other university. 
s..~.:· ..: ...... U.~ 
Brett A. Lid bury . 
. 
I 
Acknowledgments. 
I would like to firstly acknowledge the supportive superv1s1on of Dr. Ian 
Ramshaw. On the topic of supervision I would like to pay tribute to Dr. Bill Cowden 
for his contagious enthusiasm and tremendous encouragement. Members of the Viral 
Engineering and Cytokine Research group, past and present, were all very supportive. 
Some though, deserve a special mention. Jill Medvescky, Sarah Osvath, Annette 
Kazprzak and Dr. Janet Ruby were all of tremendous help by offering great 
encouragement and patience as well as being indispensable in their technical advice and 
expenence. 
My fellow students during this time deserve a mention. Early on Guna 
Karupiah, Anna Skulimowski and John MacMicking offered considerable friendship and 
assistance, while later on Liz Carpenter, Lisa Sedger, David Segal and Kah-Ho Leong 
contributed greatly to the positive feelings in the group. At times particular direct 
student colleagues also made very interesting travelling companions. Students from 
other areas of the university also contributed greatly to my time here, most particularly 
John Dearnaley from RSBS; thanks a lot for your friendship and motivation. Many 
thanks also go to the other members of the Division of Cell Biology for their support. 
Special mention must go to Dr. Kirk Rockett for numerous and very useful discussions 
on free radicals and Melissa Awburn for very conscientious and efficient technical 
input. I would like to also like to thank the boys in animal services (Wing E), namely 
Gerry, Wayne and Stewart for their vital support in providing the animals critical to the 
work. 
To Dr. Debbie Rathjen, Louise Furphy and staff at Peptide Technology (North 
Ryde) thankyou very much for all the invaluable help and advice given either over the 
phone or in person. Also thanks for the friendliness always extended to me on visits 
to your laboratories. 
Last but not least I would like to thank my family for their long distance support 
and encouragement. 
.. 
II 
Abstract 
During the 1980s much progress was made in elucidating antiviral properties and 
mechanisms of particular cytokines. In the forefront of this interest was always the 
classical antiviral protein, interferon, but as well as this another cytokine, Tumour 
Necrosis Factor (TNF) found favour after it was demonstrated that it too was directly 
antiviral and synergised with IFNs. This of course created great anticipation that such 
immunological proteins might be useful in human therapy, both in the context of 
neoplasia and viral infection. A problem that restricted the clinical application of such 
cytokines were their severe and often disease-enhancing side-effects. This situation 
emphasises the need for alternative approaches to the administration of recombinant 
cytokines as pharmacological agents. Such an approach is through the use of specific 
antibodies to enhance positive functions, such as antiviral efficacy, while inhibiting 
side-effects. 
The work of this thesis shows that particular antibodies are capable of enhancing 
the antiviral activity of TNF both in vivo and in vitro. Vaccinia virus is resistant to the 
in vivo actions of TNF if administered alone. TNF is effective against vaccinia virus 
infection when complexed to either Mab 32 or Ab 301. With Herpes simplex virus 
type 1 (HSV-1) TNF alone was effective in attenuating it's in vivo growth and the 
antibodies which enhanced TNF antiviral effect against vaccinia virus generally had no 
effect. The study of host immune factors in TNF + Ab 301 pretreated and vaccinia 
virus infected mice revealed that neither natural killer (NK) cell nor cytotoxic T 
lymphocyte (CTL) activity was enhanced. This evidence plus the observation that the 
TNF/ Ab 301 anti-vaccinia virus effects were present as early as day 1 post-infection 
suggests that an early, non-specific and probably inflammatory mechanism was 
restricting the growth of vaccinia virus. Studies of the direct in vitro antiviral effects 
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of TNF revealed some clues regarding the mechanism of TNF antiviral effects and the 
resistance of vaccinia virus to TNF compared to the sensitivity of HSV-1. It was found 
in studies with the antioxidant, butylated hydroxyanisole (BHA), that free oxygen 
radical activity was important to the resistance of L929 cells to infection with HSY -1, 
but not vaccinia virus. It also appears that pre-exposure to TNF sensitises these cells 
to the cytotoxic effects of the BHA-sensitive factor. 
Of interest also was the role of the immunoregulatory cytokine transforming 
growth factor beta (TGF P) in vaccinia virus growth. It was found that a recombinant 
vaccinia virus encoding the gene for murine TGF p2 did not have its growth attenuated 
compared to a control virus in either thymic CBA/H mice or athymic Swiss nude mice. 
Also immune cell populations, namely NK cells and CTLs did not have their function 
affected in mice infected with VV-TGF p2. This lack of activity could be related to 
the TGF P property of post cell secretion latency which, without further extracellular 
processing, renders this molecule biologically inactive . 
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Chapter 1. 
INTRODUCTION AND LITERATURE REVIEW. 
1.1 The emergence of cytokines. 
The 1960' s was a period of intense investigation of the cellular immune 
response. Through these investigations came the discovery that the supematants of 
lymphocyte cultures, sensitised with a specific antigen, yielded soluble factors which 
had properties such as lymphocyte mitogenesis and macrophage migration inhibition, 
which strongly suggested a role for these factors in cellular immune regulation. 1969 
saw the introduction of the term lymphokine (Dumonde, et al. , 1969). These factors 
were found to affect many different target cell types emphasising their importance on 
the normal physiology of immune mechanisms (Waksman, 1979). With the following 
period of consolidation in cytokine biology came the ability, via advances in molecular 
biology, to better characterise the various cytokines as well as isolate their genes· and 
produce recombinant proteins of high purity. With this greater availability of cytokines 
came more interest in studying the potential application of these immunological factors 
to disease states. The study of the role of cytokines in cancer has always been in the 
forefront. Since the early 1980' s however, there has been increasing interest in the role 
of cytokines in viral infection. The discovery of a virus as the responsible agent in 
acquired immunodeficiency syndrome (AIDS) did much to enhance this interest. 
Particular cytokines with antiviral properties have been identified. Much of the work 
which has established the antiviral potential of some of these proteins, as well as 
showing the possible mechanisms involved with these antiviral properties, has been 
done in vitro. 
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1.2 The Antiviral Cytokines. 
1.2.1 The Interferons. 
The discovery of the fundamental actions of interferons (IFNs) actually pre-dated 
the above described emergence of interest in cytokines that occurred during the 1960' s 
(Isaacs & Lindenmann, 1957). These proteins are released by virally infected cells and 
afford protection to the surrounding non-infected cells via complex mechanisms. 
Interferons were initially classified on the basis of cellular origin. Therefore IFNs were 
designated as either leucocyte interferon, fibroblast interferon or as immune interferon. 
Further to this, leucocyte IFN and fibroblast IFN displayed the same properties of heat 
and acid resistance, whereas IFN y was acid and heat labile. On the basis of these 
physicochemical characteristics leucocyte IFN and fibroblast IFN were further classified 
as type I IFNs and IFN y as type II. The above criteria for IFN classification were 
discussed and subsequently amended at a specially-convened meeting in 1980 (Stewart 
II et al., 1980). It was decided that the old system of classification was misleading 
especially as cell types like leucocytes and fibroblasts were capable of secreting 
heterogenous mixtures of IFNs and "immune" IFN could be induced via means other 
than immune recognition. It was therefore recommended that IFNs should be classified 
on the basis of antigenic specificities, with the classifications of a, P and y 
corresponding to the old classifications of leucocyte, fibroblast and immune IFNs. 
The mechanisms of IFN antiviral action has been well studied. IFN strongly 
induces (via ds RNA) the synthesis of 2' -5' -oligoadenylate (2-5 A) synthetase. This 
enzyme subsequently catalyses the conversion of ATP to oligonucleotides which 
activate RNase L, an endogenous endonuclease which degrades both host and viral 
mRNA and rRNA hence stopping protein synthesis (Kerr & Brown, 1978; Zilberstein 
et al., 1978; Baglioni, 1979). As well as 2-5 A synthetase activity IFN induces the 
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production of 48 and 68 kD subunits of a 110 kD protein kinase (Zilberstein et al., 
1978). In the presence of ds RNA the 48 kD subunit phosphorylates the 68 kD subunit 
which leads to the activation of intrinsic protein kinase activity. In this system there 
is also the phosphorylation of other substrates, for example the alpha subunit of 
eukaryotic protein synthesis initiation factor 2 (eIF2a; [Farrell et al., 1977]). The 
mechanisms and complexities of IFN action on various viruses has been recently 
reviewed by Samuel (1991). 
1.2.2 The Tumour Necrosis Factors (TNF). 
Observations of TNFs actions occurred as early as the late 1800s with a 
physician of the time, William Coley who noticed in cancer patients regression of 
tumours if there was a concurrent bacterial infection. Therefore, Coley and a number 
of other physicians attempted to infect advanced cancer patients with certain bacteria 
under more controlled conditions. Infection of these patients proved difficult and when 
infection did take there was no way to control its severity, although some antitumour 
responses were seen. In 1893 Coley therefore turned to using killed bacterial 
preparations, most particularly a mixture of Streptococcus pyogenes and Serratia 
marcescens and this preparation became known as "Coley' s toxins" (Coley, 1893; 
Coley, 1906). For a time Coley's toxin was in vogue but with the advent of alternative 
cancer therapies and the continuing controversy over the treatment led to the gradual 
diminishing of interest in its use (Old, 1985). 
Although interest in the toxin therapy lost its impetus this did not impede future 
studies of the potential of microbial products as antitumour agents. This area of interest 
led to the discovery that haemorrhagic necrosis of particular mouse tumours was 
observed soon after the injection of filtrates from cultures of Gram-negative bacteria 
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cultures. This activity was subsequently identified by Shear et al. (1943) to be due to 
a polysaccharide, namely lipopolysaccharide (LPS) which is a major constituent of the 
Gram-negative bacterial cell wall. LPS was limited as a therapeutic agent in humans, 
however, because of its toxicity. 
It was not until the 1970s-80s that the host-derived agent responsible for these 
toxin-induced antitumour effects was revealed, based on 2 distinct lines of research. 
The host factor responsible for the necrosis of tumours in ECG-infected and LPS-treated 
mice was called tumour necrosis factor (TNF; Carswell et al., 197 5). Another separate 
line of research, on cachexia in rabbits infected with Trypanosoma brucei brucei, led 
to the identification of the responsible host-derived factor. These infected animals lost 
more than half of their initial body mass due to hypertriglyceridaemia caused by the 
inhibition of the enzyme lipoprotein lipase (LPL; Rouzer & Cerami, 1980). A similar 
suppression of LPL was also observed in animals treated with LPS and this was caused 
by a transferable serum factor (Kawakami & Cerami, 1981). The LPL-inhibiting factor 
was subsequently purified and named cachectin (Beutler et al., 1985a). The comparison 
of the amino-terminal sequence and immunological properties of mouse cachectin with 
TNF a showed that these 2 entities were in fact identical molecules (Beutler et al., 
1985b; Beutler & Cerami, 1989). Since this discovery many other biological activities 
have been ascribed to this protein and it is regarded as one of the more pleiotropic 
cytokines with roles in both immune and inflammatory function as well as disease 
pathology. The term cachectin has largely disappeared and this protein is most 
commonly referred to as TNF. 
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1.3 In vitro studies on the role of cytokines in viral infection. 
Although interferon-induced antiviral activities had been known about for several 
years, the early-mid 1980s was a period of renewed interest in the interferon family of 
cytokines which, as earlier mentioned, could have been a consequence of the greater 
availability of such proteins via recombinant DNA technology. Fleischmann et al. 
(1984) carried out studies which found that both IFN a and IFN p acted synergistically 
with IFN-y in inhibiting Newcastle Disease Virus replication in a murine model. From 
this work the authors also drew conclusions that the phenomena they saw could also be 
applicable to a human system. Around the same time it was found that treatment of 
cells with E. coli derived IFN y and IFN a or IFN p1 resulted in the potentiation of 
both antiproliferative and antiviral (herpes virus) activity (Czarniecki, 1984; Oleszak & 
Stewart, 1985). Interest in the possible antiviral action of non-interferon cytokines such 
as tumour necrosis factor (TNF) also evolved during this time. It was found that hTNF 
a selectively killed herpes virus infected, but not normal cells whereas recombinant IL-
1, IL-2, IFN a and IFN y were not cytotoxic for virus infected cells (Koff & Fann, 
1986). Later, TNF a and IFN y or p were also found to be effective in nervous tissue 
against infection by the neurotropic pseudorabies virus (Schijns et al., 1991 ). 
During investigations on the possible role of TNF as an inducer of IFN, Mestan 
et al. (1986) found that recombinant human TNF was antiviral against VSV, HSY and 
EMCV in vitro. The inhibition of viral proteins was found to be induced in cells 
treated with TNF. The investigation of the possible role of the interferons in this 
antiviral state also was examined. It was found that anti-IFN a and anti-IFN y were not 
capable of blocking the antiviral induction by TNF, whereas anti-IFN P treatment 
resulted in a partial reduction of the TNF mediated effects. These workers also fo und 
that the antiviral IFN induced enzyme, 2' -5 ' oligosynthetase, was not enhanced with 
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TNF treatment, supporting the notion that IFN activity may not be important in the 
observed TNF induced antiviral effects. At the same time as the report by Mestan et 
al. came further support for the in vitro antiviral efficacy of TNF from Wong and 
Goeddel (1986). These authors showed that both TNF a and ~ were antiviral in 7860 
cells against DNA (Adenovirus-2, HSV-2) and RNA (EMCV, VSV) viruses in vitro. 
As well as this the authors found that both types of TNF synergised with IFN y against 
all the viruses examined in A549 cells. Again the possible induction of IFNs were 
considered by the authors as the mechanism by which TNF exerts its antiviral state. 
It was found subsequently that there was no significant IFN involvement, although, it 
was shown that, like IFNs, TNF induced 2' -5' -oligoadenylate synthetase, with both 
cytokines together inducing a stronger response than either cytokine alone in A549 
cells. The observation that with A549 cells TNF or IFN y alone were not antiviral 
demonstrates, however, that the upregulation of 2' -5' A synthetase activity was not a 
significant factor in the induction of an antiviral state in this model. 
The antiviral activity of TNF and IFN y against human immunodeficiency virus 
(HIV) has also been examined by Wong et al. (1988a) in vitro. In this study it was 
found that the pretreatment of HuT 78, normal CD4+ cells and RPMI 1788 cells with 
TNF or IFN y alone had marginal effects on the percentage of cells infected by HIV, 
as measured by the presence of the HIV core protein p24 and HIV RN A production. 
However, in these above-mentioned cell lines TNF in combination with IFN y showed 
a dramatic synergy in the reduction of HIV infection parameters when compared to 
treatment with either cytokine alone. The TNF/IFN y treatment was also found to be 
effective against both acutely and chronically infected HuT 78 cells. In contrast to 
these findings other studies have found that TNF can stimulate HIV-1 transcription in 
human T-cells (Israel et al., 1989; Folks et al., 1989) and TNF has also been found to 
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synergise with interleukin 6 (IL-6) in the induction of HIV-1 expression in infected 
monocytic cells (Poli et al., 1990). It appears that the influence of effector cytokines 
such as TNF depends upon the target cell type, and that while this cytokine is 
responsible for inhibiting HIV, it may also contribute to establishing a reservoir of 
infection in certain tissues. 
1.4 The mechanism of TNFs direct antiviral effects and the possible role of 
IFN p. 
These initial observations stimulated considerable interest into the putative role 
of IFNs in the TNF-induced in vitro antiviral effect. Ito and O' Malley (1987) showed 
recombinant TNF to be antiviral in human diploid fibroblasts infected with HSV-1, 
HSV-2, CMV, varicella-zoster virus, VSV and EMCV. The above observed antiviral 
actions were completely neutralised by anti-IFN p serum, but not by anti-IFN a or IFN 
y antibodies. This finding is in partial agreement with Mestan's findings but contrary 
to the earlier findings of Wong & Goeddel. Mestan et al. ( 1988) went onto further 
investigate this TNF/IFN question and found initially that TNF induces an antiviral state 
in HEp-2 cells with a synergistic effect elicited in the presence of low concentrations 
of IFN p1 or IFN y. These antiviral pathways were found to involve oligo-2 ' ,5' -
adenylate synthetase and were sensitive to an antiserum against IFN p1• From ·this 
observation came the hypothesis that the induction of an antiviral state by TNF was an 
indirect event mediated by IFN p1• Evidence on this question was also forthcoming 
from Hughes et al., ( 1988) who demonstrated that the TNF-induced potentiation of the 
IFN y antiviral state in HEp-2 cells was dependent on IFN p. 
Van Damme et al. (1987) found that IL-1 aJP as well as TNF were capable of 
inducing an antiviral (VSV) effect on diploid fibroblasts and MG-63 osteosarcoma cells, 
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and again antibodies to IFN P1 were found to neutralise this effect. In addition, thi 
treatment induced a 26 kD protein which was shown to be IFN p2• There was no good 
correlation though between the production of this protein and the antiviral effects of 
TNF and there was only weak neutralisation of the IL-1/fNF induced antiviral state by 
an antibody specific to this 26 kD protein. This evidence had these authors convinced 
that the P1 form of IFN was the most likely mediator of TNF/IL-1 induced antiviral 
effects. This was further supported by other studies which found that IFN p antibodies 
were able to abrogate the TNF a,P/IL-1 induced antiviral (VSV) state in WISH cells 
and it was thought by these workers that the IFN involved in the antiviral pathway was 
not p2• It was also found that 2-5A synthetase activity was significantly increased in 
cells which were treated with TNF doses which afforded antiviral protection (Ruggiero 
et al., 1989a; Ruggiero et al., 1989b). Although the evidence at the time seemed to be 
supporting very strongly the role of IFN p as an intermediate molecule in TNF-induced 
antiviral effects other evidence appeared that challenged these findings and supported 
the earlier work of Wong and Goeddel. Gessani et al. (1988) found, in studies which 
utilised specific IFN antibodies as well as RNA analysis, that in HeLa cells IFN p was 
not important to the TNF-mediated in vitro antiviral effect. 
More evidence to support the notion that IFN p1 is a factor in TNF induced 
antiviral effects in vitro came from work by Jacobsen et al. (1989) who also used VSV 
as a model virus. As with previous studies it was shown that TNF could induce an 
antiviral state in various cell lines. The difference of this study, however, was that the 
TNF/IFN phenomena was examined at the RNA level. It was found that after TNF 
treatment there was an increase in IFN p1 specific transcripts which followed a do e 
response, and correlated with the TNF-induced antiviral state. Up to this time the work 
had concentrated on the neutralisation of the expressed IFN proteins by antibodies. 
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Also, molecular studies to this time had tended to focus on the expression of 2' ,5' 
adenylate synthetase transcripts after TNF/IFN treatment and not so much on the direct 
induction of IFN genes. 
Herpes simplex viruses, particularly HSV-1, had been found to be sensitive to 
both interferons and TNF. Elucidation of the in vitro antiviral mechanisms of TNF and 
interferons have therefore used HSV-1 in many of these studies. Klotzbucher et al. 
(1990) found that in primary murine macrophages recombinant murine IFN y 
pretreatment caused a dose dependent decrease in progeny virus and inhibition of HSV-
1 protein synthesis; this was comparable to that found for IFN alp pretreatment. 
Expression of the immediate early IE3 gene product ICP4 in IFN y treated cells was 
found to be similar in control-infected cells, however, there was a delay in the 
accumulation kinetics of these genes with the IFN y treatment. The IFN a/p treatment 
lead to a reduction in IE3 transcripts. Thus, with the reduction of IE3 gene products 
. . 
after IFN y treatment, but no marked difference found in the RN A levels and 
transcriptional activity of the associated genes when compared to control cells, it was 
hypothesised that IFN y could be responsible for a translational inhibition of IE3 gene 
products. IFN a!P treatment resulted in decreases in ICP4-RNA with a delay in the 
accumulation of this transcript, as well as causing the reduction of IE expression at the 
protein level. It was therefore thought that IFN aJP and IFN y may have different 
antiviral mechanisms. This could explain the synergy seen between these interferons. 
Using analysis of HSV-1 protein inhibition in Hep-2 cells Feduchi and Carrasco 
(1991) recently assessed the question of TNF/IFN inhibition of HSV-1 infection in 
vitro. These authors confirmed earlier findings that TNF synergises with IFN y in 
inhibiting HSV-1 replication, as well as further supporting the involvement of IFN P 
in this process. They demonstrated that IFN p1 added exogenously displayed antiviral 
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activity, but only at high doses. IFN p2 (IL-6) did not show any anti-replication affect 
on either VSV or HSV at concentrations of up to 1000 U/ml. From this study the 
authors concluded that their findings confirmed the concept that TNF induces IFN p1 
and went on further to say that in their opinion both TNF and IFN p1 need to be present 
in the culture medium to synergise with IFN y in the inhibition of HSV-1 replication. 
These authors had also earlier shown that the synergistic blockade of HSV-1 replication 
by TNF and IFN y occurs at a stage of infection after virus entry but before, or at the 
time of, the transcription of immediate early genes (Feduchi et al., 1989). 
Clearly there was controversy involved in the putative role of IFN P in the 
induction of a TNF antiviral effect. The weight of evidence does generally support the 
involvement of IFN p as an important factor in TNF-induced antiviral effects, although, 
it should be noted that all the work has been done in vitro and the role of TNF-induced 
IFN P could well be cell specific. During the study of this enigma there has not been 
a great deal of thought, outside the traditional IFN-induced pathways, directed towards 
a definitive direct effector mechanism in cytokine-induced antiviral effects, and this 
question is considered at some length later in this thesis. 
1.5 Examination of the role(s) of cytokines in in vivo virus infections. 
The natural next step once the in vitro potential of particular cytokines to inhibit 
viral replication and/or growth had been established was to translate these findings into 
animal models. In general, attempts to induce antiviral states with exogenous cytokines 
in animals such as mice has only been moderately successful. Klavinskis et al. (1989) 
have shown that LCMV does not respond to TNF in a mouse model, whereas IFN Y 
was effective but there was no synergistic effect seen if TNF and IFN Y were 
administered together. Other examples of the failure of cytokines to be effective 
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antiviral agents in vivo also exist (Leist & Zinkernagel, 1990; Paya et al., 1990). There 
have been some successes, however, in mouse models, particularly with herpes viruses 
and IFN a (Hendricks etal., 1991) as well as HSV-1 and TNF a (Rossol-Voth etal., 
1991). It has also been recently shown that TNF a is effective against 
encephalomyocarditis virus (EMCV) in BALB/c mice (Sriram et al., 1991). The 
administration of mouse interferon to ICR mice 24 hours prior to infection with 
ectromelia was shown to decrease mortality as well as increase survival times (Imanishi 
et al., 1980; Imanishi et al., 1981 ). Shalaby et al. ( 1985) have shown also that IFN y 
is effective in protecting CD-1 mice from lethal infection by EMCV. Rodriguez et al. 
(1991) have demonstrated that the inhibition of a pox virus (in this case vaccinia virus) 
in peritoneal and spleen cells from BALB/c mice by IFN a + ~ is mediated by early 
events post-infection, most likely, in the opinion of these authors, via a translational 
block. A murine retrovirus (Raucher' s murine leukaemia virus) has also been shown 
to be responsive to the antiviral properties of IFN a (Ruprecht, 1989). This inhibition 
of retroviral growth followed a dose dependency and was found to synergise with AZT. 
The interest in this work is in the development of a small animal model to test possible 
therapies for HIV infection. As previously mentioned some in vitro studies have found 
that cytokines, particularly TNF as well as TGF ~ (Lazdins et al., 1991) can enhance 
HIV replication in certain cell types. These findings suggest the need for caution in 
future clinical trials involving cytokines and HIV infected patients. 
1.6 Studies of recombinant vaccinia viruses encoding cytokine genes. 
Original studies were done in which the mouse IL 2 gene was inserted into a 
non-essential region of the vaccinia virus genome under the influence of a vaccinia 
virus early/late promoter. Infection of cells in vitro with this VV-IL 2 showed that IL 
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2 could be expressed in this system. When this recombinant vaccinia virus was used 
to infect immunodeficient Swiss Nude mice it was found that all of the infected mice 
survived this challenge whereas the Nude mice infected with a control virus all died 
approximately 10-12 days after challenge (Ramshaw et al., 1987; Flexner et al., 1987). 
The mechanism of this protective effect has since been elucidated and involves the 
induction of greater NK cell activity by IL 2 and the resultant increase in IFN y 
production (Karupiah et al., 1990a; Karupiah et al., 1990b ). This model therefore is 
another approach to the study of cytokine-induced effects on vaccinia virus, particularly 
in vivo. These findings initiated interest in exploring the effects of other cytokines in 
this recombinant vaccinia virus model and this topic has been recently reviewed by 
Ramshaw et al., (1992). 
1. 7 The use of cytokines as antiviral agents in humans. 
Several studies have been carried out examining the potential of cytokines as 
therapeutic agents in human viral infections. A virus that has received much attention 
in this regard has been hepatitis B virus (HBV). Both IFN a (Daniels et al., 1989) and 
TNF (Sheron et al., 1990) treatments were effective in some patients with chronic HBV, 
although, with TNF therapy there were some toxic side-effects noted. Interferon gamma 
has also been examined clinically in the context of hepatitis B infection (Kakumu et al., 
1991). IFN y therapy did exert a significant inhibitory effect on HB V-associated ON A 
polymerase but it was found not to be as effective as the IFN a therapy. Another 
drawback of the IFN y therapy versus IFN a was that the side-effects induced were 
more evere even though a lower dose of IFN y was utilised. 
A recent study by Agosti et al. (1992) monitored side-effects of patients with 
AIDS related complex (ARC) to TNF and/or IFN y therapy. Patients from all 3 
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treatment groups, ie, TNF alone, IFN alone or TNF plus IFN, experienced a range of 
side-effects ranging from fever, constitutional symptoms (ie, fatigue, headaches and 
night sweats) to local reactions, although specific renal, hepatic or haematologic 
abnormalities were not observed. Further to these observations, measurement of HIV 
related parameters were also done. CD4 lymphocyte counts, p2 microglobulin, p24 
antigen, and anti-p24 antibody levels did not significantly differ during therapy. Also 
no significant change was seen in the concentration of HIV both in plasma and 
peripheral blood mononuclear cells. The pharmacologic effects of cytokines in chronic 
HIV infection has recently been reviewed (Poli & Fauci, 1992). In this review the 
relative advantages and disadvantages of certain cytokines in HIV infection are 
discussed. As mentioned earlier TNF can activate HIV replication in both T cells and 
mononuclear phagocytes. Also in T cells IL 2 provides a signal which while inducing 
cell proliferation also stimulates virus replication. In mononuclear phagocytes inhibition 
or enhancement of HIV depends on the cytokine type, for example colony stimulating 
factors (CSFs), IL 1, IL 3 and IL 6 will enhance HIV proliferation whereas IFN alp 
will suppress HIV replication in monocyte/macrophages and T cells. TGF P will be 
discussed in the context of HIV infection later in this thesis. A challenge for future 
work on the clinical application of cytokines to HIV infection and AIDS will be to 
selectively enhance the antiviral functions of these proteins while nullifying the 
properties which promote viral proliferation. 
The short plasma half-life of cytokines may prove troublesome in human studies, 
since large, potentially toxic doses may need to be administered. The promise held for 
cytokines, particularly interferons, as potential therapeutic agents has not materialised 
due principally to toxic side effects associated with their administration (Fent & 
Zbinden, 1987). Interferons are potently antiviral, however, the side-effects associated 
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with interferon therapy can often exacerbate disease symptoms. Like the interferons, 
TNF can induce a range of undesirable side-effects, for example, fever, chills, fatigue 
and life-threatening complications such as hypotension and hypoglycaemia, if 
administered in large and/or continuous doses (Spriggs et al., 1988; Creagan et al., 
1988a; Creagan et al., 1988b). 
1.8 Transforming Growth Factors beta. 
The name transforming growth factor (TGF) is a term which was applied to 2 
separate molecules, ie TGF a and TGF p, on the basis of the nature of the assay used 
in their discovery and subsequent purification. The first report of TGF bioactivity was 
by De Larco and Todaro ( 1978). These workers reported that mouse 3T3 cells, which 
had been transformed by Moloney sarcoma virus, produced polypeptide growth factors 
which were named sarcoma growth factors (SGFs). This factor was secreted into the 
extracellular medium and induced a transformed phenotype in non-neoplastic "reader" 
cells for example the rat NRK 49F fibroblast. One result of this transformed phenotype 
was that the cells acquired an anchorage independence in vitro which allowed these 
cells to grow in soft agar. With the introduction of acid-ethanol to extract transforming 
peptides from tumour cells themselves (Roberts et al., 1980) the term transforming 
growth factor was introduced as it was realised that peptides with similar properties 
could be isolated from a very diverse range of tumour cells. Furthermore, TGF activity 
could also be isolated from almost all normal mouse tissues (Roberts et al., 1981). 
With the use of high-pressure liquid chromatography (HPLC) and the NRK 49F cell 
line in soft agar assays 2 principal TGFs were isolated. The peptides, which competed 
with epidermal growth factor (EGF) for receptor binding, but did not need extra EGF 
for cell growth promotion, were termed TGF a. Peptides which did not compete with 
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EGF for receptor binding and did require EGF for the promotion of cell growth in soft 
agar were termed TGF P (Anzano et al., 1982; Roberts et al., 1983). In addition to 
these findings it was shown that EGF and TGF a together could not promote cell 
growth in the NRK system as they relied on the concomitant presence of TGF p for this 
activity (Anzano et al., 1982). With this discovery it was then possible to achieve total 
purification and characterisation of TGF p. On the basis of studies on a variety of 
tissue types, this peptide was found to be a homodimer of 25.0 kD which gave 2 
monomeric subunits of 12.5 kD upon reduction, with identical amino-terminal amino 
acid sequences (Roberts & Sporn, 1988). 
It is now known that TGF P exists as 3 distinct molecular forms in mammals, 
namely TGF P 1, TGF p2 and TGF p3. A fourth subtype has been found in birds and 
a fifth in amphibians (TGF P4, TGF P5) and it appears that these molecules may share 
some activities with mammalian forms (Jakowlew et al., 1988; Kondaiah et al., 1990; 
Roberts et al., 1990). The p2 and P3 forms of TGF are initially synthesised as larger 
precursor molecules and processed to yield 12.5 kD monomers in similar fashion to 
TGF PL The processing of TGF Pl is not perfectly understood but is known to involve 
the cleavage of a signal sequence, glycosylation and mannose-6-phosphorylation of the 
precursor, cleavage of the carboxy-terminal 12.5 kD (112 amino acid) monomer from 
a 390 amino acid precursor and disulphide isomerisation. TGF p is secreted from 
cultured cells as a form that will not bind the receptor and is therefore biologically 
inactive (Barnard et al., 1990). Activation of this latent TGF (ie, production of a form 
that will bind to the TGF receptor) can be achieved by several physico-chemical 
treatments including heat, acidification and the use of chaotropic agents such as urea 
(Lawrence et al., 1985). The enzyme plasmin has recently been shown to be capable 
of activating latent TGF and, therefore, is a likely candidate for the physiological 
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activation of TGF (Lyons et al., 1990). 
Active TGF P constitutes 2 identical 112 amino acid (12.5 kD) polypeptide 
chains joined via 9 disulphide bonds (referred to above). The amino acid sequences of 
the active TGF P chains displays high homology between the p 1, 2 and 3 forms and as 
could be expected show very similar characteristics in many assays. The human TGF 
Pl chain is approximately 71 % homologous to that of TGF p2 and 77 % homologous 
to TGF P3. TGF p2 is approximately 80 % homologous to TGF p3. The positions of 
the 9 cysteine residues are precisely conserved. TGF P primary structure is also highly 
conserved between different animal species and as may be expected show high degrees 
of cross-species activity (Derynck etal., 1988; Meager, 1991). 
TGF P has been shown to be a generally immunosuppressive molecule, effecting 
various arms of the immune response. Examples of this include, the antiproliferative 
effects on B and T lymphocytes (Kehrl et al., 199 la), inhibition of CTL development 
(Ranges et al., 1987), the inhibition of immunoglobulin (lg) production in human 
lymphocytes (Kehrl et al., 1991b; Warmold et al., 1992), and inhibition of B cell 
activation and antigen-specific B cell-Th cell physical interactions (Bartlett et al., 1991 ). 
HIV has been studied in terms of TGF p antiviral activity, and the reports on its 
effectiveness have varied. A report has shown TGF p to be effective in the restriction 
of HIV growth (Poli et al., 1991), whilst others have found that TGF P enhances the 
growth of HIV (Lazdins et al., 1991; Lazdins et al., 1992). While TGF P does not 
appear to be a useful cytokine for augmenting immune responses, the investigation of 
TGF P as an immunoregulator is essential, particularly in it's relationships with other 
cytokines and effector molecules. 
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1.9 Aims of this Thesis. 
The work of this dissertation will examine further the antiviral properties of 
cytokines, particularly from an in vivo perspective. An emphasis of much of the work 
will be on the enhancement of the antiviral actions of human TNF a by specific 
antibodies, one monoclonal and the other polyclonal. Such antibodies are of particular 
interest as potential agents to increase the therapeutic index of cytokines used in human 
disease. The enhancing properties of these antibodies allowed a more comprehensive 
study of TNF antiviral activities in vivo, particularly in a vaccinia virus infection model. 
Because of the well documented antiviral synergy with TNF, IFN y was also studied 
in the context of TNF antibody enhancement phenomenon. While much of the data 
concerns vaccinia virus infection it was also believed to be important that other viruses 
be considered in the study of TNF' s enhanced in vivo antiviral efficacy. Therefore, 
work was also done using essentially similar models on herpes simplex virus l (HSV-
1). HSV-1 also became an important tool in in vitro investigations on the direct 
antiviral effects of TNF plus antibodies. 
This thesis also addresses the potential activities of transforming growth factor 
beta (TGF P) in vaccinia virus infection. The approach used for this investigation was 
to construct a recombinant vaccinia virus containing the TGF p gene. This strategy 
resulted in a virus capable of producing its own TGF p, thereby, allowing investigations 
on the direct regulation of virus activity by this protein. 
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Chapter 2. 
General Materials and Methods. 
Mice. 
Female CBA/H, BALB/c, C57 /B6 and outbred pathogen-free Swiss Nude mice 
between the ages of 6-8 weeks were obtained from the animal breeding establishment 
of the John Curtin School of Medical Research. 
Viruses. 
i) Vaccinia virus. 
The vaccinia virus used in the experiments with recombinant TNF and/or mIFN-
y (unless otherwise stated) contained both the HSV thymidine kinase gene (TK+) and 
the influenza haemagglutinin gene (VV-HA-TK). This virus was constructed from a 
previously described recombinant, VV-PR8-HA6 (Andrew et al., 1986). The HA gene 
was from influenza A/PR/8/34 virus and the L929 cell-adapted WR vaccinia strain (VV-
WR-L929: Wokatsch, 1972) was used as the parent virus for the construction of the 
recombinants. The arrangement of the recombinant HA gene in the vaccinia virus 
genome is described by Ramshaw et al., (1987). 
The construction of the thymidine kinase negative (TK-) recombinant vaccinia 
virus encoding TGF p2 is detailed in chapter 8. 
Virus stocks were propagated in CV-1 cells infected with a MOI* equal to 0.01 
of the relevant vaccinia virus. This procedure was carried out in 2.0 litre acid-washed 
Schott roller bottles. The titrated, aliquoted stocks were stored in sterile vials at -70°C 
until required. The stock virus was diluted in 2.0 mls of gelatin (0.5 % ) saline to the 
desired concentration and sonicated at 50 watts for 5 x 2 second bursts using a Branson 
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Sonifier (Branson Sonic Power Company, Danbury, CT., USA). 
* MOI (multiplicity of infection) is the number of virus plaque forming units per cell. 
ii) Herpes Simplex Virus type 1. 
Herpes simplex virus type l strain SC16 (HSV-1, SC16: Field et al., 1979) was 
provided by Dr. A. Simmons of the Institute of Medical and Veterinary Science, 
Adelaide, South Australia. Stocks of the virus were propagated in Vero (green monkey 
kidney) cells infected at a MOI of 0.1 for 48 hours. After this period the infected Vero 
cells were washed/scraped into the culture media and then sonicated (as described 
above). The titrated stocks were then aliquoted and stored at -70°C until required. 
Cell lines. 
. . 
All cell lines were maintained at 37°C in a humidified atmosphere containing 5 
% CO2• Cells at a concentration of 1.0-2.0 x l 06 cells were seeded into 80 cm3 or 175 
cm3 flasks (Nunclon) for routine passage. 143 B cells (Rhim et al., 1975) were 
maintained in DMEM (Gibco, NY, USA) supplemented with 5 % heat inactivated (56°C 
for 30 minutes) FCS (Cytosystems, Sydney), 145 mg/litre glutamine, and antibiotics 
(penicillin, streptomycin and neomycin). The green monkey kidney derived cell lines 
Vero (ATCC, CCL 81) and CV-1 (Jensen et al.,1964) were maintained in RPMI 
(Cytosystems, Sydney) supplemented with 5 % heat inactivated FCS, 5.0 mls 5 % 
sodium bicarbonate and antibiotics. L929 cells (H-2k), a mouse fibrosarcoma derived 
from C3H mice (Sanford et al., 1948) and the mink lung fibroblast cell line, Mv-1-Lu 
(ATCC, CCL 64) were also maintained under these media conditions. The human 
cervical carcinoma cell line, HeLa (Gey et al., 1952) was maintained in EMEM 
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(Cytosystems, Sydney) supplemented with 5 % heat-inactivated FCS and antibiotic . 
All of the above cell lines, with the exception of 143 B cells, when confluent 
(3-4 days) were treated with 0.1 % trypsin plus EDT A/versene to remove the cells from 
the surface of the flask. 143 B cells were treated with 0.05 % trypsin plus 
EDT Nversene. All of the cell lines, once the trypsin/versene had been added, were 
subjected to a short period at 37°C (5-10 minutes) aftefwhich the cells were resuspended 
in medium plus FCS, washed once and re-seeded as described above. 
The non-adherent cell line Y AC-1 (H-2a) which originated from a Moloney 
leukaemia virus-induced lymphoma in A/Sn mice (Kiessling et al., 1975) was 
maintained in DMEM plus 10 % heat inactivated FCS, supplemented with 5mM sodium 
pyruvate (Gibco, NY), 145 mg/litre glutamine, 5mls 5 % sodium bicarbonate, antibiotics 
(PSN) and 0.05% 2-mercaptoethanol. The cells were passaged every 3-4 days through 
the wells of a 24 well Linbro flat-bottomed plate (Flow Laboratories, McLean, VA). 
These cells were kept at 37°C in a humidified atmosphere containing 5 % CO2• 
Antibodies. 
The production of the specific human TNF monoclonal antibodies has been 
described previously (Rathjen et al. 1991 ). Monoclonal antibody 32 (Mab 32) is of the 
IgG2bK isotype and has been found not to inhibit TNF cytotoxicity on WEHI-164 cells 
in vitro (Rathjen et al., 1991; Rathjen et al., 1992). 
The mapping of overlapping hTNF peptides with Mab 32 has recently shown 
that the regions 1-10, 40-42, 44-46, 107-114 and 127-130 are the areas in exposed loop 
structures of the TNF molecule to which Mab 32 binds (Rathjen & Aston, in press). 
The polyclonal antibody (Ab 301; Peptide Technology, Sydney) was raised in 
sheep challenged with a peptide sequence, in Freund's adjuvant, from human TNF to 
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* which Mab 32 binds. Pre-immune sera were collected from sheep challenged with 
Freund' s adjuvant alone. 
The preparation of univalent Fab' fragments from Mab 32. 
Mab 32 was first digested with agarose immobilised papain (Pierce) according 
to the manufacturer's instructions. The Fab' region was separated from the Fe antibody 
fragments by a protein A-Sepharose affinity column (Pharmacia). The Fab' fraction was 
then checked for size by SDS-PAGE analysis and the binding properties confirmed via 
radioimmunoassay with 125I-TNF. The preparations of Fab' fragments were found to 
be essentially endotoxin free as determined by a Sigma (St.Louis, USA) kit method. 
Cytokines. 
Recombinant human tumour necrosis factor alpha (hTNF) was supplied by 
Bissendorf (Germany). The TNF was yeast derived with a specific activity of 3.2 x 107 
units/ mg as determined by a L929 ( + mitomycin C) cytotoxicity assay. Purity of this 
cytokine was greater than 97 %. 
E. coli-derived murine gamma interferon (mIFN y) was provided by Dr. G. 
Adolf, Boehringer Ingleheim, Vienna. The specific activity of this cytokine was 
1.0 x 107 units /mg as determined by antiviral activity induced in mouse L-cells to 
encephalomyocarditis virus (ECMV). 
* For specificity, see Rathjen & Aston (1993); Bioinorganic and Medicinal Che111istry Letters. 
3:457-462. 
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Chapter 3. 
The Enhancement of the in vivo Antiviral Efficacy of human Tumour Necrosis 
Factor alpha (hTNF a) by Antibodies in Vaccinia Virus Infection. 
INTRODUCTION. 
There has been much interest recently on the potential antiviral properties of 
cytokines. This interest increased with reports that TNF a!P and IFN y were directly 
antiviral in vitro in a number of cell lines and for a variety of RNA and DNA viruses. 
It was also found in this system that TNF and IFN together were synergistic in their 
direct antiviral effects (Wong & Goeddel, 1986; Mestan et al. , 1986). These 
observations resulted in a more intense pursuit for the application of TNF/IFN mediated 
antiviral effects in vivo. There has been some success in mouse models with the 
administration of TNF to mice infected with HSV-1 (Rossol-Voth et al. , 1991 ) and 
encephalomyocarditis virus (EMCV; Sriram et al. ,1991). TNF however has not been 
uniformly effective as an antiviral agent in vivo. Work by Paya et al. ( 1990) has 
demonstrated, that although TNF administration did inhibit Theiler' s virus-induced 
demyelination there was no inhibition of virus replication in the central nervous system 
by TNF. Another study using a specific antibody to block endogenous murine TNF 
activity found that this approach had no effect on lymphocytic choriomeningitis virus 
(LCMV) viral titres in the liver or LCMV-induced disease progression (Leist & 
Zinkernagel, 1990). Further to this a study by Klavinskis et al. , (1989) showed that 
while IFN y induced an antiviral effect on LCMV in mice , TNF did not and there was 
no antiviral synergy when the 2 cytokines were co-administered. IFN has been shown 
to be an effective antiviral agent in previous studies. The treatment of ICR mice with 
mouse interferon (L cell or brain) 24 hours before challenge with ectromelia virus 
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resulted in both decreased mortality rates and increased survival times (lmanishi et al., 
1980; Imanishi et al., 1981). 
Recent studies with cytokines such as IFN a and TNF a in humans infected 
with Hepatitis B virus have shown some encouraging results for the possible application 
of cytokines as clinical antiviral therapies, although cytokine-induced side effects were 
also observed (Daniels et al., 1989; Sheron et al., 1990). The initiation of secondary 
pathologies by cytokines is well documented (Fent & Zbinden, 1987: Spriggs et al., 
1988; Creagan et al., 1988) and is the major drawback to using cytokines such as TNF 
therapeutically. One possible strategy to overcoming this problem is to use specific 
antibodies to epitopes of cytokines and thereby modify some of their activities. Rathjen 
et al., (1991; 1992) have recently described a monoclonal antibody against hTNF which 
selectively enhances anti-tumour effects but blocks the pro-coagulant activity of TNF 
in cultured endothelial cells. 
This chapter examines the enhancement of the antiviral efficacy of hTNF in 
mice challenged with vaccinia virus by both the above mentioned monoclonal antibody 
and a polyclonal antibody specific to the same region of TNF recognised by the 
monoclonal antibody. 
MATERIALS and METHODS. 
Treatment of mice with human TNF alone or in complex with monoclonal antibody 
32 (Mab 32) or Fab fragments foil owed by infection with vaccinia virus. 
CBNH mice were injected intraperitoneally (i.p.) with either PBS or doses of 
hTNF (Bissendorf, Germany) between 2-20 µg. For experiments with monoclonal 
antibody 32 (Mab 32, 5.0 mg/ml: Peptide Technology, Sydney) 2 µg hTNF was 
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complexed with 0.3 mg, 0.5 mg, 1.0 mg or 2.0 mg of Mab 32. The TNF and Mabs 
were mixed and left to stand for 1 hour at room temperature before administration. The 
control Mabs (25 and 47) were only used at a concentration of 0.5 mg with 2 µg hTNF. 
Fab fragments were used at concentrations of 0.25 mg or 0.50 mg in complex 
with 2 µg hTNF. As with the Mab plus hTNF treatments the Fabs were also left for 
1 hour at room temperature before intraperitoneal administration. 
Twenty-four hours after these treatments, the mice were injected i.p. or i.v. with 
107 or 106 plaque forming units (pfu) of a vaccinia virus WR strain. 
Treatment of mice with human TNF plus Ab 301 and / or murine gamma 
interferon (mlFN-y) followed by vaccinia virus infection. 
The protocol for this experiment was similar to that described above except for 
the following differences. The antibody (Ab 301, 5.0 mg/ml; Peptide Technology, 
Sydney) complexed to TNF was a polyclonal (described in chapter 2). This antibody 
was diluted 1:50 before mixing with 6 µg TNF. Treatments were administered by i.p. 
injection as follows: 1) hTNF plus Ab 301; 2) 105 U mIFN-y and 3) combined 
treatments with TNF and Ab 301 plus mIFN-y. In the latter treatment the mIFN-y was 
not mixed with the TNF:Ab 301 complex until after the 1 hour room temperature 
incubation of TNF with the antibody. Mice were injected 24 hours later with 106 pfu 
vaccinia intravenously (i.v.). This protocol was also followed for the experiments using 
BALB/c and C57 /B6 mice. 
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Measurement of vaccinia virus growth. 
Mice were sacrificed 4 days post-infection (unless otherwise indicated) and the 
ovaries, spleens and/or lungs aseptically removed. As vaccinia grew to high titres in 
the ovaries these organs were chosen to monitor virus growth in the Mab 32 studies. 
The organs were homogenised in 1.0 ml of phosphate-buffered saline (PBS) afterwhich 
l 00 µl of homogenate was incubated at 37°C for 30 minutes in 0.1 % trypsin. 
Trypsinisation was stopped by the addition of heat-inactivated foetal calf serum (FCS ; 
Cytosystems, Sydney). Samples were then serially diluted 10 fold in a HEPES buffered 
saline solution containing 0.5% gelatin and the dilutions absorbed for 60 minutes at 
37°C in a humidified atmosphere containing 5.0% CO2 onto a confluent monolayer of 
143B human osteosarcoma cells in Linbro 6 well plates (Flow Laboratories, McLean, 
VA). The cells had been seeded into the L-6 plates the previous day in Autopow media 
(Flow Laboratories, North Ryde) supplemented with 5 % heat inactivated FCS , 145 
mg/litre L-glutamine, 20 mls 5 % sodium bicarbonate, 1.5 mls 1.0 M hydrochloric acid 
(HCl) and PSN (Penicillin, streptomycin, neomycin). After the l hour virus absorption 
period the cells were overlaid with Autopow containing 5.0% heat-inactivated FCS. 
Forty-eight hours later the Autopow was removed and the cells stained with 0.1 % (w/v) 
crystal violet in 20% (v/v) ethanol. The plates were air dried and the plaques counted. 
The log10 virus concentration was then calculated and statistical significance determined 
by unpaired Student's t-test. 
It should be noted that the virus plaque assay technique is limited to the 
measurement of titres greater than two logs. Therefore individual titrations less than 
two logs were counted as 1.8 logs of virus. 
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Radioimmunoassay for hTNF binding to Mab 32. 
Human TNF was iodinated (1 25I; Amersham, 1 OOmCi/ml) via the lactoperoxidase 
method (Aston et al., 1985). 125I-TNF was diluted and adjusted to 20 000 CPM per 50 
µl. Mab 32 was initially diluted 1/50 and then serially diluted by a factor of log 5 
( 1/50-1/ 156 250). Fifty microlitres of each dilution was dispensed into duplicate tubes, 
with 50 µl of PBS being added to the non-specific binding (NSB) tubes. To each of 
these tubes, as well as the total count tubes, 50 µl of the diluted 1251-TNF was added. 
These tubes were incubated overnight at 4°C. The next day 100 µl of second antibody 
coated cellulose (SAC) cells (Pharmacia) were added to all tubes except the total count 
tubes. The tubes were then incubated for 20 minutes at room temperature, subsequently 
washed once with 1.0 ml of PBS, centrifuged (Beckman, TJ-6) at 2500 rpm for 5 
minutes and the radioactivity of the SAC cell pellet counted in a Packard Auto-Gamma 
counter. The NSB was subtracted from each value and the mean CPM calculated for 
each dilution. The binding curve for each Mab 32 concentration tested is shown in 
Figure 3.1. 
* The expe1iments perfonned in this chapter were all done at least twice unless othe1wise 
indicated. Please note that (n =) refers to the number of animals or samples in an expe1i 1nental 
or control group. 
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RESULTS. 
Treatment of CBA/H mice with hTNF alone. 
Table 3.1 shows the vaccinia virus titres in the ovaries, lungs and spleens of 
CBNH mice that had been treated with 10 or 20 µg of TNF alone at the same time as 
infection. The doses of TNF used did not have an effect on the growth of the virus, 
with the exception of a small but statistically significant increase in the vaccinia titres 
found in the spleen. 
TABLE 3.1 Mean concentration of vaccinia virus in the organs of CBA/H mice treated 
with hTNF O hours before infection (107 pfu/mouse, i.p.). 
Log10 Virus Titre (pfu/ml) ± SEM 
Organ PBS 10 µg hTNF 20 µg hTNF 
(n=7) (n=3) (n=4) 
Spleen 2.79 + 0.06 3.41 + 0.06+ 3.29 + 0.07+ 
Lungs 3.04 + 0.04* 3.05 + 0.03 2.75 + 0.15 
Ovaries 8.89 + 0.02 8.94 + 0.02 8.75 + 0.06 
* (n=2) 
+ p < 0.001 versus titre of the PBS treatment in the spleen. 
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Complexing hTNF to a monoclonal antibody (Mab 32) enhances the antiviral 
efficacy of this cytokine. 
Figure 3.2 shows the titre of vaccinia virus in the ovaries collected from CBA/H 
mice 4 days after infection with 106 plaque forming units (pfu) of vaccinia. Twenty-
four hours prior to infection the mice were treated with 2 µg of TNF either alone or 
combined with various doses of monoclonal antibody 32 (Mab 32). The binding of 
125I-TNF to the doses of Mab 32 used in this experiment are shown in Figure 3.1. The 
results outlined in Fig. 3.2 show that the TNF treatment alone did not significantly 
decrease the titre of vaccinia virus in the ovaries when compared to the control PBS 
treatment. With increasing Mab 32 concentration, however, there was a dose dependent 
decrease of viral titre in the ovaries, with 2 µg of TNF in complex with 0.5 mg Mab 
32 displaying the greatest enhancement of antiviral activity when compared to TNF 
treatment alone. With further increases in the Mab 32 concentration enhancement of 
the antiviral effect was less pronounced. Ovaries from mice treated with Mab 32 alone 
contained an almost identical concentration of vaccinia as ovaries from PBS pre-treated 
mice. Two other hTNF monoclonal antibodies (Mabs 25 and 47) did not show an 
enhancement of. antiviral activity when complexed to 2 µg TNF at the same 
concentration as optimal for Mab 32 (table 3.2). 
Enhancement of TNF antiviral activity by Mab 32, as measured by virus titration 
in the ovaries, was also seen if the mice had been infected with 107 pfu of vaccinia 
(data not shown). 
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TABLE 3.2 Mean growth of vaccinia virus in the ovaries of CBA/H mice treated 24 
hours before infection (106 pfu/mouse, i.v.) with hTNF plus Mabs 25 or 47. 
Treatment Log10 virus titre (pfu/mJ) 
±SEM 
PBS (n=4) 8.03 + 0.04 
2 µg TNF + 0.5 mg Mab 25 7.48 + 0.22 
(n=5) 
2 µg TNF + 0.5 mg Mab 47 8.10 + 0.11 
(n=5) 
For both Mab treatments plus TNF there was no significant decrease in virus titre 
(p > 0.05) versus PBS. Mabs 25 and 47 were derived fro1n the same panel of 
monoclonal antibodies as Mab 32 (see page 20). 
With the finqing of optimal enhancement of TNF it was then investigated to see 
whether increasing or decreasing the dose of TNF in the ratio of 2 µg TNF : 0.5 mg 
Mab 32 would further enhance the antiviral effects shown in Figure 3.2. As outlined 
in Figure 3.3 a dose of 1.0 µg TNF with the relevant amount of Mab 32 showed no 
decrease compared to PBS treatment. Notable decreases in virus titre were evident with 
the 2, 4 and 6 µg plus Mab 32 treatments but as TNF dose increased the effects were 
less pronounced in much the same way as seen with increasing Mab 32 doses in the 
presence of 2 µg TNF (Fig. 3.2). It appears that this enhancing effect is confined to a 
narrow TNF and Mab 32 dose window. 
The complex of TNF and univalent Fab' fragments of Mab 32 were also tested 
to investigate the possible role of Fe region effects and bivalency (Table 3.3). At a 
concentration of 0.25 mg Fab'32 (plus TNF) there was no significant decrease in 
ovarian viral titre when compared to the PBS treatment. Treatment with 0.5 mg Fab'32 
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plus TNF did cause a decrease in virus concentration but this was not as pronounced 
as that found with the complex of TNF with intact Mab 32. 
TABLE 3.3 The mean growth of vaccinia virus in the ovaries of CBNH mice treated 
with hTNF in complex with univalent Fab fragments, derived from Mab 32, twenty-four 
hours before infection with 106 pfu vaccinia virus/mouse, i. v. 
Treatment Log10 virus titre (pfu/ml) 
+SEM 
PBS (n = 4) 7~31 + 0.24 
2 µg hTNF + 0.5 mg Mab 32 6.29 + 0.24 * 
(n = 5) 
2 µg hTNF + 0.25 mg Fab'32 7.03 + 0.20 
(n = 5) 
2 µg hTNF + 0.5 mg Fab'32 6.52 + 0.27 + 
(n = 5) 
* Significantly lower titre (p = 0.022) compared to the PBS treatment. 
+ Virus inhibition at a significance level of p = 0.068 versus PBS treatment. 
Complexing TNF to a specific polyclonal antibody (Ab 301) enhances the antiviral 
efficacy of TNF. 
Table 3.4a) shows vaccinia virus titres in the ovaries of CBNH mice treated 
following the same protocol as with Mab 32 above, except that in this case the antibody 
to which TNF was complexed was a polyclonal antibody (Ab 301). This sheep 
antibody was raised against a TNF peptide to which Mab 32 binds. Mice treated with 
TNF in complex with Ab 301 showed a greatly reduced titre of vaccinia virus in the 
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ovaries, confinning the earlier results with the monoclonal antibody and showing, via 
a different approach, the presence of an "enhancing" epitope on TNF. This effect was 
optimal at a dose of 6 µg TNF. As with Mab 32 increasing TNF concentration in the 
presence of Ab 301 resulted in less pronounced antiviral effects (data not shown). The 
control treatment consisting of 6 µg hTNF mixed with a 1/50 dilution of pre-immune 
sera (table 3.4b) did not show a significant decrease in comparison to the 6 µg hTNF 
alone treatment. The difference between the PBS treatment and the TNF alone 
treatment was also not significant. Pre treating mice with l 05 U mIFN y, however, 
resulted in a significant decrease in virus titre (table 3.4a). 
TABLE 3.4a) Mean growth of vaccinia virus in the ovaries of CBA/H mice treated 
24 hours before infection (106 pfu/mouse, i.v) with TNF plus antibody 301 alone or 
murine gamma interferon alone. 
Treatment Log10 virus titre (pfu/ml) 
±SEM 
PBS (n=5) 8.20 + 0.29 
6 µg TNF + 1/50 Ab 301 5.93 + 0.33 * 
(n=4) 
105 U mIFN-y (n=5) 5.66 + 0.35 * 
* p < 0.001 versus PBS treatment. 
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TABLE 3.4b) Mean growth of vaccinia virus in the ovaries of CBA/H mice treated 
24 hours before infection (106 pfu/mouse, i.v) with TNF alone or TNF with pre-immune 
serum. 
Treatment Log10 virus titre (pfu/ml) 
+ SEM 
PBS (n = 5) 8.17 + 0.15 
6 µg TNF alone (n = 4) 7.66 + 0.29 
6 µg TNF + 1/50 7.41 + 0.24 
Pre-immune sera (n = 5) 
*The above desc1ibed data were the results of a single control experiment. 
The enhancement of TNF antiviral activity by Ab 301 is not restricted to 
administration 24 hours before infection. 
The enhancement of the antiviral effects of TNF by Ab 30 l was shown to also 
be effective if administered at timepoints other than 24 hours prior to infection. Figure 
3.4 demonstrates that a significant antiviral effect is produced even when the TNF plus 
Ab 301 is administered 72 hours before infection. Administration of TNF plus Ab 30 l 
at the 48, 24 and O hour timepoints also resulted in significant reductions of vaccinia 
virus growth compared to the non-TNF treated controls. There were no significant 
differences between the TNF plus Ab 301 treatments. 
Note that at O hours before vaccinia infection doses of l O and 20 µg TNF alone 
(table 3.1) were not effective in decreasing vaccinia virus titres in the ovaries whereas 
6 µg plus Ab 30 l was effective in significantly reducing vaccinia titres at this time of 
administration. 
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Human TNF in complex with Ab 301 administered with murine gamma interferon 
(mlFN-y) leads to a synergistic antiviral effect in vivo. 
The antiviral effects of combined therapy with TNF and Ab 301 plus murine 
gamma interferon (mIFN y) in CBNH mice are illustrated in Table 3.5. TNF plus Ab 
301 was potently antiviral, as was the murine IFN y treatment. The combination of 
TNF plus Ab 301 with mIFN y, however, displayed an even greater antiviral efficacy 
when compared to either the TNF plus Ab 301 or mIFN y treatments alone. This 
enhanced antiviral effect was in contrast to that observed when TNF alone was 
combined with mIFN-y (Figure 3.5). There were also differences seen when TNF plus 
Ab 301 was administered 4 hours before mIFN-y and vice versa. There was no 
significant difference noted between the TNF plus Ab 301/mIFN-y same time treatment 
and the treatment of IFN administered 4 hours prior to TNF plus Ab 301. The therapy 
of TNF plus Ab 301 administered 4 hours before IFN resulted in a significantly higher 
titre of vaccinia virus in comparison to the IFN before TNF plus Ab 301 treatment. 
The TNF plus Ab 301 before IFN treatment was not significantly different to the TNF 
plus Ab 301 with IFN (same time) treatment. 
33 
TABLE 3.5 Mean growth of vaccinia virus in the ovaries of CBA/H mice treated 24 
hours before infection (106 pfu/mouse, i.v) with TNF plus Antibody 301 and gamma 
interferon together. 
Treatment Log10 virus titre (pfu/ml) 
± SEM 
PBS (n=5) 8.20 + 0.29 
6 µg TNF + 1/50 Ab 301 and <3.14 + 0.84 + 
105 U mIFN-y 
(same time: n=5) 
6 µg TNF + 1/50 Ab 301 4 4.90 + 0.37 * 
hours before 105 U mIFN-y 
(n=5) 
105 U mIFN-y 4 hours before <2.88 + 0.68 + 
6 µg TNF + 1/50 Ab 301 (n=5) 
TNF plus Ab 301 with mIFN-y administered at the same time gave a significantly lower 
titre than both the TNF plus Ab 301 alone (p = 0.027) and mIFN-y alone (p = 0.024) 
therapies (SEE TABLE 3.4a). 
* p = 0.031 versus the treatment of IFN administered 4 hours before TNF plus Ab 301. 
+ Three from five mice in these groups had no detectable virus growth, ie , < 2.0 logs. 
Table 3.6 shows a similar study done in BALB/c mice. In this mouse strain 
there was a distinct lack of antiviral activity found with either of the cytokine 
treatments which were effective in CBA/H mice, namely 6 µg TNF in complex with Ab 
301 alone and mIFN-y alone. The combination of 6 µg TNF plus Ab 301 with mIFN-y 
did, however, result in a significant reduction of vaccinia virus in the ovaries when 
compared to the TNF plus Ab 301 treatment or the mIFN-y treatment. 
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In PBS treated C57 /B6 mice (Table 3.7), vaccinia virus grew to only 6.5 log , 
whereas in similarly treated CBA/H and BALB/c mice more than 8.0 logs of virus were 
present in the ovaries at 4 days post infection. In C57 /B6 mice, treatment with TNF 
alone had no effect against vaccinia but when in complex with Ab 301, a small, but 
significant enhancement of the antiviral effect was seen. Murine IFN-y was 
considerably more effective in reducing virus titres than the combined therapy of TNF 
plus Ab 301. The antiviral effect of the combination of TNF plus Ab 301 with mIFN-y 
was not significantly different to mIFN-y alone nor was there a statistical difference 
found when this treatment was compared to the TNF plus Ab 301 therapy. 
TABLE 3.6 Mean growth of vaccinia virus in the ovaries of BALB/c mice treated with 
cytokines 24 hours before infection (106 pfu/mouse, i.v). 
Treatment Log 10 virus titre (pfu/ml) 
+SEM 
PBS (n=5) 8.17 + 0.28 
6 µg TNF (n=4) 8.02 + 0.28 
6 µg TNF + 1/50 Ab 301 8.05 + 0.36 
(n=5) 
105 U mIFN-y (n=4) 8.16 + 0.47 
6 µg TNF + 1/50 Ab 301 and 6.75 + 0.09 * 
105 U mIFN-y (n=3) 
* Significantly lower titre than both the TNF plus Ab 301 alone (p = 0.035) and 
mIFN-y alone (p = 0.05) therapies. 
35 
TABLE 3.7 Mean growth of vaccinia virus in the ovaries of C57 /B6 mice treated with 
cytokines 24 hours before infection (106 pfu/mouse, i.v). 
Treatment Log 10 virus titre (pfu/ml) 
+ SEM 
PBS (n=5) 6.50 + 0.39 
6 µg TNF (n=5) 6.56 + 0.17 
6 µg TNF + 1/50 Ab 301 5.88 + 0.24 * 
(n=5) 
105 U mIFN-y (n=5) 4.14 + 0.56 + 
6 µg TNF + 1/50 Ab 301 5.21 + 0.41 
and 105 U mIFN-y (n=5) 
* Significant decrease in viral titre compared to TNF alone (p = 0.048). 
+ Significantly lower (p = 0.021) titre in comparison to TNF plus Ab 301 therapy. 
The enhanced antiviral efficacy of TNF with Mab 32 are seen as early as day 1 
post infection. 
Table 3.8 describes results of an experiment which examines the kinetics of 
vaccinia virus growth in TNF + Mab 32 treated mice between days 1 and 4 post 
infection. At every timepoint after infection there is a notable decrease in virus titre 
in the TNF plus Mab 32 treated mice in comparison to the PBS control mice. This is 
also found when the TNF plus Mab 32 results are compared to those of the TNF alone 
treatments with the exception of the day 2 TNF alone result which also shows a 
decrease in virus titre. There were no significant differences found between the titres 
of the PBS treated mice and the TNF alone treated mice at any timepoint post infection. 
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TABLE 3.8 Time course of the growth of vaccinia virus in the ovaries of mice 
(CBNH) treated with hTNF either alone (n=3) or with Mab 32 (n=3) twenty-four hours 
before infection ( 106 pfu/mouse, i. p.). 
Log10 Virus Titre (pfu/ml) 
Days (p.i.) PBS 4 µg TNF 4 µg TNF + 
(n=3) 1.0 mg Mab 32 
1 3.22 + 0.22 3.23 + 0.19 2.32 + 0.30** 
2 6.62 + 0.50 5.56 + 0.31 5.80 + 0.06 
3 7.50 + 0.30 7.54 + 0.27 6.43 + 0.30+ 
4 8.82 + 0.04 8.95 + 0.29 6.99 + 0.01 *+ 
* n=2; the third mouse had no detectable growth of virus, ie, < 2.0 logs. 
** p = 0.06 versus day 1 TNF alone treatment. 
+ p < 0.05 versus TNF alone treatments of the same day post infection. 
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SUMMARY. 
This chapter details the enhancement of the antiviral efficacy of human TNF by 
a monoclonal antibody and a specific polyclonal antibody in vaccinia virus infected 
mice. Treatment of mice with TNF alone either before or at the same time as infection 
with vaccinia virus resulted in little or no effect on in vivo virus growth. Antiviral 
activity was displayed, however, if TNF was in complex with either Mab 32 or Ab 30 l 
at optimal doses. This effect was so potent that administration of TNF with Ab 301 3 
days prior to infection still resulted in a significant reduction in vaccinia virus growth. 
Further to this, if the TNF, Ab 301 complex was co-administered with murine IFN y 
there was a further significant reduction in vaccinia virus growth when compared to the 
individual therapies. TNF administered alone with IFN y did not display any additional 
antiviral effects. Data presented in this chapter also suggest that the induction of an 
antiviral effect by TNF plus enhancing antibodies occurs within the first 24 hours 
following infection (this is dealt with in greater detail in chapter 5). It therefore appears 
that specific antibodies can enhance TNF's antiviral activity. 
IFN-y was also potently antiviral. The response to the above desc1ibed antiviral therapies 
vaiied according to the genetic background of the mice. 
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Figure 3.1 The binding of I-TNF to varying doses of Mab 32 in a 
radioimmunoassay using SAC cells. 
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Figure 3.2 Mean growth of vaccinia virus in the ovaries of CBA/H mice 
treated 24 hours before infection with either TNF alone, Mab 32 alone 
or TNF in complex with Mab 32 at the indicated doses. 
* p = 0.029 versus TNF alone. 
The TNF alone treatment was not significantly different from the PBS 
control (p = 0.163). 
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Figure 3.3 Mean growth of vaccinia virus in the ovaries of CBA/H 
mice treated 24 hours before infection with increasing doses of TNF 
in complex with increasing concentrations of Mab 32, following 
the ratio of 1 µg TNF : 0.25 mg Mab 32. 
* p = 0.08 versus PBS treatment. 
+ p = 0.05 versus PBS treatment. 
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Figure 3.4 Mean growth of vaccinia virus in the ovaries of CBA/H mice 
treated with 6 µg TNF plus 1/50 Ab 301 at 72, 48, 24 and O hours before 
infection. 
All TNF + Ab 301 therapies had significantly lower virus titres 
compared to the PBS control (0.01 > p > 0.001). 
The virus titres for the TNF + Ab 301 therapies did not differ 
significantly (0.35 > p > 0.10). 
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Figure 3.5 Mean growth of vaccinia virus in the ovaries of CBA/H mice 
treated with IFN y either alone or in combination with TNF at 24 hours or 
24 and O hours before infection. The ovaries were removed for titration at 
day 2 post infection. 
All IFN + TNF therapies resulted in significantly lower titres compared to the 
PBS control (p < 0.01). 
There were no significant differences between the titres for the IFN + TNF 
treatments (p > 0.10). 
Chapter 4. 
Enhancement of the Antiviral Efficacy of TNF, by Antibodies/or Herpes 
Simplex Virus type 1 (HSV-1) Challenged Mice. 
INTRODUCTION. 
Past in vitro studies have highlighted the marked sensitivity of HSV-1 to the 
antiviral effects of TNF and/or IFN y (Wong & Goedde!, 1986; Mestan et al. , 1986; 
Koff & Fann, 1986). Interest in the anti-HSY properties of TNF and IFN has been 
sufficient to encourage investigation of the molecular mechanisms behind these 
observations (Klotzbucher et al., 1990; Feduchi & Carrasco, 1991). A report by Rossol-
Voth et al., ( 1991) has shown that TNF alone is capable of significantly extending the 
survival of HSV-1 infected mice, while IFN a has been implicated as the endogenous 
agent responsible for the inhibition of HSV-1 corneal disease in mice (Hendricks et al. , 
1991). These results demonstrate the potential of particular cytokines to be effective 
against HSY infection. 
As described in the preceding chapter the antiviral efficacy of TNF against 
vaccinia virus in mice could be enhanced by specific anti-TNF antibodies. Whether this 
finding was a general phenomenon in virus infection or restricted to only certain virus 
types needed investigation. This chapter examines the enhancement of TNF by 
antibodies in the context of HSV-1 infection. 
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MATERIALS and METHODS. 
Treatment of mice with cytokines and infection with HSV-1. 
Six micrograms of hTNF was mixed with a 1/50 dilution of Ab 30 1 and allowed 
to stand for 1 hour at room temperature. This TNF/ Ab 301 ratio was the most effective 
in the vaccinia virus models. After the incubation period this stock solution was diluted 
according to the required TNF concentration (ie, 0.25 , 0.5, 1.0 or 2.0 µg/m ouse) in 
sterile PBS. TNF and Ab 301 were therefore at the same ratio across the TNF dose 
range used. TNF without Ab 301 was also made up in sterile PBS at the concentrations 
described. These TNF treatments were subsequently administered i.p. to CBA/H mice. 
In some experiments CBA/H mice received 105 U mIFN y alone or a 
combination treatment of 2 µg TNF and 105 U mIFN y again administered i.p. BALB/c 
and C57/B6 mice only received the 2 µg TNF alone, 105 U mIFN-y alone or a 
combination of the TNF and IFN treatments i.p. Twenty-four hours after cytokine 
treatment the mice were infected i.p. with 107 pfu of HSV-1. Three days post infection 
the relevant organs were removed for titration. 
N.B. In the experiment described in Fig. 4.4 the mice were first infected i.p. with 107 
pfu of HSV-1 and at 4 and 24 hours post infection treated i.p. with 2 µg TNF alone or 
2 µg TNF plus Ab 301. 
Measurement of virus growth in vivo. 
As with vaccinia virus the growth of HSV-1 was determined via measuring virus 
growth in particular organs. HSV-1 also grew to comparatively higher titres in the 
ovaries, hence the choice of this organ in these experiments. HSV-1 was found to grow 
to low titres in the spleen and liver. The adrenal gland has been described as a model 
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organ for HSV-1 studies previously (Hill et al. , 1986; Potratz et al. , 1986) . 
Three days post infection (p.i.) the mice were sacrificed by cervical dislocation 
and the ovaries and/or adrenal glands aseptically removed. These organs were 
subsequently homogenised in 1.0 ml of sterile PBS afterwhich 100 µl of homogenate 
was incubated at 37°C for 30 minutes in 0.1 % trypsin. Trypsinisation was stopped by 
the addition of foetal calf serum (FCS; Cytosystems, Sydney). These homogenates were 
10-fold serially diluted in sterile PBS and 100 µl of these dilutions plated out on a 
confluent monolayer of Vero cells that had been seeded into Linbro flat-b ottomed 6 
well plates at a concentration of 106 cells / well the previous day in RPMI or MEM 
(F15) plus 5 % heat-inactivated FCS. The plates containing the virus dilutions were left 
at 37°C (5% CO2, humidified atmosphere) for 1 hour before being overlaid with 2.5 mls 
of medium. The plates were then incubated for 2 days at 37°C afterwhich the medium 
was aspirated and the cell monolayers stained with 0.1 % (w/v) crystal violet in 20 % 
(v/v) ethanol. The plates were air-dried, the plaques were counted and the mean 
( +SEM) concentration of virus (Log10 virus [pfu/ml]) calculated. Statistical significance 
was calculated using an unpaired Student's t-test. As with the vaccinia virus titrations 
described previously, this assay is limited to the measurement of virus titres greater than 
2.0 logs; i.e. , 1 plaque at the 10-1 dilution. Samples with no detectable virus were 
counted as having 1.8 logs of virus. 
* The expe1i111ents petfonned for thi chapter were all done at least twice unless othe1wise 
indicated. Please note that (n = ) refers to the nu111ber of animals or sainple in an experimental 
or control group. 
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RESULTS. 
Ab 301 does not enhance the antiviral effect of TNF at doses of 2 or 6 µg in the 
adrenal glands or ovaries of HSV-1 challenged mice. 
TNF concentrations which were enhanced by Mab 32 and Ab 301 in the 
previously described vaccinia virus model were tried for activity against HSV-1 in 
CBA/H mice. In both the adrenal glands (Fig. 4.1 a) and ovaries (Fig. 4.1 b) no 
enhancement of antiviral effect was seen when TNF was used at either dose in the 
presence of Ab 301. The TNF treatments alone however did have antiviral activity as 
opposed to the findings with vaccinia virus. In the adrenal glands both doses of TNF 
alone resulted in significant decreases in HSV-1 titre compared to the PBS treated 
controls. In the ovaries only the 2 µg TNF treatment showed a significant reduction in 
HSV-1 titre compared to the PBS treated controls. In both organs tested there was no 
significant difference in virus titre between the two TNF alone doses. 
The enhancement of TNF doses less than 2.0 µg by Ab 301. 
Figure 4.2 a) shows that at the doses of 1.0 and 2.0 µg TNF alone there was a 
significant decrease in the HSV-1 titre compared to PBS treated controls. At neither 
of these doses was an enhancement of this antiviral effect seen with Ab 301. The TNF 
dose of 0.5 µg did not result in a significant decrease in HSV-1 titre in comparison with 
the PBS control. This dose in complex with Ab 301 did, however, display a significant 
reduction of HSV-1 titre in comparison with the PBS treated controls. When 0.5 µg 
TNF plus Ab 301 was compared to the 0.5 µg TNF alone treatment a conspicious 
decrease in HSV-1 titre was also evident (Fig. 4.2 a,b ). At the 0.25 µg TNF 
concentration (Fig. 4.2 b) there was no significant decrease in HSV-1 titre either with 
or without Ab 301 compared to PBS treatment nor was there an enhancement of the 
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antiviral efficacy of this TNF dose in the presence of Ab 301 (Fig. 4.2 b ). 
The effects of TNF and mIFN y co-administration in HSV-1 challenged mice. 
Unlike vaccinia virus HSY-1 is responsive to prior administration of TNF, at 
certain doses, without Ab 301. Experiments were therefore performed with 2 µg of 
TNF and 105 U mIFN yin CBA/H mice to look for synergy in the antiviral effects of 
these cytokines. It was also of interest to see whether TNF and IFN either alone or 
together were effective in BALB/c (HSY susceptible) and C57/B6 (HSY resistant) mice. 
Figure 4.3 shows the results of an experiment where TNF and IFN were 
administered to CBA/H mice. As demonstrated earlier the 2 µg TNF alone dose 
resulted in a significant decrease in HSY- I titre in comparison to the PBS treatment 
The IFN alone treatment also resulted in a significant decrease in HSY-1 titre compared 
to the control treatment. The titres for the TNF alone and IFN alone therapies did not 
significantly differ. When TNF and IFN were co-administered there was a significant 
decrease in HSY- I titre in comparison to the titres found for the individual cytokine 
therapies. 
The administration of 2 µg of TNF alone 24 hours before infection to C57 /B6 
mice had a dramatic effect on the growth of HSY- I (Table 4.1). The mean virus titre 
was reduced to below detectable limits ( < 2.0 log10). PBS treated mice had mean HSY-
1 titre of 4.78 log10• The doses of 105 U mIFN-y alone and together with TNF also 
showed dramatic reductions in the growth of HSY-1. The TNF plus IFN therapy was 
not significantly different to the IFN alone therapy. These findings highlight the 
sensitivity of a HSY resistant mouse strain, C57 /B6, to exogenous treatment with TNF 
and/or IFN. Table 4.1 also shows the results of the same experiment done with 
BALB/c mice. Although HSY- I grew in PBS treated BALB/c mice to a titre similar 
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to that for PBS treated C57 /B6 mice the response of this strain to HSV-1 growth 
restriction by TNF and IFN either individually or together was not significant. These 
results may delineate important mechanisms in the relative resistance/susceptibility of 
these 2 mouse strains to HSV-1 infections. 
TABLE 4.1 Mean growth of HSV-1 (Log10 virus titre [pfu/ml] + SEM) in the ovaries 
of cytokine pre-treated C57 /B6 and BALB/c mice. 
Treatment CS7/B6 BALB/c 
PBS 4.78 + 0.19 4.24 + 0.52 
2 µg TNF < 2.0 * 4.15 + 0.10 + 
105 U mlFN-y 2.43 + 0.35 * 3.64 + 0.18 + 
2 µg TNF + 105 U 2.23 + 0.26 * 3.92 + 0.18 + 
mIFN-y 
* p < 0.001 versus C57/B6 PBS treatment. 
+ 0.89 > p > 0.27 versus BALB/c PBS treatment. 
The clearance of HSV-1 by the administration of TNF alone or TNF in complex 
with Ab 301 at 4 and 24 hours post-infection. 
It has been noted in the past that TNF is able to selectively lyse HSV-1 infected 
cells in vitro (Koff & Fann, 1986). An experiment was therefore performed to address 
the possibility of this selective targeting occurring in vivo as well as observing the 
influence of Ab 301 on this effect. 
There was no significant difference in HSV-1 growth between the PBS treated 
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controls and the 4 hour or 24 hour post infection (p.i.) therapies either with or without 
Ab 301 (Fig. 4.4). There were ome interesting effects seen between the TNF alone 
and TNF plus Ab 301 therapies. At the 4 hour p.i. time point there was an increase in 
the HSV-1 titre resulting from the TNF plus Ab 301 therapy compared to the TNF 
alone therapy. At the 24 hour p.i. time point the mean HSV-1 titre for TNF plus Ab 
301 was lower in comparison to the TNF alone treatment but this difference was not 
significant. The HSV-1 titre however was significantly lower at the 24 hour p.i. time 
point for the TNF plus Ab 301 treated mice compared to the titre found in similarly 
treated mice at 4 hours p.i. There was no significant difference found between the TNF 
alone treatments at the 4 and 24 hour p.i. time points. 
It appears that the TNF plus Ab 301 complex is more active in this HSV-1 pre-
infection model than TNF alone. The results also suggest that HSV-1 growth can vary 
on exposure to TNF according to the time that the infection has been in progress. 
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SUMMARY. 
This chapter examined the enhancement of TNF antiviral effect by antibodies 
in HSV-1 infections. Using an in vivo infection model similar to that used for vaccinia 
virus, it was found that the response of HSV-1 to TNF both with and without Ab 301 
was very different to that found for vaccinia virus. TNF alone treatments were able to 
significantly inhibit the in vivo growth of HSV-1, and no significant enhancement of 
antiviral effects were seen when TNF was in complex with Ab 301. Studies of TNF 
alone with IFN y showed an additive reduction in HSV-1 growth in CBNH mice. It 
did appear, however, that the magnitude of antiviral response was dependent upon the 
genetic background of the mouse. This was highlighted in the comparison of TNF 
and/or IFN y responses in C57 /B6 (HSV resistant) versus BALB/c (HSV sensitive) 
mice. Dramatic reductions in virus growth were seen in B6 mice for each cytokine 
therapy tested (particularly TNF alone), whereas BALB/c mice showed little antiviral 
response when treated with the same cytokines. It also appears that the timing of 
exogenous TNF exposure to mice already infected with HSV-1 can be a factor in HSV-
1 growth. 
The results of this chapter emphasise that the enhancement of TNF antiviral 
efficacy by antibodies is not a general property to be applied to all virus families. 
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Figure 4.1 a) Mean growth of HSV-1 in the adrenal glands of 
CBNH mice pre-treated with 2 or 6 µg TNF ± Ab 301 24 hours 
before infection. (n = 4) for each treatment. 
* p < 0.02 versus PBS treatment . 
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Figure 4.1 b) Mean growth of HSV-1 in the ovaries of CBAJH mice 
pretreated with 2 or 6 µg TNF + Ab 301 24 hours before infection. 
* p = 0.025 versus PBS treatment. 
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Fi'gure 4.2 a) Mean growth of HSV-1 in the ovaries of CBA/H 
mice pretreated with 0.5, 1.0 or 2.0 µg TNF + Ab 301 24 hours 
before infection. 
* 0.035 > p > 0.005 versus PBS treatment. 
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Figure 4.2 b) Mean growth of HSV-1 in the ovaries of CBAJH 
mice pretreated with 0.5 or 0.25 µg TNF + Ab 301 24 hours before 
infection. 
* p = 0.079 versus 0.5 µg TNF alone treatment. 
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Figure 4.3 Mean growth of HSV-1 in the ovaries of CBAJH 
mice pretreated with 2 µg TNF and 105U mIFN y either alone or 
together 24 hours prior to HSV-1 infection. 
* p = 0.046 versus PBS treatment. 
** p = 0.005 versus PBS treatment. 
+ Significantly different to the TNF alone (p = 0.035) and IFN alone 
(p = 0.038) therapies. 
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Figure 4.4 Mean growth of HSV-1 in the ovaries of CBA/H mice 
that had been first infected (107 pfu, i.p.) and at 4 and 24 hours post 
infection treated with 2 µg TNF + Ab 301. 
* p = 0.07 versus TNF plus Ab 301 at 4 hours post infection. 
+ p = 0.011 versus TNF plus Ab 301 at 4 hours post infection. 
*The above desc1ibed data were the results of a single expe1i1nent. 
Chapter 5. 
The Role for Host-Immune Factors in the Antibody Enhanced Antiviral Effect 
of TNF. 
INTRODUCTION. 
The role of host immune factors in the control of viral infection has been well 
documented, for example in pox virus infections (reviewed by Buller & Palumbo, 
1991), herpes virus (reviewed by Wildy & Gell, 1985) and influenza virus (reviewed 
by Mitchell et al., 1985). Information on how exogenous cytokines may augment host 
immune responses is beginning to emerge. Klavinskis et al., (1989) have examined the 
role of TNF and IFN y in LCMV infection and have discussed their findings in terms 
of CTL activity. Studies have been done describing the host immune response to a 
recombinant vaccinia virus encoding IL-2. In this model an increase in NK cell activity 
and a resultant increase in endogenous IFN y were considered to be the major host 
factors responsible for the observed attenuated growth of this VV-IL-2 (Karupiah et al., 
1990a, 1990b). Similarly constructed recombinant vaccinia viruses encoding TNF 
(Sambhi et al., 1991) or mIFN y (Kohonen-Corish et al., 1990) have also been shown 
to have attenuated growth in vivo, but contributing host factors have not been clearly 
defined. 
This chapter examines the role of host immune factors in the observed antibody 
enhanced antiviral effects of TNF in a vaccinia virus infection. As well as considering 
immune cell activity in this phenomena, some attention will also be given to the 
possible induction of non-specific effector molecules in mice that had been pre-treated 
with TNF + Ab 301 and ub equently infected with vaccinia viru . 
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MATERIALS and METHODS. 
Irradiation of mice. 
CBA/H female mice were sub-lethally gamma-irradiated (650 Rads) by a Cobalt-
60 (6°Co) source in order to deplete their proliferative cellular immune response. 
Twenty-four hours post-irradiation animals were treated with cytokines and 24 hours 
later the mice were infected with 106 pfu vaccinia virus i.v. 
Natural Killer (NK) Cell assay. 
i) Preparation of Spleen (effector) cells. 
Groups of CBA/H female mice (n = 3 per treatment) were treated i.p. with one 
of the following regimes: PBS, 6 µg hTNF alone, 6 µg hTNF plus 1/50 Ab 301, 105 U 
mIFN y or a combination of TNF, Ab 301 and mIFN at the doses indicated (this 
treatment was performed exactly as described in chapter 3). Twenty-four hours later 
these cytokine treated mice were challenged with 107 pfu of vaccinia virus i.v. An 
additional group of 3 mice which were neither cytokine treated nor challenged with 
vaccinia virus served as controls. Two days post-infection the mice were sacrificed by 
cervical dislocation and the spleens aseptically removed, collected into DMEM + 10 % 
FCS and immediately placed on ice. The spleens from each treatment group were 
pooled. The pooled spleens were passed through a sterile stainless steel mesh with a 
syringe plunger. Erythrocytes were removed by water lysis (isotonic conditions were 
returned by adding 10 x HBSS). The cell and tissue debris was allowed to settle, the 
cell containing supernatants transferred to a clean sterile tube and centrifuged 
(Beckman, TJ-6) at 1500 RPM for 5 minutes. The remaining lymphocytes were then 
counted, washed once and resuspended in DMEM plus 10 % FCS at the desired 
concentration. These cells were then plated in triplicate into Linbro 96-well round-
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bottomed plates ( 100 µl / well) at the indicated ratio to Y AC-1 (NK cell sensitive) 
target cells. Effector : target ratios used were; 2: 1, 7: 1 and 20: 1. 
ii) Preparation of YAC-1 target cells. 
Y AC-1 cells (2 x 106) were labelled with sodium chromate (51Cr: Amersham, 
U.K.) in a volume of 200 µl DMEM plus 10 % FCS for 1.5 hours at 37°C. A dose of 
50 µCi was used per 2 x 106 cells. After the 1.5 hour labelling period the Y AC-1 cells 
were washed 3 x in DMEM plus 10 % FCS. The labelled cells were diluted 
accordingly in DMEM plus 10 % FCS and placed into a round-bottomed 96-well plate 
(containing the spleen lymphocytes) at a concentration of 2.0 x 104 cells/ well in 100 
µl. 
iii) Estimation of Specific lysis. 
The plates were incubated for 4 hours at 37°C in a humidified atmosphere 
containing 5 % CO2• NK cell activity was measured as the amount of radioactivity 
released from the 51Cr labelled Y AC-1 cells into the assay supematants and counted (as 
CPM) on a Packard Auto-Gamma counter. The specific lysis of the NK cell sensitive 
Y AC-1 target cells was calculated by the following formula: 
% Specific Lysis = Experimental release - Spontaneous release 
Maximal release - Spontaneous release x 100. 
Spontaneous release was measured as the amount of radioactivity in the supematants 
of 51Cr labelled Y AC-1 cells incubated under assay conditions but without spleen cells. 
Maximum release was the radioactivity released into the supematants of 51Cr labelled 
Y AC-1 cells incubated in 1.0 % Triton-X detergent. Spontaneous release ranged 
between 10-15 % for Y AC-1 cells. 
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Cytotoxic T-cell (CTL) assay. 
i) Preparation of Spleen (effector) cells. 
Groups of 3 female CBNH mice were administered one of the following 
treatments i.p.: PBS, 6 µg TNF or 6 µg TNF + 1/50 Ab 301. Twenty-four hours later 
these mice were challenged with l 07 pfu vaccinia virus (VV-WR-L929) i. v. An 
additional group of 3 mice which were neither treated with cytokines nor infected 
served as controls. Six days p.i. the mice were sacrificed by cervical dislocation and 
the spleens removed and processed as described for the NK cell assay (except that 
RPMI plus 5 % FCS was used). Effector : target ratios used were; 2: 1, 7: 1, 20: 1 and 
60:1. 
ii) Preparation of L929 (target) cells. 
L929 cells (2 x 106) were incubated with 51Cr (50 µCi / 2 x 106 cells) in a 
volume of 200 µl of RPMI plus 5 % FCS for 1.5 hours at 37°C in the presence of VV-
WR-L929 (MOI = 20). Another set of L929 cells were also labelled with 51 Cr at the 
same dose but not infected with VV-WR-L929. These cells were controls to gauge the 
degree of non-specific lysis of targets by spleen cells from infected mice. After the 
labelling/infection period the cells were washed 3 x in RPMI plus 5 % FCS, diluted 
accordingly in RPMI plus 5 % FCS and plated out into round-bottomed 96 well plates 
(containing the effector cells) at a concentration of 2.0 x 104 cells / well. 
iii) Estimation of Specific lysis. 
The plates were incubated for 6 hours at 37°C in a humidified atmosphere 
containing 5 % CO2• After this incubation period the supernatants were collected and 
processed exactly the same way as described for NK cells (see above). Spontaneous 
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release for L929 cells (infected and non-infected) ranged between 10-15 %. 
Differentiation of resident peritoneal cells in TNF ± Ab 301 treated and vaccinia 
infected mice. 
Groups of 3 female CBNH mice were injected i.p. with either PBS, 6 µg TNF 
or 6 µg TNF + Ab 301. Twenty-four hours later these mice were challenged with 107 
pfu vaccinia virus i. v. A control group of 3 mice were left untreated and uninfected. 
At day 1 p.i. the mice were sacrificed and their peritoneal cavities lavaged with 1.0 ml 
of sterile and ice-cold PBS. The peritoneal washings were then microfuged (Eppendorf) 
for 5 minutes at 1500 RPM. The supematants were U.V. irradiated (10 cm for 5 
minutes), transferred to sterile eppendorf tubes and kept for an antiviral assay and RNI 
estimation (see below). The cell pellet was resuspended in 10 µl of sterile PBS, 
vortexed and a smear made on clean glass slides. The smears were air-dried, fixed and 
stained using the Diff-Quick (Lab-Aids, Narrabeen, NSW, Australia) method. It must 
be noted that the manufacturers warn that this method does not reliably stain 
eosinophils and basophils. The stained slides were subsequently examined under oil-
immersion and the percentage macrophage/monocytes, lymphocytes and 
polymorphonuclear cells determined. 
Antiviral activity of peritoneal lavage supernatants. 
The U.V. irradiated supernatants of the above resident peritoneal macrophages 
were examined for their ability to induce an antiviral state in L929 cells. 
One hundred microlitres of these supernatants were placed into individual wells 
of Linbro 24 well plates. One millilitre of RPMI plus 5 % FCS containing 5.0 x 105 
L929 cells were then added to the supernatant containing wells. These plates were then 
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incubated at 37°C in a humidified atmosphere containing 5 % CO2 for 24 hours. When 
this 24 hour period had elapsed the medium was removed and the cell monolayers 
infected with HSV-1 * (MOI = 1.0) in 100 µl of PBS for 1.0 hour at 37°C. After the 
1.0 hour absorption period the virus plus PBS was removed and fresh RPMI plus 5 % 
FCS added to each well. The plates were incubated for 48 hours at 37°C after which 
the plates were frozen and thawed twice. The cell lysates were titrated ( 10 fold serial 
dilutions) in PBS and were plated out on Vero cells for a standard HSY -1 plaque assay 
(described in chapter 4). The reduction in the number of plaques compared to a group 
of control mice was taken to indicate antiviral activity in the resident peritoneal 
macrophage lavage supematants. 
* Vesicular stomatitis virus (VSV) is often used as an indicator virus for interferon bio-
activity. VSV is not available in Australia. In earlier studies it was found that HSV-1 
was exquisitively sensitive to mIFN y, especially at HSV-1 concentrations of MOI 1.0 -
2.0. 
Detection of RNis. 
Reactive nitrogen intermediates were detected in the peritoneal lavage 
supematants by an assay which utilises a copper-cadmium-zinc catalyst to convert 
nitrate to nitrite before exposure to Greiss reagent. This technique has been previously 
described (Rockett et al., 1992). The standards were diluted in PBS. 
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Detection of exogenous human TNF ± Mab 32/ Ab 301 in the murine peritoneal 
cavity. 
i) Labelling of specific hTNF antibody probes. 
Specific hTNF monoclonal antibodies (Mab 11 and Mab 42; both IgG 1) derived 
from a panel of monoclonals mapped and described by Rathjen et al. ( 1991) were 
biotinylated according to the method described by Hudson and Hay (1989). Briefly, the 
antibodies were equilibrated in 0.1 M sodium bicarbonate buffer (pH 8.4) by dialysis. 
The concentration of the antibodies was adjusted to 1.0 mg/ml in bicarbonate. The 
required amount of biotin succinimide ester (Sigma, St. Louis) was weighed out and 
dissolved in dimethyl sulphoxide at a concentration of 1.0 mg/ml immediately before 
use. For every 1.0 mg of protein 120 µl of biotin succinimide ester in DMSO was 
added and the solution mixed immediately. This mixture was incubated at room 
temperature with agitation for 4 hours. The conjugate solution was finally dialysed 
overnight against PBS plus 0.02 % azide. 
ii) Sandwich ELISA assay for the detection of hTNF. 
Nunc maxisorp plates were coated with a cocktail of monoclonal antibodies 
(Mabs 1, 37, and 54; all IgG 1) specific to a hTNF domain that did not overlap with the 
domain to which the above described biotinylated Mabs would bind. These capture 
antibodies were from the same panel as described above (Rathjen et al., 1991). The 
capture antibodies (20 µg/ml) were coated onto the plates in 0.05 M carbonate buffer, 
pH 9.6, and left overnight at 4°C. The plates were blocked by the addition of 1.0 % 
BSA in PBS and left for 60 minutes at 37°C. The samples were then added and the 
plates incubated at 37°C for 60 minutes. After this incubation the biotinylated probe 
antibodies were added at a concentration of 10 µg/ml to the plates after which the plates 
53 
were incubated at 4°C overnight. Both the samples and the biotinylated Mabs were 
diluted in PBS plus 1 % BSA. At the completion of the overnight incubation a 
streptavidin-peroxidase conjugate was made using an AV-ABC kit (Vectstain, Vector, 
Calif., USA) with the manufacturers directions being followed to make this conjugate. 
The conjugate was added to the plates for 1 hour at 37°C. The plates were washed six 
times between each of the above steps with PBS containing 0.05 % Tween 20. Finally 1 
the peroxidase substrate was added. This substrate consisted of 10 mg 1,2-phenylene 
diamine (Sigma, St. Louis) and 9.4 µl 30 % hydrogen peroxide per 12.5 mls 0.3 M 
citrate/phosphate buffer. The plates were then left at room temperature for 30 minutes 
in the dark, after which 50 µl of 2.5 M sulphuric acid (H2S04) was added to each well. 
The plates were then read immediately at 490 nm (690 nm reference) on a Dynatech 
plate reader. The unknown values were calculated from a hTNF standard curve (3rd 
order polynomial transformed). Murine TNF could not be detected using this ELISA 
method (see Fig. 5.1). The data is represented as mean + SEM. The binding of TNF 
alone in relation to TNF + Mab 32 or TNF + Ab 301 is also described in Fig. 5.1. 
* The experirnents perfonned for this chapter were all done at least twice. The results 
described in Tables 5.4, 5.5 and 5.6 were obtained from the sa1ne groups of CBA/H mice, and 
are the results of only one experiment. Please note that (n = ) refers to the number of anirnals 
or samples in an expeiimental or control group. 
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RESULTS. 
Ab 301 increases the persistence of TNF in the peritoneal cavity of CBA/H mice. 
The comparative detection of TNF either alone or plus Mab 32 or Ab 301 is 
shown in Fig. 5.1. This figure also shows that using this ELISA method murine TNF 
is not significantly detected. Because the detection of TNF plus Ab 301 had the 
greatest similarity to that found for TNF alone this antibody was used in the in vivo 
studies. TNF plus Mab 32 registered higher optical density readings, particularly in the 
lower dilutions, than TNF plus Ab 301 or TNF alone. 
Table 5.1 describes the measurement by ELISA of exogenous hTNF either alone 
or plus Ab 301 in peritoneal lavage samples at certain time points post i.p. treatment. 
In experiment 1 the amount of TNF detected with or without Ab 301 at O hours post 
treatment did not differ significantly. For both treatments there was a large decrease 
in TNF concentration by 6 hours post injection. From 6 to 24 hours there were 
significantly higher concentrations of TNF detected in samples from mice injected with 
TNF plus Ab 301 compared to samples from TNF alone treated mice. This is 
particularly so at the 24 hour post-injection time point (ie, the normal time of virus 
inoculation). A repeat experiment (experiment 2) following this procedure showed 
again that TNF concentration did not vary significantly at O hours post-treatment, but 
there was significantly more TNF present at 6 hours post-treatment in the samples from 
TNF plus Ab 301 treated mice. The level of TNF detected in TNF plus Ab 301 treated 
mice did not significantly vary between the O and 6 hour time points. After 24 hours 
no TNF could be detected in the lavage samples from TNF alone treated mice whereas 
a trace of TNF was detected in the samples from the mice treated with TNF plus Ab 
301. Therefore it appears that the presence of Ab 301 does enhance the persistence of 
TNF in the peritoneal cavity of CBNH mice. 
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TABLE 5.1 The detection, following i.p. injection, of hTNF either alone or in complex 
with Ab 301 ( 1/50) in the peritoneal cavity of CBA/H female mice. 
Mean hTNF (ng) + SEM 
Experiment 1 Experiment 2 
6 µg TNF 6 µg TNF 6 µg TNF 
Hours (n=3) + Ab301 (n=3) 
(n=3) 
167.87 207.43+ 24.91 
0 + 39.27 + 42.77 + 5.94 
15.74 31.22 3.01 
6 + 5.13 (n=l) + 3.01 
18.17 36.31 ** N.D 
15 + 3.01 + 2.89 
11 .40 32.36** 0 
24 + 2.04 + 4.13 
(n = 3) for each treatment unless indicated otherwise. 
+ p > 0.50 for TNF alone versus TNF plus Ab 301. 
* p < 0.04 for TNF alone versus TNF plus Ab 301. 
** p < 0.015 for TNF alone versus TNF plus Ab 301. 
6 µg TNF 
+ Ab301 
(n=3) 
26.73+ 
+ 8.17 
46.46* 
+ 13.90 
N.D 
0.86 
+ 0.86 
N.D = not done. 
The sensitivity of the antiviral effect induced by TNF plus Ab 301 ( + IFN) to sub-
lethal irradiation. 
To ascertain whether the antiviral effects of TNF plus Ab 301 are mediated by 
proliferating immune effector cells, for example NK cells, LAK cells and CTLs, mice 
were exposed to 650 Rads (sub-lethal dose) of gamma irradiation to deplete uch 
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activity. Table 5.2 shows that in CBNH mice exposed to sub-lethal irradiation there 
was no loss of antiviral activity either in animals treated with TNF plus Ab 301, IFN 
y alone or TNF plus Ab 301 and IFN together (for comparison see tables 3.4 a. and 
3.5). This indicates that a proliferating effector cell population such as those described 
above do not have a role in the antiviral effects induced by these treatments. This is 
supported by the NK cell and CTL data which follows (Table 5.3 and Fig. 5.2). 
TABLE 5.2 Mean growth of vaccinia virus in the ovaries of CBNH mice which were 
first exposed to sub-lethal y irradiation (650 R) followed 24 hours later by cytokine 
treatment. 106 pfu of vaccinia virus was injected i.v 24 hours after cytokine therapy. 
Treatment Mean log10 virus titre 
(pfu/ml) ± SEM 
PBS (n = 5) ·7.94 + 0.24 
6 µg TNF + 1/50 4.68 + 0.67* 
Ab 301 (n = 5) 
105 U mIFN y 6.20 + 0.37* 
(n = 5) 
6 µg TNF + 1/50 2.85 + 0.98*+ 
Ab 301 + 105 U 
mIFN y (n = 4) 
* p < 0.005 versus PBS treatment. 
+ p = 0.010 versus 105 U mIFN y treatment. 
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Natural Killer cell activity is not responsible for the TNF plus Ab 301 mediated 
antiviral effects. 
Table 5.3 describes the NK cell activity in the spleens of CBNH mice pre-
treated with cytokines and challenged with 107 pfu vaccinia virus ( 106 pfu was found 
not to elicit very strong NK activity). In mice pre-treated with 6 µg TNF alone there 
was no difference in NK cell activity compared to the control PBS treated mice. The 
NK cell activity in PBS and IFN pre-treated mice was also identical. In mice that had 
been treated with TNF plus Ab 301 there was less NK cell activity compared to the 
PBS control. NK activity was also noticeably lower for mice that had been pre-treated 
with the TNF plus Ab 301 and IFN y therapy compared to the PBS control and the IFN 
y alone treatment. The NK cell activity for the TNF plus Ab 301 treated mice was 
however generally similar to that of the TNF plus Ab 301 and IFN y treated animals. 
These results suggest that the TNF/ Ab 301/IFN-induced treatment is restricting the 
growth of vaccinia virus earlier than day 2 thereby preventing the stimulation of NK 
cells to normal levels of activation. This is supported by table 3.8 (see chapter 3). 
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TABLE 5.3 The Natural Killer (NK) cell activity in the spleens of CBA/H mice 
treated 24 hours before Vaccinia virus infection (107 pfu/mouse) with various cytokine 
therapies. 
Effector : Target ratio 
(% Specific lysis; YAC-1 targets). 
Treatment 2 : 1 7 : 1 20: 1 
Not Infected 1.9 + 0.4 2.9 + 0.12 6.6 + 0.7 
PBS 6.0 + 0.5 15.6 + 0.9 31.5 + 1.6 
6 µg TNF 7.2 + 1.3 19.8 + 1.2 30.9 + 1.3 
105 u 6.8 + 0.2 16.4 + 0.8 31.9+0.5 
mIFNy 
6 µg TNF 3.6 + 0.4 5.5 + 0.6 25.0 + 1.1 
+ Ab 301 
6 µg TNF + 3.4 + 0.2 8.0 + 0.7 16.9 + 1.2 
Ab 301 + 
105 U mIFN y 
Cytotoxic T Lymphocyte (CTL) activity to vaccinia virus after TNF plus Ab 301 
therapy. 
CBNH mice that had been treated with TNF + Ab 301 and challenged with 
vaccinia virus 24 hours later had their spleens removed at day 6 post infection to 
estimate CTL activity. Figure 5.2 a) shows that mice pre-treated with TNF alone 
exhibited CTL activity not significantly different to that found for the PBS pre-treated 
controls. TNF plus Ab 301 pre-treated mice showed lower CTL activity at all 
effector:target ratios in comparison to both the PBS and TNF alone pre-treated mice. 
Again this indicates that in TNF plus Ab 301 pre-treated mice the vaccinia virus growth 
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is controlled to such a degree that CTL activity is not fully stimulated. In the non-
infected target cells none of the above described treatments induced non-specific CTL 
activity greater than 5 % (Fig. 5.2 b ). 
Profile of cell types in the peritoneal cavity of TNF + Ab 301 treated and vaccinia 
infected mice. 
Table 5.4 shows a differential profile of leucocytes recovered, at day 1 post-
infection, from the peritoneal cavities of TNF pre-treated and vaccinia virus infected 
mice. The percentage of lymphocytes increased in the samples from PBS, TNF alone 
and TNF plus Ab 301 pre-treated, vaccinia infected mice compared to the samples from 
the non-treated/non-infected controls. There was no difference seen in the percentage 
of lymphocytes when the TNF alone pre-treated samples were compared to the TNF 
plus Ab 301 pre-treated lavage samples. The TNF plus Ab 301 treatment did not 
greatly differ in lymphocyte percentage compared to the PBS pre-treated controls. 
There was a noticeable difference in lymphocyte percentage however between the TNF 
alone group and the PBS group. Macrophage/monocyte percentages also did not show 
great variation between the vaccinia virus infected groups. Also no outstanding 
variation in the percentages of polymorphonuclear cells was observed between any of 
the groups whether infected with vaccinia virus or not. 
At day 1 post-infection the number of peritoneal cells recovered from the virus-
infected treatments were higher when compared to the non-infected controls. However, 
there were no significant variations in peritoneal cell number between PBS, TNF or 
TNF plus Ab 301 treated mice which had been vaccinia virus infected (data not shown). 
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TABLE 5.4 Differentiation of cells, on day 1 post-infection, from the peritoneal 
cavities of CBNH female mice pre-treated with PBS, hTNF or hTNF plus Ab 301 and 
infected with 107 pfu vaccinia virus 24 hours later. 
Mean percentage ± SEM 
Treatment Macrophages/ Lymphocytes Polymorpho-
monocytes nuclear cells 
Not treated 75.0 + 4.7 24.0 + 5.7 1.0 
/not infected 
PBS 64.3 + 2.7 34.0 + 2.1 1.7 + 0.9 
6 µg hTNF 58.0 + 1.7 40.7 + 1.5 1.3 + 0.3 
6 µg hTNF + 62.3 + 1.8 36.7 + 2.6 1.0 
Ab 301 
(n = 3) for each treatment. 
The cells were stained with Diff-Quick. This stain does not give reliable staining of 
basophils and eosinophils. 
The detection of non-specific antiviral activity in peritoneal lavage samples from 
TNF or TNF plus Ab 301 treated and vaccinia virus infected mice. 
Table 5.5 summarises the antiviral effect of supematants derived from peritoneal 
washings of TNF + Ab 301 treated and vaccinia virus infected mice. HSV-1 was used 
as the indicator virus in this assay as VSV, which is routinely used elsewhere in bio-
assays for IFN activity, is not available in Australia. 
The results show that between the PBS pre-treated mice, the TNF alone and 
TNF plus Ab 301 treated mice there is no obvious increase in antiviral effect. The non-
infected controls show only a very slight increase in HSV-1 titre in comparison to 
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ample from the vaccinia virus infected mouse groups. 
TABLE 5.5 Absence of a non-specific antiviral state by U.V. irradiated peritoneal 
washings from CBA/H female mice that had been treated with hTNF or hTNF plus Ab 
301 24 hours before infection with 107 pfu vaccinia virus. Reduction of HSV-1 titre 
was used to measure this activity. 
Treatment Mean log 10 virus titre 
(pfu/ml) ± SEM 
Not treated/not infected 5.84 + 0.05 
PBS 5.72 + 0.04 
6 µg hTNF 5.75 + 0.01 
6 µg hTNF + Ab 301 5.75 + 0.05 
(n = 3) for each treatment. 
Reactive Nitrogen Intermediate (RNI) levels in the peritoneal cavities of mice 
treated with TNF or TNF plus Ab 301 before vaccinia virus infection. 
The levels of RNI in the peritoneal cavities of CBNH mice treated with TNF 
alone or TNF in complex with Ab 301 are shown in table 5.6. The data shows that 
compared to controls there was no significant increase in RNI activity in samples from 
PBS, TNF alone or TNF plus Ab 301 treated mice that had been infected with vaccinia 
virus. 
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TABLE 5.6 Levels of reactive nitrogen intermediates (RNI) in the peritoneal washings 
of female CBNH mice treated with hTNF + Ab 301 24 hours before infection with 107 
pfu vaccinia virus. 
Treatment Mean RNI (µM) ± SEM 
Not treated/not infected 9.27 + 0.92 
PBS 8.24 + 0.15 
6 µg hTNF 9.72 + 1.67 
6 µg hTNF + Ab 301 9.56 + 0.59 
(n = 3) for each treatment. 
SUMMARY. 
Chapter 5 examined the host-immune response to vacc1n1a virus 1n mice 
pretreated with TNF plus Ab 301. The antiviral effect induced by TNF plus Ab 301 
(with and without IFN y) was not sensitive to sub-lethal gamma irradiation, indicating 
that a proliferative immune cell was not responsible for the observed attenuated vaccinia 
virus growth. This was further evidenced by NK cell and CTL studies which showed, 
when compared to controls, TNF plus Ab 301 treated animals had decreased spleen NK 
cell and CTL activities. This suggests, along with data in chapter 3, that a non-specific 
factor, effective earlier than day 2 post-infection, is responsible for the restriction of 
vaccinia virus growth. Enhanced IFN nor RNI activity could not be detected in the 
peritoneal cavities of TNF plus Ab 301 pretreated and vaccinia virus infected mice at 
day 1 post-infection. 
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Figure 5.1 Comparison of the binding of hTNF alone to hTNF in 
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Chapter 6. 
The Effect of Enhancing Antibodies on TNF, TNF-Receptor Interactions. 
INTRODUCTION. 
In early TNF receptor studies it was unanimously agreed that receptor binding 
was necessary for TNF to assert its biological functions (Kull et al., 1985; Rubin et al., 
1985; Baglioni et al., 1985). Assumptions were made by some workers that sensitivity 
to TNF (eg cytotoxic effects) were closely correlated to the density of TNF receptors 
on particular cell types (Baglioni et al., 1985; Lehmann & Droge, 1986; Holtmann & 
Wallach, 1987), whereas, others argued that receptor binding interactions alone were not 
sufficient to explain variation in sensitivity to TNF mediated effects (Kull et al., 1985; 
Yoshie et al., 1986). The later argument was supported by Tsujimoto et al. ( 1985) who 
provided evidence that receptor binding alone did not account for differences in TNF 
cytotoxicity between cell lines, and further to this showed that the internalisation of 
TNF did not vary between a TNF sensitive and TNF resistant cell line. 
For all of the above evidence it was assumed that only one major class of TNF 
receptor existed. Many groups employed radiolabelled TNF cross-linking techniques 
to study TNF receptor properties and subsequently found varying sizes of cross-linked 
products according to cell type (Yoshie et al., 1986; Tsujimoto et al., 1986; Creasey et 
al., 1987; Bakouche et al., 1988). The discovery of a second major class of TNF 
receptor (Hohmann et al., 1989) provided further insights into TNF:receptor 
relationships and may account for some of the differences seen in TNF activities. A 
review of the 2 known TNF receptors has been recently published (Tartaglia & 
Goedde!, 1992). 
This chapter examines binding properties of TNF to its receptor(s) where TNF 
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is in complex with the specific enhancing antibodies described earlier. Two cell lines 
with different sensitivities to TNF antiviral effects were examined in this context. Also, 
the expression of receptors to TNF in cells that had been pretreated with TNF and 
subsequently virus infected will be discussed. 
MATERIALS and METHODS. 
Radio-receptor assay for L929 cells and HeLa cells. 
Cells were harvested by trypsinisation, diluted to the concentration of l x l 07 
cells per ml in EMEM plus l % heat-inactivated FCS and kept on ice until required. 
Human TNF was iodinated (Iodine-125, [125I]; Amersham, 100 mCi/ml) by a 
lactoperoxidase method which has been previously described (Aston et al., 1985). The 
stock 125I-TNF was diluted to approximately 50 000 CPM / 50 µl for the assay. To 
triplicate sets of tubes non-iodinated ("cold") TNF in 100 µl of EMEM containing 1 % 
FCS was added at the concentrations of 1, 10, 100, 500, 1000, 5000 and 10 000 ng per 
tube. To another set of triplicate tubes 100 µl of Mab 32 (5.0 mg/ml) or Ab 301 (5.0 
mg/ml) serially diluted in EMEM (1/10 - 1/100 000) was added. To these tubes 50 µl 
of 125I-TNF was added followed by 200 µl of L929 cells or HeLa cells. The tubes were 
vortexed and incubated for 3 hours at 37°C (with periodic mixing). After the incubation 
period had elapsed 1 ml of EMEM-FCS was added, the tubes vortexed and then 
centrifuged (Beckman, TJ-6) for 5 minutes at 1600 g. The supernatants were discarded 
and as much residual media as possible drained from the cell pellets before counting 
the tubes in a Packard-Auto Gamma counter. Background levels of radiation were 
determined by control tubes which were treated exactly as described above except that 
no cells were added. 
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Scatchard Analysis of radio-receptor assay data. 
Calculations to determine the amount of 125I-TNF bound to the cells (Brnax) and 
the binding affinity (Kd) of this radio-ligand were performed using the principles 
originally described by Scatchard ( 1949). For the 125I-TNF alone treatment the above 
parameters were determined by examining the amount of radio-labelled ligand displaced 
at the various concentrations of non-iodinated (cold) TNF. The binding of 125I-TNF in 
the presence of 10 000 ng cold TNF represented the non-specific binding. For the 
1251-TNF plus Mab 32 treatments the Brnax and Kd were calculated on the basis of the 
extra quantity of 125I-TNF binding to the cells at each Mab 32 dilution (based on the 
Brnax value calculated for 125I-TNF alone binding). For ease of calculation the data was 
linearised. The method for this as well as the methods for Brnax and Kd determination 
were performed according to the procedures of Baxter and Funder ( 1979) and Munson 
and Enna (1984). 
Internalisation of 1251-TNF + Mab 32. 
Studies on the internalisation of hTNF + Mab 32 were done according to the 
method described by Tsujimoto et al. (1985). The Mab 32 (5.0 mg/ml) was diluted 
1/10 for this assay. Briefly, this method takes advantage of the property that at 4°C 
125I-TNF will bind to its cellular receptors but will not become internalised. After an 
initial 4°C binding period the cells were washed and then allowed to warm to 37°C, 
whereafter, at time intervals of 1, 2 and 3 hours, samples were treated with a pH 3.0 
glycine.HCl buffer to remove external receptor: 125I-TNF complexes. The CPM of the 
pellet, which had been solubulised in 0.1 % sodium dodecyl sulphate (SDS), represented 
the internalised 125I-TNF. 
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Studies on TNF receptor expression post hTNF treatment and/or HSV-1 infection. 
L929 cells (5 x l 05 cells I well) in RPMI containing 5 % FCS were seeded into 
the wells of Lin bro 24 well plates with TNF at the doses of l 0, l 00 and 400 ng in the 
presence or absence of Mab 32. TNF and Mab 32 were complexed at a ratio of 4 µg 
TNF to 1.0 mg Mab 32 for l hour at room temperature before this stock TNF:Mab 32 
complex was diluted to the appropriate TNF doses and added to the wells of the L-24 
plate. Some TNF treatments were also performed in the presence of 5000 U IFN y. 
Twenty-four hours later the TNF + IFN containing medium was removed and HSV-1 
(MOI = 1.0) in 100 µl PBS or 100 µl PBS alone (mock infection) was absorbed onto 
the cell monolayers for l hour at 37°C. The HSV-1 containing PBS was then removed 
and fresh medium put into each well. Eighteen hours later the cells were scraped from 
the wells and placed into plastic counting tubes washed once and reconstituted with 300 
µl of medium. Fifty microlitres of 125I-TNF (50 000 CPM / 50 µl) was then added, the 
tubes mixed and incubated at 37°C for 3 hours with periodic agitation. After the 
incubation period had elapsed 1 ml of EMEM-FCS was added and the tubes centrifuged 
(Beckman, TJ-6) for 5 minutes at 1600 g. The supematants were discarded and as 
much residual media as possible drained from the cell pellets before counting the tubes 
in a Packard-Auto Gamma counter. Background levels of radiation were determined 
by control tubes which were treated exactly as described above except that no cells 
were added. 
* The expe1i1nents perfoimed for this chapter were all done at least twice unless otherwise 
indicated. Please note that (n = ) refers to the number of ani1nals or sainples in ai1 experimental 
or control group. 
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RESULTS. 
The binding of 1251-TNF to L929 cells and HeLa cells is increased in the presence 
of Mab 32 and Ab 301. 
Figure 6.1 a) shows the binding of 125I-TNF either alone or in the presence of 
either Mab 32 or Ab 301 to L929 cells in vitro. Figure 6.2 b) describes the same effect 
of Mab 32 on TNF binding to HeLa cells. For both cell lines the presence of Mab 32 
with 1251-TNF resulted in a dramatic increase in the binding of this radio-labelled ligand 
to the cells. Ab 301 at higher concentrations (Fig. 6.1 a) enhanced the 1251-TNF 
binding, although the increase of binding in the presence of Ab 301 was not as dramatic 
as that for Mab 32. 
Scatchard analysis of 1251-TNF binding with or without Mab 32. 
The Scatchard plots for the binding of 1251-TNF alone and 1251-TNF plus Mab 32 
to L929 cells are described in Figs. 6.2 a) and 6.2 b) respectively. The single line 
generated to describe the 1251-TNF alone binding indicates that on L929 cells human 
TNF is binding to one class of high affinity receptor only. In the presence of Mab 32 
the TNF binding is represented as a curve. A major class of high affinity receptor is 
represented as the steeper of the 2 lines which can be extrapolated · to intersect the x-
axis. The second line which does not intersect the x-axis usually indicates either the 
presence of a second low affinity TNF receptor or a high level of background radiation. 
The dynamics of 125I-TNF binding in the Scatchard analysis for HeLa cells (Figs. 6.3 
a and 6.3 b) are similar to that found in the L929 cells. Again TNF alone binding is 
represented by a single line that indicates in HeLa cells human TNF is binding to one 
class of high affinity receptor only. In the presence of Mab 32 the Scatchard analysis 
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for HeLa cells is again represented by a curve with the bottom line not intersecting the 
x-axis. 
The Bmax and Kct values for the above-described Scatchard analyses are 
summarised in Table 6.1. The presence of Mab 32 increases the binding of 1251-TNF 
to L929 cells by a factor of approximately 2.2 times. This extra bound TNF did not 
appear to greatly compromise the affinity of TNF for its receptor as indicated by similar 
Kct values. For HeLa cells the increase in TNF binding in the presence of Mab 32 is 
approximately 2.3 times greater than that of TNF alone. However, the enhanced 
binding of TNF with Mab 32 was associated with a change in the affinity of TNF for 
its receptor on HeLa cells as the Kct value for TNF plus Mab 32 is approximately three 
times higher than that of TNF alone. 
TABLE 6.1 Scatchard analysis summary. Binding of 1251-hTNF either alone or in the 
presence of Mab 32 to the surface of L929 cells and HeLa cells. 
L929 cells HeLa cells 
Treatment Bmax Kd Bmax Kd 
1251-TNF 19.60 pM 2.59 pM 13.70 pM 1.14 pM 
alone 
i2sl-TNF 43.10 pM 3.07 pM 31.40 pM 3.70 pM 
+ Mab 32 
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Internalisation of 1251-TNF in the presence of Mab 32. 
Figures 6.4 a) and 6.4 b) describe the comparison of 125I-TNF internalisation 
with or without Mab 32 in L929 cells and HeLa cells respectively. For both cell lines 
the presence of Mab 32 greatly enhances the internalisation of 125I-TNF. This occurs 
within the first hour of incubation for both L929 cells and HeLa cells. Over the 3 hour 
incubation period the levels of internalised 125I-TNF for both TNF alone and TNF plus 
Mab 32 treatments remain relatively constant in both cell lines. The amount of 
125I-TNF internalised in the presence of Mab 32 was marginally higher in L929 cells, 
particularly at the 1 and 3 hour time points, when compared to the same treatments in 
HeLa cells. In the presence of a control monoclonal antibody (Mab 42) internalisation 
of 1251-TNF into L929 cells was similar to that observed for the 125I-TNF alone treatment 
(data not shown). 
Post TNF ( + IFN y) treatment and HSV-1 infection expression of TNF receptors 
in L929 cells. 
Pretreatment of L929 cells with TNF that were subsequently mock-infected led 
to a dose dependent increase of TNF receptors (TNF-R). At no dose of TNF used was 
there a significant enhancement of TNF-R expression by Mab 32 (Fig. 6.5 a). Fig. 6.5 
b) shows that in cells that had been pretreated with 10 ng TNF (+ Mab 32) and infected 
24 hours later with HSV-1 (MOI = 1.0) there was a large increase of TNF-R expression 
compared to similarly treated cells that had been mock-infected (Fig. 6.5 a). Marginal 
increases for the 100 and 200 ng TNF ( + Mab 32) treatments were also observed with 
HSV-1 infection. However, the infection of non-TNF treated L929 cells with HSV-1 
also resulted in a dramatic increase in TNF-R expression very similar to that found for 
the TNF pretreated cells, suggesting that any increases of TNF-R expression seen 
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compared to the mock-infected cells are directly due to the HSV-1 infection. 
Inclusion of IFN y alone in the cultures for the first 24 hours of the assay 
ignificantly increased TNF-R expression in mock-infected cells compared to controls 
(Fig. 6.6 a). The treatments of TNF (10-200 ng) alone plus IFN y did not significantly 
vary the TNF-R expression compared to the IFN y alone treatment. When the cells had 
been pretreated, with 100 or 200 ng TNF in complex with Mab 32 plus IFN, greater 
levels of TNF-R expression were observed compared to IFN treatment alone. The TNF-
R expression was significantly enhanced by Mab 32 at the 200 ng TNF dose. 
In cells that had been pretreated with TNF + Mab 32 and IFN and then infected 
with HSV-1 24 hours later (Fig. 6.6 b) the profile of TNF-R expression was different 
to that found for mock-infected cells. In cells treated with IFN alone before infection 
there was significantly less TNF-R expression in comparison to the cells that had only 
been infected with HSV-1. The level of TNF-R expression for these IFN-treated, HSV-
1 infected cells was also lower than that found for cells that had been IFN treated and 
mock-infected. For all of the TNF alone plus IFN treatments there were small increases 
in TNF-R expression compared to that observed for cells that had only been infected 
with HSV-1. There were no significant differences observed in TNF-R expression when 
the three TNF alone (plus IFN) doses were compared. There was a notable, but not 
significant decrease in TNF-R expression for the 10 ng TNF plus Mab 32 (plus IFN) 
treatment compared to the 10 ng TNF alone (plus IFN) treatment, whereas at the 100 
and 200 ng TNF doses (plus IFN) significant enhancement of TNF-R expression was 
observed if Mab 32 was present. 
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SUMMARY. 
The presence of Mab 32 with TNF enhances both the binding of TNF to the 
surface of L929 cells and HeLa cells in vitro, as well as enhancing the internalisation 
of this ligand into both of these cell lines. The enhancement of these properties are 
very similar for both cell lines with the only possible difference in binding 
characteristics being that the presence of Mab 32 slightly compromises the binding 
affinity of TNF to the HeLa cell TNF receptor (TNF-R). These overall similarities in 
TNF binding and internalisation properties are particularly interesting in relation to the 
sensitivities of these 2 cell lines to TNF antiviral activity (ie, L929 cells are sensitive; 
HeLa cells are resistant). 
The expression of TNF-R in TNF and/or IFN y exposed cells, both with and 
without HSV-1 infection, was examined. TNF alone could induce a dose dependent 
increase in TNF-R which was not significantly increased by Mab 32. IFN y alone also 
induced TNF-R expression. HSV-1 infection of L929 cells resulted in a significant 
upregulation of TNF-R expression which was partially reversed if the cells had been 
pre-exposed to IFN y. The pre-exposure of L929 cells to TNF plus IFN y before 
infection did not show any dramatic effects except for the significant enhancement of 
TNF-R expression if exogenous TNF (100 and 200 ng doses) was present with Mab 32. 
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Chapter 7. 
The Enhancement by Antibodies of the Direct Antiviral Efficacy of TNF in 
vitro. 
INTRODUCTION. 
With the greater availability of cytokines through recombinant DNA technology> 
much interest was stimulated in studies on cytokine biological properties. At the 
forefront of this interest was the interferon family of cytokines, with antiviral activity 
receiving most attention. Much early work focused on the interactions of type I (IFN 
a/~) and type II (IFN y) interferons in antiviral and antiproliferative functions , and the 
general conclusions reached suggested that the 2 types of IFNs could act together to 
potentiate those functions (Fleischmann et al., 1984; Czarniecki et al. , 1984; Oleszak 
& Stewart, 1985). 
As described in the introduction to chapter 3 the first reports of TNF being 
directly antiviral in vitro were recorded in 1986 (Wong & Goeddel; Mestan et al. ). 
Mechanisms of direct antiviral effects by interferons had, at this stage, been largely 
determined. With the discovery of another directly antiviral cytokine, which synergised 
with type II IFN, much interest resulted in the mechanisms by which TNF exerted this 
effect. The prime interest of many investigators was the induction of TNF mediated 
antiviral effects via IFN or IFN-induced antiviral pathways, for example, 2-5A 
synthetase. In Wong and Goedde!' s original paper on TNFs direct antiviral effects they 
maintained that IFN-induction was not important in this effect } and while 2-5A 
synthetase was induced its presence did not correlate with observed TNF antiviral 
effects. Over ensuing years studies on the role of IFNs and IFN-induced compounds 
nevertheless continued with much interest. This area of past research is fully discussed 
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in chapter l of this thesis. 
The primary interest of this chapter is to examine whether the documented direct 
zn vitro antiviral properties of TNF can be enhanced by the antibodies which, as 
described earlier, potentiated TNFs in vivo antiviral effects. Further to this, evidence 
of an alternative mechanism of TNF-mediated virus growth restriction in vitro is 
presented in the context of both vaccinia virus and HSV-1 infection. 
MATERIALS and METHODS. 
In vitro antiviral assays. 
L929 cells in RPMI plus 5 % PCS or HeLa cells in EMEM plus 5 % PCS were 
seeded into the wells (5 x 105 cells/ml/well) of Linbro 24 well (L-24) plates with TNF 
at the indicated doses in the presence or absence of Mab 32. TNF and Mab 32 was 
complexed at a ratio of 4 µg TNF to 1.0 mg Mab 32 for l hour at room temperature 
before this stock TNF:Mab 32 complex was diluted to the appropriate TNF doses and 
added to the wells of the L-24 plate. A control containing Mab 32 alone was also done. 
Twenty-four hours later the TNF containing medium was removed and HSV-1 (M0Is 
= 0.1 - 2.0) in l 00 µl PBS was absorbed onto the cell monolayers for l hour at 37°C. 
The HSV-1 was subsequently removed and fresh medium put into each well. The 
plates were then incubated for 48 hours at 37°C in a humidified atmosphere containing 
5 % CO2 after which the plates were frozen and thawed twice. These cell lysates were 
serially diluted by a factor of l O fold in PBS and the titre of virus determined via a 
plaque assay using Vero cells. For vaccinia virus the method was essentially the same 
except for the following differences: 1) the virus was sonicated before absorption onto 
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the L929 cells, 2) the cell lysates were incubated in 0.1 % trypsin for 30 minutes at 
37°C before titration and 3) the serial dilutions were done in HEPES-buffered saline 
containing 0.5 % gelatin. 
(N.B. - A more comprehensive description of plaque assays for vaccinia virus and HSV-
1 are to be found in chapters 3 and 4 respectively). 
MTT cell cytotoxicity assays. 
Twenty thousand L929 cells in RPMI plus 5 % FCS were seeded into the wells 
of a Linbro flat-bottomed 96 well plate with 0.4, 4.0, 8.0 or 16 ng of TNF + Mab 32. 
The same TNF:Mab 32 ratio was used as described above. These plates were incubated 
for 24 hours at 37°C. After incubation the TNF containing media were removed and 
the confluent L929 cells were either mock-infected (50 µl PBS alone) or infected with 
HSV-1 (MOI = 0.1) in 50 µl of PBS for 1 hour at 37°C. The virus-containing media 
were removed, fresh media added and the plates incubated for 48 hours at 37°C. At the 
completion of this incubation 10 µl of 5 mg/ml MTT (in PBS) was added and the plates 
incubated for 6 hours at 37°C in a humidified atmosphere containing 5 % CO2• After 
this the wells were treated with 100 µl of 10 % SDS in 0.01 M HCL and incubated 
overnight at 37°C. The absorbances were then read at 600 run (reference 630 nm) on 
a Dyna-Tech plate reader. It should be noted that unlike the standard MTT assay 
actinomycin D was not added. 
Measurement of murine TNF. 
Murine TNF was assayed via a specific sandwich ELISA technique. The capture 
antibody (TN3-19.12), a hamster anti-mouse TNF-a/~ monoclonal antibody was coated 
onto the wells of a 96 well Nunclon maxisorp plate in a carbonate coating buffer, pH 
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9.6. The plates were left at 4°C overnight. The plates were then blocked with PBS 
plus 3 % BSA and 0.1 % tween 20 for 2 hours at room temperature. The standards and 
samples were then added to the coated and blocked plates and incubated overnight at 
4°C. After the overnight incubation a polyclonal rabbit anti-mouse TNF probe antibody 
(raised in our laboratory by Sue Fordham) which had been diluted 1/500 was added and 
the plates incubated for 2 hours at room temperature. This was followed by the 
addition of an alkaline phosphatase conjugated sheep anti-rabbit lg (Silenus, Hawthorn, 
Australia) which had been diluted to 1/ 1000. The plates were incubated for 60-90 
minutes at room temperature. After this incubation had finished the alkaline 
phosphatase substrate was added (alk. phos. tablets [Sigma, St. Louis] dissolved in pH 
9.8 diethanolamine/MgC12 buffer) and the plates then incubated at room temperature for 
30-60 minutes. The absorbances were read on a Dyna-Tech automatic plate reader at 
410 nm (reference = 630 nm). The plates were washed 6 times between each of the 
above steps with PBS plus 0.1 % tween 20. The dilution of samples, standards and 
antibodies were all done in PBS plus 1 % BSA and 0.1 % tween. 
Measurement of interleukin-I activity. 
The L929 supematants from infected wells were first U. V. irradiated* (5 minutes 
at 10 centimetres). These irradiated supematants were then tested for IL 1 bioactivity 
in a D 1 O.G4. l cell proliferation assay that has been described previously (Kaye et al., 
1984; Ruby et al., 1991). 
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Examination of L929 cellular DNA. 
L929 cells were prepared exactly as described in the in vitro antiviral assay 
procedure; the TNF dose used was 400 ng. The cells were mock-infected or infected 
with HSV-1 at a MOI equal to 0.1. Four and forty eight hours+ post infection the cells 
were scraped out of the wells, suspended in 1.0 ml PBS plus pronase buffer and 
incubated overnight with 50 µl 10 mg/ml pronase at 37°C. Three million cells were 
harvested for each treatment. After the pronase treatment the DNA was extracted with 
2 x phenol/chloroform treatments and then precipitated with a 2.5 x volume of cold 
absolute ethanol after which the tubes were stored at -70°C overnight. The precipitated 
DNA was collected by centrifugation in an eppendorf microfuge for 30 minutes at 
14 000 RPM. The DNA pellets were washed twice with 70 % ethanol and were then 
dried under vacuum. The dried pellets were rehydrated with 120 µl of 10 mM EDTA 
and kept at 4°C overnight. These tubes were then treated with 4 µl of 20 mg/ml 
RNAase A and incubated for 4 hours at 37°C. Sixteen microlitres of each sample was 
subsequently loaded into the wells of a 1.5 % agarose gel and the DNA 
electrophoretically separated at 50 volts for 2.5 hours in T AE buffer containing 0.05 
mg/ 100 mls ethidium bromide. 
+ Four hours is tbe time point at which apoptotic changes normally occur and 48 hours post-
infection corresponded to peak CPE. 
Detection of cytotoxicity in L929 cell culture supernatants. 
L929 cells were seeded into L-24 plates as described above with 400 ng TNF 
+ Mab 32. The TNF-treated L929 cell monolayers were either mock-infected or 
infected with HSV-1 (MOI = 0.1) 24 hours later and incubated for 48 hours at 37°C. 
After this time had elapsed the culture supematants were removed from the L929 cells 
and U.V. irradiated* (5 minutes at 10 centimetres). Another set of 2 x 106 L929 cells 
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were incubated with 51Cr (50 µCi/ 2 x 106 cells) in a volume of 200 µl of RPMI plus 
5 % PCS for 1.5 hours at 37°C. These cells served as targets for any cytotoxic factors 
present. One hundred microlitres of the U. V. irradiated L929 cell supematants were 
added to the wells of a 96 well round bottomed Linbro microtitre plate. To these wells 
were then added 100 µl of RPMI plus 5 % PCS containing 2.0 x 104 thrice washed 
51Cr-labelled L929 cells. Plates were then incubated for 24 and 48 hours at 37°C in a 
humidified atmosphere containing 5 % CO2• The supernatants were collected at the 24 
and 48 hour time points, counted on a Packard Auto-Gamma counter and the specific 
lysis estimated exactly as described in chapter 5. Non-specific lysis at both 24 and 48 
hours was approximately 25 %. 
* Samples from irradiated supernatants were plated onto confluent Vero cells and found 
not to contain any active HSV-1. 
Treatment of L929 cultures with butylated hydroxyanisole (BHA). 
BHA (Sigma, St. Louis) was dissolved to the required concentration in 70 % 
ethanol. From this stock a concentration equivalent to l 00 µmoles/ml of RPMI plus 
PCS was added. It has been suggested (Schulze-Osthoff et al., 1992) that the 
concentration of the organic solvent in cell culture should not exceed 0.4 %. The 
concentration of the organic solvent in this case was less than 0.1 %. 
L929 cells were treated with TNF and infected with HSV-1 (MOI = 0.1) in L-24 
plates as described above. However in these experiments BHA ( l 00 µmoles/ml/well) 
was added at 2 time points, ie, before HSV-1 infection (therefore the BHA was present 
at the same time as TNF) and immediately after the absorption of the virus onto the cell 
monolayers. These cultures were left for 48-72 hours at 37°C in a humidified 
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atmosphere containing 5 % CO2• During this time the cultures were observed and 
photographed (Ilford Pan-F, ASA 50) when appropriate control levels of CPE had 
developed. Immediately after the photographs had been taken the cells were frozen and 
thawed twice and titrated on Vero cells as previously described. 
The response of vaccinia virus to BHA treatment was also tested as described 
above for HSV-1. BHA was only included in these cultures after the vaccinia virus 
infection of the cell monolayers. 
Treatment of L929 cultures with Ne Ethyl-L-Arginine acetate (NELA). 
L929 cells were TNF-treated and infected with HSV-1 as described above. 
Immediately after infection relevant cultures were supplemented with RPMI plus 5 % 
FCS containing 50 µmoles/ml of NELA. The stock NELA was dissolved in RPMI 
containing 5 % FCS. The NELA was produced in our lab by a previously described 
method (Cho et al., 1984). 
Treatment of L929 cultures with cyclooxygenase/lipoxygenase inhibitors. 
L929 cells were seeded into L-24 plates (without TNF) as previously described. 
This time however the cultures contained between I 0-100 µmoles of one of the 
following cyclooxygenase/lipoxygenase inhibitors; ibuprofen (Sigma, St. Louis), BW A 
137C (Huang et al., 1989) or BW 755C (Challend et al., 1981). All of these inhibitors 
were dissolved in propane dial (final concentration of propane dial in culture was 
approximately 0.1 % ). Twenty-four hours later the L929 cells were infected with HSV-
1 (MOI = 0.1) and fresh media containing the same quantities of the above described 
compounds placed into the corresponding wells. These culture were incubated at 37°C 
for 48 hours, frozen and thawed twice and titrated on Vero cells as previously 
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described. 
Detection of superoxide clismutase (SOD) in TNF-treated and virus-infected L929 
cultures. 
L929 cells were treated with 400 ng TNF alone or with Mab 32 and 24 hours 
later were either mock-infected (PBS alone) or infected with HSV-1 or vaccinia virus 
(MOI = 0.1) in L-24 plates as previously described. This assay was performed in RPMI 
without phenol red (Gibco, Melbourne). The RPMI was supplemented with 5 % heat-
inactivated FCS. These plates were incubated for 48 hours at 37°C after which they 
were frozen and thawed twice. The cell lysates were then tested for superoxide 
dismutase activity. The method followed for this assay was based on the principle of 
the inhibition of pyrogallol autoxidation by SOD as originally described by Marklund 
and Marklund (1974). The experimental method followed was similar to that described 
by Minami and Yoshikawa (1979) and Wei et al., (1991) with the reaction volume 
being scaled down to 140 µl so the assays could be performed in flat-bottomed 96 well 
Linbro microtitre trays. To differentiate the predominant type of SOD produced in 
these assays,10 µl of 0.3 M sodium cyanide was included in repeat assays. CuZn SODs 
are inhibited by cyanides whereas Mn and Fe SODs are not affected (Marklund and 
Marklund, 1974). Negative controls were RPMI plus FCS alone and a Sigma (St. 
Louis) standard SOD (S 8254) was used. The plates were read on a Dyna-tech 
automated plate reader at 540 run. The unknown values were calculated from an 
exponentially transformed standard curve. 
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Detection of Reactive nitrogen intermediates (RNls) in the supernatants of TNF-
treated and virus-infected L929 cells. 
L929 cells were TNF-treated and infected as described above. This time 
however, the assays were performed in EMEM plus 5 % PCS and not RPMI. RPMI 
contains a large quantity of nitrate which interferes with the RNI measurements. 
EMEM contains no nitrates. After the 48 hour post infection culture period the L929 
cell supematants were removed for an RNI assay. The standards were diluted in 
EMEM plus PCS. RNis were detected by an assay which utilises a copper-cadmium-
zinc catalyst to convert nitrate to nitrite before exposure to Greiss reagent. This 
technique has been described in detail recently (Rockett et al., 1992). 
* The expe1iments perfonned for this chapter were all done at least twice unless otherwise 
indicated. Please note that (n =) refers to the number of anilnals or samples in an expe1imental 
or control group. 
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RESULTS. 
The antiviral effects of TNF can be enhanced directly in vitro. 
Figures 7.1 a) and 7.1 b) show the titres of HSV-1 and vacc1n1a virus 
respectively in L929 cells that had been treated with TNF + Mab 32 twenty-four hours 
before infection. Both viruses were used at a MOI equal to 2.0. For the HSV-1 
infected cells 10 ng TNF alone did not significantly inhibit the growth of the virus 
whereas at higher TNF doses (100-400 ng) there was a significant antiviral effect. The 
complex of TNF with Mab 32 showed significant enhancement of HSV-1 growth 
inhibition at the TNF doses of 10 and 200 ng. This was particularly apparent at the 
TNF dose of 10 ng because this 10 ng TNF dose alone did not elicit a significant effect. 
Pre-treatment of L929 cells with Mab 32 alone ( 100 ng) did not significantly effect the 
HSV-1 titre compared to the PBS control. In cells pre-treated with TNF + Mab 32 and 
infected with vaccinia virus again the 10 ng TNF alone treatment had no significant 
antiviral effect whereas TNF alone doses of 100 and 400 ng were significantly antiviral. 
The. 10 ng TNF plus Mab 32 treatment caused a significant decrease in vaccinia titre 
when compared to the 10 ng TNF alone treatment. At no other TNF dose tested was 
a significant enhancement of antiviral effect seen with Mab 32. 
It is important to note that at no TNF dose tested, whether with or without Mab 
32, was there an antiviral state induced in HeLa cells to HSV-1 (data not shown). As 
described in chapter 6 both L929 cells and HeLa cells showed enhanced TNF binding 
and internalisation in the presence of Mab 32. 
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TNF pre-treatment of L929 cells enhances HSV-1 induced cytopathogenicity. 
L929 cells that were treated with TNF + Mab 32 as described above but infected 
24 hours later with a 20 times lower dose of HSV-1 (MOI = 0.1) showed varying 
degrees of microscopically visible cytopathic effect. If the L929 cells had been pre-
treated with 400 ng TNF either alone or in complex with Mab 32 and then mock-
infected 24 hours later there were no visible signs of cytopathic effect (Fig. 7 .2 a and 
Fig. 7.2 b). However, if following 400 ng TNF plus Mab 32 pre-treatment the cells 
were infected with HSV-1 (MOI = 0.1) there appeared very obvious and widespread 
cytopathogenicity (Fig. 7 .2 d) which was much more pronounced than that found if the 
cells had been pre-treated with 400 ng TNF alone (Fig. 7.2 c). Cells which had been 
treated with PBS 24 hours before infection with the lower dose of HSV-1 displayed no 
general cytopathogenicity (see Fig. 7.5 c). 
The presence of Mab 32 with TNF in vitro enhances quantitative L929 cell death 
upon HSV-1 infection. 
L929 cells that had been exposed to varying TNF concentrations with or without 
Mab 32 and either mock-infected or challenged with HSV-1 (MOI = 0.1) 24 hours later 
were stained with MTT to assess the extent of cell death (Fig. 7.3 a and 7.3 b). In the 
mock-infected L929 cells there were no significant differences in the amount of cell 
death between the TNF alone and the TNF plus Mab 32 treatments. In cells that had 
been treated with TNF the same way as above but infected with HSV-1 there was 
significantly greater cell death induced at every dose when TNF in complex with Mab 
32 was compared to the TNF alone treatments. This degree of cell death in TNF plus 
Mab 32 treated cells was also greater than that found for cells which had not been pre-
exposed to TNF (ie, PBS treated) and subsequently infected with HSV-1. 
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Possible mechanisms of enhanced cytopathogenicity in TNF plus Mab 32 pre-
treated and HSV-1 infected L929 cells. 
To elucidate the mechanism of enhanced cytotoxicity in TNF plus Mab 32 
treated L929 cells on HSV-1 infection both the cells and cell supernatants were 
examined. Fig. 7 .4 shows photographs of cellular DNA extracted from TNF + Mab 32 
treated and HSV-1 or mock-infected L929 cells. No detectable changes in DNA profile 
could be seen between the treatments at the 4 hours post-infection stage and for every 
treatment the DNA was largely intact. At 48 hours post-infection, even though there 
was demonstrable CPE in the relevant treatments, there was again no difference in the 
appearance of the DNA between treatments and again the DNA was generally intact. 
However at this 48 hours post-infection time point some smearing of the DNA was 
observed in most treatments which indicates the onset of cellular necrosis. No 
treatment at either time point displayed DNA profiles indicative of apoptosis (ie, 
"laddering" of DNA due to nuclease digestion at approximately 200 base pair intervals). 
Table 7 .1 shows a comparison of the lysis of L929 target cells by supernatants 
from TNF pre-treated and either mock-infected or HSV-1 infected L929 cells. This 
study showed that at both 24 and 48 hours there was no enhanced cytotoxicity in the 
supematants from TNF plus Mab 32 pre-treated and HSV-1 infected cells when 
compared to controls that had been TNF plus Mab 32 treated and mock-infected. There 
was generally more cytotoxicity seen in the supernatants of TNF plus Mab 32 pre-
treated cells when compared to supematants from cells that had been pre-treated with 
TNF alone, except at the 48 hour time point for HSV-1 infected cells. 
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TABLE 7.1 Specific lysis of 51 Cr labelled L929 cells by U.V. irradiated supematants 
from TNF treated and mock or HSV-1 (MOI = 0.1) infected L929 cells. 
I I 24 Hours I 48 Hours I 
Treatment Mock infected 
NohTNF 9.4 % + 0.9 % 16.5 % + 1.1 % 
400 ng hTNF 5.0 % + 0.8 % 17.6 % + 1.2 % 
400 ng hTNF 15.4 % + 1.4 % 27.5 % + 5.4 % 
+ Mab 32 
HSV-1 (MOI= 0.1) 
HSV-1 alone 1.8 % + 0.2 % 13.4 % + 0.7 % 
400 ng hTNF 5.4 o/o + 0.7 % 18.5 % + 0.5 % 
+ HSV-1 
400 ng hTNF + 11.7 % + 1.8 % 16.5 % + 1.4 % 
Mab 32 + HSV-1 
Supernatants from the above-described TNF + Mab 32 treated and mock/HSV-1-
infected cells were also screened for the presence of m urine TNF and m urine IL-1. 
Neither TNF nor IL-1 could be detected in the supernatants from L929 cells treated in 
this way (data not shown). 
Possible involvement of free-radicals in HSV-1-induced cytotoxicity evident in TNF 
plus Mab 32 treated cells. 
To investigate the possible role of free-radicals in this phenomenon butylated 
hydoxyanisole (BHA), a resonance stabilised free radical scavenger (Cowden et al., 
1985), was tested in this in vitro model. Fig. 7.5 (a] and b]) shows photographs taken 
of L929 cells which had been treated with TNF plus Mab 32 and then infected with 
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HSV-1 (MOI = 0.1). After infection of the cells, BHA (100 µmoles) was included in 
the fresh culture media of the relevant wells (Fig. 7.5 b). This treatment drastically 
reduced the general cytopathic effect (CPE) compared to non-BHA treated cultures 
(Fig.7.5 a). In cells which had been treated with PBS before infection and not exposed 
to BHA very little CPE was evident (Fig. 7.5 c]). In similarly treated cells that had 
BHA included in the culture medium after HSV-1 infection, however, CPE was evident 
(Fig. 7 .5 d]). This is an opposite finding to that observed for cells that had been 
exposed to TNF plus Mab 32 before infection. 
Correlation of cytopathic effect (CPE) with HSV-1 growth in vitro. 
As stated earlier TNF can be directly antiviral for HSV-1 (MOI = 2.0) infected 
cells and furthermore Mab 32 can enhance these in vitro antiviral effects (Fig. 7 .1 a]). 
This was also found if the TNF + Mab 32 treated cells were infected with HSV-1 at a 
MOI equal to 0.1. Fig. 7 .6 shows the comparison of in vitro HSV-1 growth in L929 
cells that had been treated with TNF either alone or in complex with Mab 32 and 
exposed to BHA either before or after HSV-1 (MOI = 0.1) infection. There were no 
significant differences in the HSV-1 growth between PBS, TNF alone or TNF plus Mab 
32 pre-treated cells that had either been exposed to BHA before infection or not 
exposed to BHA at all. If BHA was included in the cultures after the infection of the 
L929 cells dramatic increases in HSV-1 growth were seen for the PBS, TNF and TNF 
plus Mab 32 treatments. The virus growth in cells that were exposed to PBS before 
infection was significantly greater compared to both of the TNF pre-treatments and 
there was no significant difference between the TNF alone and TNF plus Mab 32 
treatments. This suggests that while a BHA sensitive factor was important TNF may 
also activate other antiviral effects in these cells. Alternatively, the dose of BHA used 
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might not have been sufficient to completely nullify the action of TNF. For both the 
non-BHA treated controls and the cells exposed to BHA before infection the TNF alone 
treatments significantly inhibited the growth of HSV-1 compared to the respective PBS 
treatments. There was also some noticeable enhancement of this effect if TNF was in 
complex with Mab 32. 
A titration of BHA-induced effects on HSV-1 growth in both PBS and 400 ng 
TNF alone treated L929 cells is described in Fig. 7.7. The maximum BHA effect was 
observed at the 100 and 200 µM doses. At every BHA dose tested there were 
significantly lower HSV-1 titres in the 400 ng TNF pretreated cells. This included the 
dose of 200 µmoles BHA (double what was routinely used) which supports the above 
statement that it is likely that other non-BHA sensitive antiviral factors were being 
induced by TNF in these cells. 
Vaccinia virus induced cytopathic effect and growth in response to BHA treatment. 
Fig. 7.8 shows photographs of L929 cells that were pre-treated with TNF + Mab 
32 exactly the same way as previously described but this time infected with vaccinia 
virus (MOI = 0.1). One hundred micromolar BHA was included in the relevant cultures 
after vaccinia infection. Fig. 7 .8 a) shows cells that were pre-treated with TNF plus 
Mab 32 and not exposed to BHA after vaccinia infection. CPE was evident in these 
cultures although not as severe as that found for HSV-1 infected cells. With the 
inclusion of BHA in the cultures after infection the CPE effect was markedly reduced 
(Fig. 7.8 b]). In cells that had the control treatment of PBS before vaccinia infection 
(Figs. 7.8 c]) no obvious CPE was present due to virus alone. With the inclusion of 
BHA (Fig. 7.8 d]) in such cultures again no obvious vaccinia-induced CPE was evident, 
which is in contrast to what was found for HSV-1. 
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The growth of vaccinia virus in the above-described culture system with BHA 
is shown in Fig. 7.9. In the L929 cells that had been pre-treated with TNF + Mab 32 
a significant decrease in virus growth was observed compared to the PBS control both 
with and without BRA. The presence of BRA in the cultures after infection did not 
result in the dramatic increase of virus growth that was observed with RSV-1. In cells 
that had been pre-treated with PBS the growth of vaccinia was identical for BHA and 
non-BHA treated cultures. In the cells treated before infection with TNF alone there 
was a small but non-significant increase in growth due to BRA. Cells pre-treated with 
TNF plus Mab 32 showed a small increase in vaccinia virus growth in the presence of 
BRA compared to the other TNF ( + BHA) treatments. As previously mentioned 
however in no case was there an increase in vaccinia virus growth due to BHA 
treatment similar in magnitude to that observed for HSV-1. 
Superoxide Dismutase (SOD) activity in TNF + Mab 32 treated and HSV-1 or 
Vaccinia virus infected L929 cells. 
To gauge the comparative activity of free-oxygen radicals, particularly that of 
the superoxide radical (02-), TNF treated and HSV-1 or vaccinia virus infected L929 
cultures were measured for SOD. The findings of this experiment are presented in Fig. 
7.10. The SOD activity was significantly greater for both the TNF alone and TNF plus 
Mab 32 pre-treatments in RSV-1 infected cultures compared to similarly pre-treated 
L929 cell cultures infected with the same dose of vaccinia virus. This was particularly 
apparent in the cells pre-treated with TNF plus Mab 32. Cells pre-treated with PBS 
also showed greater SOD activity with HSV-1 infection compared to vaccinia virus 
infection. There was no significant variation in SOD activity between PBS and TNF 
alone pretreated cultures which had been infected with RSV-1 and this was also true 
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for the PBS and TNF pretreatments in vaccinia virus infected cells. A small non-
significant increase in SOD activity was seen with TNF plus Mab 32 treatment 
compared to the TNF alone treatment in vaccinia virus infected cells. The comparison 
of TNF alone and TNF plus Mab 32 treatments for HSV-1 infected cells showed 
approximately a 2 fold mean increase in SOD activity for the TNF plus Mab 32 treated 
cells. Cell cultures that had been pre-treated with PBS, TNF alone or TNF plus Mab 
32 and mock-infected displayed no detectable SOD activity (data not shown). 
To differentiate the type of SOD produced in these virus-infected cells sodium 
cyanide was included in repeat assays. For PBS, TNF alone and TNF plus Mab 32 pre-
treated L929 cells infected with vaccinia virus or HSV-1 SOD activity was almost 
totally inhibited by the inclusion of sodium cyanide. This indicates that copper/zinc 
SOD is the class of this enzyme produced by HSV-1 and vaccinia virus infection under 
these experimental conditions ( data not shown). 
Reactive Nitrogen Intermediates (RNis) in the control of HSV-1 growth in vitro. 
To examine the possible role of RNis as a factor in the regulation of HSV-1 
growth by BHA, a specific nitric oxide synthetase (the enzyme which produces nitric 
oxide) inhibitor N°-ethyl-L-arginine acetate (NELA) was tested in the established in 
vitro model. Fig. 7 .11 shows that with PBS, TNF alone or TNF plus Mab 32 pre-
treatment of L929 cells no significant increase in HSV-1 growth was seen in the 
presence of NELA added after infection suggesting no significant role for RNis in the 
direct control of HSV-1 growth. The lack of a role for RNis is supported by table 7 .2 
which shows no significant differences in the amount of RNI secreted from PBS or 
TNF + Mab 32 treated cells subsequently infected with HSV-1 (MOI = 0.1) either with 
or without BHA present. In control cells that were mock-infected (data not shown) 
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there were no significant differences in RNI secretion seen when compared to the above 
described HSV-1 infected cells. 
TABLE 7.2 Levels of Reactive Nitrogen Intermediates (RNI) in the supematants of 
TNF treated L929 cell cultures infected with HSV-1 (MOI= 0.1) 24 hours later. BHA 
was added to relevant cultures. 
REACTIVE NITROGEN 
INTERMEDIATES (µM) 
PBS 400 ng TNF 400 ng TNF 
+ Mab 32 
NoBHA 5.53 + 0.76 6.98 + 1.99 6.38 + 0.40 
BHA 5.30 + 0.50 7.35 + 0.69 8.43 + 1.36 
(100 µmoles) 
*The above described data were the results of a single expeiiment. 
The influence of cyclooxygenase/lipoxygenase inhibitors on HSV-1 growth in vitro. 
BHA as well as being a free-radical scavenger can also inhibit part of the 
arachidonic acid cascade. To test whether this was involved in the observed effects of 
BHA on HSV-1 growth 3 inhibitors of the arachidonic acid cascade ( via 
cyclooxygenase, lipoxygenase pathway inhibition) were tested. These inhibitors were 
1) ibuprofen (cyclooxygenase pathway; Dunn & Chuluyan, 1992), 2) BWA 137C 
(lipoxygenase pathway; Bhattacherjee et al., 1988) and 3) BW 755C (cyclooxygenase 
and lipoxygenase pathways; Bhattacherjee et al., 1988; Dunn & Chuluyan, 1992). The 
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dose range tried for the inhibitors did not cause any visible cell toxicity with the 
exception of the 100 µmole BWA 137C treatment. Fig. 7.12 shows the growth of HSV-
1 in L929 cells treated with the 3 mentioned inhibitors. For ibuprofen and BW A 137C 
there was no significant effect on viral growth compared to the organic solvent alone 
control (the organic solvent control did not differ from the PBS control). BW 755C 
however showed a dose related inhibition of HSV-1 growth, suggesting that its effects 
are different to those of BHA as the presence of BHA increased HSV-1 growth under 
these experimental conditions. 
SUMMARY. 
Mab 32 was shown to be capable of enhancing the direct anti viral effects of 
TNF in L929 cells for both HSV-1 and vaccinia virus. This antiviral effect for HSV-1 
was characterised by enhanced CPE in TNF pretreated cells which was further 
potentiated if Mab 32 had been present with TNF. Further study of this phenomenon 
showed, through the use of an antioxidant (BHA), that free oxygen radicals were 
possibly responsible for this CPE effect, which when reversed by BHA resulted in 
dramatic increases in HSV-1 growth. Direct free radical production appears to be 
important to the control of HSV-1 growth in vitro, and prior exposure of such cells to 
TNF, particularly with Mab 32, sensitised the cells to damage by free radicals induced 
by HSV-1 infection. Vaccinia virus did not exhibit the same degree of CPE in TNF 
exposed L929 cells, and did not show a significant increase in growth on BHA 
exposure. These comparative effects observed for HSV-1 versus vaccinia virus suggests 
an interesting dichotomy in the response of viruses to free radical induction. This 
difference was further supported by SOD studies which showed that superoxide activity 
was greater in HSV-1 infected cells, particularly if they had been pre-exposed to TNF 
+ Mab 32. 
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Figure 7.1 a) Mean growth of HSV-1 (MOI = 2.0) in TNF + Mab 
32 pretreated L929 cells. (n = 3) for each treatment. 
* p = 0.017 and+ p = 0.05 versus the TNF·alone treatments at the same 
dose. 
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Figure 7.1 b) Mean growth of Vaccinia virus (MOI = 2.0) in TNF + Mab32 
pretreated L929 cells. (n = 3) for each treatment. 
* p = 0.028 versus the 10 ng TNF alone treatment. 
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Fig. 7.2 Cytopathic effect obseived in L929 cells that had been, 
a) pre-treated with 400 ng TNF alone and mock-infected 24 hours later; 
b) pre-treated with 400 ng TNF plus Mab 32 and mock-infected 24 hours 
later. (Magnification = X 400). 
c) 
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Fig. 7 .2 ( continued) Cytopathic effect observed in L929 cells that had been, 
c) pre-treated with 400 ng TNF alone and HSV-1-infected (MOI = 0.1) 24 hours 
later; d) pre-treated with 400 ng TNF plus Mab 32 and HSV-1-infected (MOI 
=0.1) 24 hours later. (Magnification= X 400). 
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Figure 7.3 a) Cell death estimated by MTI staining for L929 
cells pretreated with TNF + Mab 32 and mock-infected 24 hours 
later. (n = 6) for each treatment. 
TNF alone versus TNF + Mab 32 treatments were not significantly 
different at any TNF dose tested (0.50 > p > 0.110). 
*The above described data were the results of a single expe1irnent. 
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Figure 7.3 b) Cell death estimated by MIT staining for L929 
cells pretreated with TNF + Mab 32 and HSV-1-infected 
(MOI = 0.1) 24 hours later. (n = 6) for each treatment. 
TNF alone versus TNF + Mab 32 treatments were significantly 
different in at every TNF dose tested; * 0.010 > p > 0.001; 
** p < 0.001. 
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Fig. 7.4 DNA profile of L929 cells pre-treated with TNF (with and without 
Mab 32) and either infected with HSV-1 (MOI = 0.1) or mock-infected. 
Treatments were as follows; 
a) Not treated/not infected, 
b) HSV -1 infection alone, 
c) 400 ng TNF alone, 
d) 400 ng TNF plus Mab 32 alone, 
e) 400 ng TNF plus HSV-1 infection, 
O 400 ng TNF plus Mab 32 plus HSV-1 infection. 
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Fig. 7.5 Cytopathic effect observed in TNF plus Mab 32 pre-treated L929 
cells that were infected 24 hours later with HSV-1 (MOI = 0.1) and a) not 
exposed to BHA, or b) Exposed to 100 µM/ml BHA. (Magnification= X 400). 
c) 
d) 
Fig. 7.5 (continued) Cytopathic effect observed in PBS pre-treated L929 
cells that were infected 24 hours later with HSV-1 (MOI = 0.1) and c) not 
exposed to BHA, or d) Exposed to 100 µM/ml BHA. (Magnification= X 400). 
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Figure 7.6 Mean growth of HSV-1 (MOI = 0.1) in TNF + Mab 32 
pretreated L929 cells which were also treated with 100 µmoles of 
BHA either before or after infection. 
There were no significant differences between any treatment when 
the non-BHA treated controls were compared to the cells exposed to 
BHA before infection, (0.36 > p > 0.08). 
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Figure 7.7 Titration of BHA (0-200 µmoles) effects when added 
after HSV-1 (MOI = 0.1) infection of L929 cells pretreated with 
PBS or 400 ng TNF. 
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Fig. 7.8 Cytopathic effect observed in TNF plus Mab 32 pre-treated L929 cells 
that were infected 24 hours later with Vaccinia virus (MOI = 0.1) and a) not 
exposed to BHA, or b) Exposed to 100 µM/ml BHA. (Magnification = X 400). 
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Fig. 7.8 (continued) Cytopathic effect observed in PBS pre-treated L929 
cells that were infected 24 hours later with Vaccinia virus (MOI = 0.1) and 
c) not exposed to BHA, or d) Exposed to 100 µM/ml BHA. 
(Magnification = X 400). 
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Figure 7.9 Mean growth of Vaccinia virus (MOI = 0.1) in TNF + Mab 32 
pretreated L929 cells which were also treated with 100 µmoles of BHA after 
infection. 
* p = 0.08 versus TNF + Mab 32 pretreated cells not exposed to BHA after 
vaccinia virus infection. 
For PBS and TNF alone pretreated cells there were no significant 
differences in virus titre between BHA exposed and BHA non-exposed cells 
(0.23 > p > 0.15). 
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Figure 7.10 Mean Superoxide Dismutase (SOD) activity in L929 
cell cultures which had been pretreated with PBS, TNF or 
TNF + Mab 32 and infected (MOI = 0.1) with either HSV-1 or 
Vaccinia virus. (n = 3) for each treatment. 
* p = 0.077 versus PBS treated, vaccinia virus infected cells. 
** p = 0.043 versus TNF treated, vaccinia virus infected cells. 
+ p = 0.035 versus TNF + Mab 32 treated, vaccinia virus 
infected cells. 
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Figure 7.11 Mean growth of HSV-1 (MOI = 0.1) in PBS, TNF or 
TNF + Mab 32 pretreated L929 cells exposed to 50 µmoles 
N~ethyl-L-arginine acetate (NELA) after infection. 
(n = 3) for each treatment. 
There were no significant differences in virus titre for PBS, TNF or TNF + 
Mab 32 pretreated cells that had been exposed to NELA after infection 
compared to cells which had not been exposed to NELA, 
(0.62 > p > 0.11). 
*The above desciibed data were the results of a single experiment. 
--0- Ibuprofen 
• BWA 137C 
• BW755C 
Propane diol control 
5.0 
::>s~ :i= ,.-._ • -0 ~ 4.5 s 
:s 
~ 4.0 
'.._I 
QJ 
i. 
...... 
. ,.. 3.5 ...... 
r.l'1 
= i. 
.,.. 3.0 ~ 
0 
~ 
el) 2.5 0 
~ 
2.0 
0 20 40 60 80 100 120 
Inhibitor (µmoles) 
Figure 7.12 Growth of HSV-1 in L929 cells which had been exposed to 
between 10-100 µmoles of cyclooxygenase / lipoxygenase inhibitors for the 
duration of cell culture. 
Chapter 8 
The Immunobiology of a Vaccinia Virus Construct Encoding Transforming 
Growth Factor beta 2 (TGF 02). 
INTRODUCTION. 
Transforming growth factor beta (TGF 0) is a cytokine which displays a 
remarkable array of physiological properties including both the stimulation and 
inhibition of cell proliferation (reviewed by Barnard et al., 1990). Of much current 
interest is the role of TGF P in immune regulation. The overall view from past studies 
is that TGF P is largely an immunosuppressive molecule. Examples of the negative 
effects of TGF P on immune systems include reports on the inhibition of CTL 
development (Ranges et al., 1987), the inhibition of immunoglobulin (lg) production 
in human lymphocytes (Kehrl et al., 1991 b; Warm old et al., 1992), and inhibition of 
B cell activation and antigen-specific B cell-Th cell physical interactions (Bartlett et al., 
1991). In addition to these properties TGF p has been shown to have anti-proliferative 
effects on B and T lymphocytes (Kehrl et al., 199 la). The inhibitory effects of TGF 
P on immune function extend much further than the above examples both in vitro and 
in vivo and Palladino et al. (1989) gives a comprehensive summary of both TGF P 
mediated inhibitory effects as well as immune functions enhanced by TGF p. As 
documented in this review the immunosuppressive effects of TGF far outweigh the 
immuno-enhancing effects of this molecule. One interesting property of TGF both in 
vitro and in vivo is that it is capable of both augmenting and inhibiting TNF a 
production. There has been a study which has examined the effects of TGF PI on 
immune function in a whole animal model (Strassmann et al., 1991). In this study it 
was found that the administration of liposome associated TGF P 1 to mice which had 
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been previously infected with Corynebacterium parvum reduced both the spleen ize 
and the number of splenocytes compared to controls. As well as this there were 
inhibited DTH responses to Listeria monocytogenes in mice treated with the liposome-
TGF P 1 complex compared to control treated animals. 
The aim of this chapter is to examine the role of TGF p2 in vaccinia virus 
infection using the recombinant vaccinia virus system which has been previously 
applied to the study of other cytokines (Ramshaw et al., 1992). 
MATERIALS and METHODS. 
Construction of the recombinant vaccinia virus encoding murine TGF p2• 
The full length cDNA for murine TGF p2, in a pBluescript II KS +/- vector 
(Stratagene), was generously provided by Dr. F. Denhez of the National Institute of 
Health, Maryland USA. The entire mTGF p2 coding sequence was removed from the 
bluescript vector using Hine II (Pharmacia) and Xba I (Pharmacia) endonucleases. The 
Xba I end of the gene was filled using the Klenow fragment of DNA polymerase I and 
the TGF gene then blunt-end ligated into the Hine II site of the pBCB07 vaccinia 
expression vector (Boyle et al., 1985; Andrew et al., 1987). The inserted TGF P gene, 
which had it's orientation checked by restriction analysis, was directly downstream from 
the P7 .5 vaccinia early/late promoter. This recombinant plasmid was used to transfect 
confluent 143 B cells which had been infected an hour earlier with VV-WR-L929 
(marker rescue). This strategy placed the gene by homologous recombination into the 
J region of the vaccinia virus genome and therefore resulted in a TK- virus (Mackett et 
al., 1982) which was subsequently plaque purified 3 times in the TK- 143 B cell line 
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under Bromo-deoxyuridine (BuDr) selection. Stocks were prepared in CV 1 cells a 
described in chapter 2. The presence of the gene was verified by both Southern blotting 
of the recombinant virus DNA (Fig. 8.1) and plaque hybridisation techniques (Fig 8.2), 
using a random primed, 32P-labelled full-length mTGF p2 gene as the probe. 
N.B. Extra references relevant to the construction of recombinant vaccinia viruses are 
given in chapter 2. 
Bioassay for TGF p2• 
143 B cells in EMEM plus 5 % heat-inactivated PCS were grown to confluency 
1n Linbro 24 well plates and subsequently infected with the recombinant TGF p 
vaccinia virus or a non-TGF P control vaccinia virus (MOI = 5.0). At 1, 5, 17, 24, 48 
and 72 hour intervals post-infection, supematants were collected from the infected cells 
and UV-irradiated (5 minutes at approximately 10 cm) to inactivate the vaccinia virus. 
The supematants from the control vaccinia virus infected cells were collected at the 72 
hour time point only. Supematants were also collected from 143 B cells that had been 
cultured over the same time period but not challenged with virus. These supematants 
were then tested for their ability to inhibit the proliferation of the M v-1-Lu cell line as 
determined by tritiated thymidine ( 1.0 µCi/well) incorporation. The method for this 
assay as well as the procedure for the determination of unknown TGF P values has been 
recently reviewed by Meager (1991). TGF pis often secreted in vitro as a latent form 
which requires physical or chemical treatment for activation. After testing the normal 
supematants for TGF bio-activity, the assay was repeated with supematants which had 
been heated to l00°C for 3 minutes to activate any TGF present as the inactive 
precursor form (Lawrence et al., 1985). Recombinant TGF Pl was used to calibrate the 
assay. It has been reported that TGF p 1 and TGF p2 have equivalent inhibitory activity 
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in Mv-1-Lu cell bioassays, although this property is not universal for all cell type 
(Jennings et al., 1988). 
Growth of VV-TGF p2-TK- in Swiss (athymic) Nude mice. 
Female nude mice ( 6-8 weeks old) were infected with either VY -TGF p2-TK-
or a similarly constructed TK- control virus whose growth was not attenuated by the 
inserted gene (for this study, VY-IL 5-TK-) at the doses of 5 x 106 pfu or l x 107 pfu 
intravenously (i.v). The mice were then observed for mortality as an indication to 
whether the presence of the TGF P gene was inducing in vivo enhanced or attenuated 
growth of the vaccinia virus. 
Growth of VV-TGF p2-TK- in thymic CBA/H mice. 
Female CBNH mice (6-8 weeks old) were infected i.v with 5 x 106 pfu of VV-
TGF P2-TK- or VY-IL 5-TK-. At days 2, 4 and 7 post-infection the mice were 
sacrificed by cervical dislocation and the ovaries removed for virus growth titration. 
The protocol for vaccinia measurement in the ovaries was performed as described in the 
methods section of chapter 3. 
Natural Killer (NK) cell activity in the spleens of VV-TGF p2-TK- infected mice. 
CBNH mice (n = 3; 6-8 weeks old) were infected with l x 107 pfu VV-TGF 
P2-TK- i.v. Control mice (n = 3) were infected with the same dose of VV-WR-TK-. 
At day 2 post-infection the mice were sacrificed by cervical dislocation and the spleens 
collected into ice-cold RPMI plus 10 % heat-inactivated FCS. Spleens were al o 
collected from non-infected mice for NK cell activity testing. The preparation of the 
spleen cells, labelling of Y AC-1 target cells and the measurement of specific lysis were 
95 
all performed as described in the methods section to chapter 5. 
Cytotoxic T lymphocyte (CTL) activity in the spleens of VV-TGF P2-TK- infected 
mice. 
CBNH mice (n = 3; 6-8 weeks old) were infected with 1 x 107 pfu VV-TGF 
P2-TK- i.v. Control mice (n = 3) were infected with the same dose of VV-WR-TK-. 
Six days post-infection the mice were sacrificed by cervical dislocation and the spleens 
collected into ice-cold RPMI plus 5 % heat-inactivated FCS. Spleens were also 
collected from non-infected mice for CTL activity testing. The preparation of the 
spleen cells, labelling of L929 target cells and the measurement of specific lysis were 
all performed as described in the methods section to chapter 5. The L929 (target) cells 
were infected with VV-WR-TK- at a MOI of 20 during 51Cr labelling. 
The experiments performed for this chapter were all done at least twice unless otherwise 
indicated. Please note that (n = ) refers to the number of animals or samples in an experimental 
or control group. 
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RESULTS. 
Expression of vaccinia virus encoded TGF p2 in vitro. 
The time course of TGF P2 production in in vitro infected 143 B cells is 
described in Fig. 8.3. As can be seen there is a gradual increase in TGF p2 bioactivity 
with peak activity being reached at 24 hours post infection. TGF p2 bioactivity in 
supematants collected at the 48 and 72 hours post infection time points were not 
significantly different compared to the 24 hour time point. The supematants for the 
above described data had been heat-activated before the assay. Supematants which did 
not have an activating step before the assay did display TGF p bioactivity, but it was 
generally not as pronounced or as consistent (ie, TGF p levels did not increase 
consistently with increased time) as that found for the heated samples (data not shown). 
This indicates that there is only partial activation of the TGF p secreted from VV-TGF 
P infected 143 B cells. Supematants from 143 B cells infected with a control vaccinia 
virus at the same dose did not display any detectable inhibition of Mv-1-Lu cell 
proliferation ( data not shown). 
Growth of vaccinia virus encoding TGF p2 (VV-TGF p2-TK·) in Swiss nude mice. 
The growth of VV-TGF P2-TK- in athymic Swiss nude mice was monitored as 
the relative survival of these mice compared to nude mice infected with a control 
vaccinia virus. Fig. 8.4 shows the kinetics of the survival in VV-TGF P2-TK- versus 
VY-IL 5-TK· infected mice at 2 virus doses. At the 1 x 107 dose there was a slight, but 
statistically not significant increase in the survival of the VV-TGF P2-TK- infected mice 
and this is reflected in the mean time to death (MTD) figures (Table 8.1 ). The 5 x 106 
pfu dose showed a more pronounced increase in survival for VV-TGF P2-TK- infected 
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mice compared to mice infected with the control virus. However, statistical analysis 
of the MTD for VV-TGF P2-TK- infected mice again did not exhibit a significant 
difference when compared to the MTD for the control virus infected mice. 
TABLE 8.1 The mean time to death (MTD) of Swiss nude mice infected i.v with 
either VV-TGF p2-TK- or VV-IL 5-TK- (n = 5 for each group). 
Virus dose Mean Time to Death (days) 
(pfu/mouse) +SEM 
VV-IL 5-TK· VV-TGF P2-TK· 
5 X 106 14.4 + 0.6 18.6 + 3.6 
1 X 107 12.4 + 0.2 13.8 + 0.7 
At both virus doses there was no significant difference in the MTD of mice infected 
with VV-TGF p2-TK- compared to VV-IL 5-TK- (0.29 > p > 0.10). 
Growth of VV-TGF P2-TK· in the ovaries of thymic CBA/H mice. 
Figure 8.5 describes the comparative growth of VV-TGF P to the growth of the 
control virus in the ovaries of mice at intervals of 2, 4 and 7 days post-infection (p.i.). 
At day 2 p.i. there was a decrease in the growth of the VV-TGF compared to the 
control virus but this was not significantly different. At both days 4 and 7 p.i. lower 
vaccinia virus titres were observed in the ovaries of VV-TGF infected mice but as with 
the day 2 time point there was not a statistically significant difference found when 
compared to the growth of the control virus. 
Serum samples from both control virus and VV-TGF p infected mice had no 
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detectable TGF p bioactivity at the peak of virus growth (ie, day 4 p.1.; data not 
shown). 
Natural KiJler (NK) cell activity in CBA/H mice infected with VV-TGF P2-TK-. 
Fig. 8.6 describes the comparative NK cell activity in CBA/H mice infected with 
VV-TGF p2-TK- compared to mice infected with a control virus. The NK cell activity 
was not significantly different in VV-TGF p2-TK- infected mice compared to mice 
similarly infected with the control vaccinia virus. At day 2 post infection in CBA/H 
mice the growth of VV-TGF P was not significantly different to that of the control virus 
(Fig. 8.5). This correlation to virus growth supports the finding that NK cell activity 
is not increased. 
Cytotoxic T Lymphocyte (CTL) activity in CBA/H mice infected with VV-TGF P2-
TK-. 
Fig. 8.7 describes the activity of CTLs at day 6 p.i. in mice infected with VV-
TGF P compared to mice infected with a control virus. There was not a significant 
difference in CTL activity for VV-TGF p infected mice compared to mice infected with 
the control virus. This supports the growth data (Fig. 8.5) which shows that at the time 
of peak CTL activity there was no difference in vaccinia virus growth in the ovaries of 
VV-TGF P infected versus control virus infected CBA/H mice. The lysis of non-
infected targets did not exceed 5 % for either virus. 
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SUMMARY. 
This chapter describes some characteristics of a recombinant vacc1n1a v11Us 
encoding TGF p2 (VV-TGF P). TGF P bioactivity could be detected in the 
supematants of cells which had been infected with VV-TGF p, but to see consistent 
activity the supematants had to be boiled to activate latent TGF p molecules expressed 
by the recombinant virus. Studies showed no differences in growth characteristics 
compared to a control virus for both athymic nude mice and thymic CBNH mice. 
There were also no differences found for both splenic NK cell and CTL activities in 
VV-TGF p infected mice versus animals infected with a control virus. These results 
may reflect the in vitro findings, which suggest that TGF P is not fully activated under 
normal physiological conditions after expression from a vaccinia virus vector. 
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1) 2) 
Fig. 8.1 Southern blots* of the viral DNA from, 1) the parent vaccinia 
virus (VV-WR-L929), and 2) the recombinant vaccinia virus encoding TGF 
p2 (VV-TGF P2-TK-). 
1) 2) 
Fig. 8.2 Hybridisation* of viral plaques in 143 B cells from, 1) the parent 
vaccinia virus (VV-WR-L929), and 2) the recombinant vaccinia virus 
encoding TGF p2 (VV-TGF P2-TK-). 
* A random primed, 32P-labelled full length mTGF p2 cDNA was used as the 
probe . 
8000 
7000 
6000 
,.... 5000 8 
ob 4000 ~ 
3000 
2000 
1000 
0 
0 20 40 60 80 
Hours (post-infection) 
Figure 8.3 TGF p bioactivity in boiled supernatants from 143B 
cells infected with a recombinant vaccinia virus encoding TGF P2 
(VV-TGF P2-TK). 
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Figure 8.4 b) Survival of Swiss Nude mice infected with VV-TGF ~2 
versus a control vaccinia virus at the dose of 5 x 10
6 
pfu (i.v). 
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Figure 8.5 Mean growth of VV-TGF ~2-TK-versus a control 
Vaccinia virus in the ovaries of CBNH mice at days 2, 4 and 7 
post-infection. 
There were no significant differences in virus titre between 
VV-TGF ~2 and the control virus at day 2, 4 or 7 post-infection 
(0.35 > p > 0.13). 
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Figure 8.6 Natural Killer (NK) cell activity against Y AC-1 target cells 
in the spleens of CBA/H mice infected with VV-TGF ~2 versus a 
control virus. 
*The above desc1ibed data were the results of a single experiment. 
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Figure 8.7 a) Cytotoxic T Lymphocyte (CTL) activity against Vaccinia 
virus-infected target cells (MOI = 20) from the spleens of VV-TGF P2 
infected mice versus control virus infected mice. 
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Figure 8.7 b) Cytotoxic T Lymphocyte (CTL) activity against non-infected 
target cells from the spleens of VV-TGF p2 infected mice versus control 
virus infected mice. 
*The above desc1ibed data were the results of a single experiment. 
Chapter 9. 
DISCUSSION and CONCLUSIONS. 
9.1 Enhancement of TNF antiviral efficacy by antibodies. 
This study shows that TNF can induce potent anti-vaccinia virus effects in vivo 
if complexed to antibodies (Mab 32/ Ab 301) specific to a particular region of the TNF 
protein. TNF administered alone at a range of doses before or at the time of infection 
showed little or no anti-vaccinia virus activity. The TNF-Ab 301 complex was also 
able to synergise with mIFN yin vivo where TNF alone with mIFN y was not. A study 
with LCMV has also shown that TNF and mIFN y were not capable of synergistically 
reducing LCMV titres in vivo (Klavinskis et al. , 1989). Other Mabs specific to hTNF 
were also tested and found not to enhance the antiviral activity of TNF, thereby 
showing that the simple binding of an antibody to TNF was not responsible for the 
enhancing effects. The phenomenon of TNF enhancement by Mab 32 has also recently 
been demonstrated in a tumour model (Rathjen et al. , 1992). Furthermore that study 
showed that while Mab 32 enhanced TNF mediated tumour regression, it significantly 
inhibited procoagulant activity in cultured endothelial cells. It appears in the tumour 
model that there can be selective enhancement of the biological activities of TNF with 
Mab 32. Antibody 301 has also been shown to enhance the anti-tumour efficacy of 
TNF (Rathjen & Aston, in press). 
The treatment of mice with TNF in complex with univalent Fab ' fragments of 
Mab 32 showed a weak antiviral effect. The reduction of virus titre observed with 0.5 
mg Fab 32 plus TNF was not as pronounced as that found with the whole Mab 32 plus 
TNF. A possible explanation may be that the removal of the Fe region fro m the 
monoclonal antibody results in a more labile Fab ' region (Rathjen, pers. comm.) and 
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therefore the longer more involved preparation procedures needed to produce the Fab ' 
fragments could have partially compromised enhancing activities. A recent study has 
shown that bivalency and/or Fe mediated effects were not important in the ability of 
Mab 32 to augment the anti-tumour effects of TNF as Fab 32 enhanced TNF to the 
same degree as whole Mab 32 (Rathjen et al., 1992). 
The phenomenon of antibody enhancement has been known of for several years 
1n relation to endocrine hormone activity. To decide on mechanisms of antibody 
enhancement of TNF it is therefore useful to consider the past literature concerning 
endocrine hormone enhancement by antibodies. Favoured mechanisms of endocrine 
hormone enhancement include, slow release (depot effect), bivalency and Fe region 
effects, conformational changes induced in the protein by the antibody, and receptor 
"restriction" effects (reviewed by Aston et al., 1989). The evidence provided above in 
the studies with Fab' fragments suggest that the induction of conformational changes 
in the TNF molecule due to Mab/ Ab binding could be very likely. It also appears quite 
likely that the antibodies may be acting in a similar fashion to carrier proteins that 
afford protection to other proteins, like TNF, from in vivo degradation, and hence 
extend physiological half-lives. A recent report has shown that bioactive oligomeric 
TNF will convert into an inactive monomeric form at picomolar concentrations under 
physiological conditions and the authors conclude that this instability might be 
important in the regulation of TNF cytotoxicity (Corti et al., 1992). This finding raises 
interesting questions regarding the ability of Mab 32 or Ab 301 to prevent the 
conversion of TNF into inactive monomers and hence introduce greater stability to the 
TNF molecule. Change in conformational structure could also contribute to 
prolongation of TNF half-life. Results in chapter 5 show that TNF in complex with Ab 
301 did persist longer in the peritoneal cavity of CBNH mice compared to mice 
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injected with TNF alone, therefore supporting this notion. It is most likely that the 
underlying mechanisms of antibody enhancement are multi-faceted. Another putative 
mechanism which might be related to antibody-induced conformational changes is the 
Mab 32 mediated enhancement of TNF binding to cells in vitro. This will be discussed 
in more detail later. 
A concept that is gaining more acceptance is that different regions of the TNF 
molecule are responsible for its various biological activities. The TNF epitopes to 
which Mab 32 bind have been described (Rathjen & Aston, in press), and it could be 
that the antibody is selectively inhibiting certain TNF functions by blocking the regions 
responsible for those activities. The evidence discussed earlier (Rathjen et al. , 1992) 
certainly supports this concept. Some very recent work (Van Ostade et al. , 1993) has 
shown that mutant forms of the TNF molecule have altered or restricted biological 
activities. Through this approach, ie. , altering particular regions of TNF, it was found 
that it was possible to stop the binding of TNF to one class of receptor (ie, TNF-R75 ; 
this is discussed in more detail later), and thereby influence the biological activity. It 
was found that one mutant retained its antitumour activity in Nude mice, and like the 
Rathjen et al., (1992) studies concluded that such approaches to TNF therapy could be 
of great use as the desirable (eg, antitumour) effects could be retained while the 
undesirable side-effects are lost. 
9.1.1. Response of Herpes Simplex Virus type 1 (HSV-1) growth in vivo to TNF 
treatment with and without Ab 301. 
The response of HSV-1 in CBNH mice to the TNF therapies, with or without 
Ab 301 , contrasted dramatically with that found for vaccinia virus infec tion. TNF 
treatments alone induced significant reductions in virus growth both in the ovaries and 
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the adrenal glands. Of foremost interest, however, were the observations that at TNF 
doses of 1.0, 2.0 or 6.0 µg there was no enhancement of anti-HSY-1 effects by Ab 301 
in vivo. Both of these findings are in stark opposition to what was found with vaccinia 
virus infection in CBA/H mice. To see any enhancement of TNF' s antiviral activity 
against HSY-1 the TNF dose had to be reduced to a level which alone had no effect on 
HSY-1 growth (this enhancement was not statistically significant). There is evidence 
that vaccinia is intrinsically resistant to TNF and IFN y. For example a study has 
shown that while the translation of HSY proteins was blocked by the combined action 
of TNF with low doses of IFN y, vaccinia virus translation continues unaffected in cells 
treated with both of these compounds (Feduchi et al., 1989). These results suggest that 
in vivo TNF' s antiviral capability cannot be augmented further if the virus, for example 
HSY-1, is already very sensitive to this antiviral cytokine. The fact that Mab 32 and 
Ab 301 do augment the in vivo antiviral effects of TNF against a normally TNF/IFN 
resistant virus such as vaccinia virus raises the possibility that TNF/ Ab 301 or Mab 32 
complexes induce additional antiviral mechanism(s). This could be, by virtue of the 
ability of Ab 301/Mab 32 to stabilise TNF in vivo, that there is interference with an 
event which occurs after translation. The fact that HSY is vulnerable to very early 
TNF/IFN mediated antiviral effects (ie, inhibition of HSY protein translation; Feduchi 
et al., 1989) may make redundant the presence of an enhancing antibody with TNF as 
secondary non-specific and early TNF-induced effects would not be required. In 
addition, the dichotomy in the response of vaccinia virus and HSY-1 to in vivo TNF 
therapy with or without enhancing antibodies is underpinned by interesting in vitro 
findings concerning possible direct antiviral effector mechanisms. This will be 
discussed in greater detail later (section 9.5). 
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9.2 Host immunity to Vaccinia virus and HSV-1 infection. 
For both vaccinia virus and HSV-1 the mouse strains BALB/c and C57 /B6 were 
tested for their response to various TNF therapies. It has previously been shown that 
resistance to herpes simplex virus infection in inbred mouse strains is variable and 
genetically controlled. For example, BALB/c mice have been shown to be very 
susceptible to HSV infection whereas C57 /B6 mice are resistant to infection with HSV 
(Zawatzky et al., 1981). Similar observations have been made in studies with 
ectromelia (mousepox) virus (Buller & Palumbo, 1991). It was found that C57 /B6 mice 
were better able to control the growth of vaccinia virus compared to either BALB/c or 
CBNH mice. In the present study, in regards to vaccinia virus, different responses to 
exogenous antiviral agents between these three inbred mouse strains were observed, for 
example BALB/c mice were not responsive to either TNF plus Ab 301 or mIFN-y alone 
whereas the CBA/H and C57 /B6 strains were. The variation in response to TNF and 
IFN y either alone or together between the 3 mouse strains was more pronounced for 
HSV-1 infection. This was particularly seen when BALB/c mice were compared to 
C57 /B6 mice. The BALB/c mice showed no significant decrease in viral growth in 
response to the exogenous cytokine therapies whereas dramatic reductions in HSV-1 
growth were observed in B6 mice, particularly with the TNF alone treatment. It 
therefore appears that responses to cytokines in the context of viral infection has a 
genetic basis. 
Pox virus infection elicits a range of immune responses both of a non-specific 
and specific nature. Non-specific factors like interferon have been shown to protect 
mice from ectromelia infection (Imanishi et al., 1980; Imanishi et al., 1981) and 
complement activation is thought to be involved (eg, increased phagocytosis via C3b 
receptors; Hirsch, 1982) although there has not been a direct demonstration of its role. 
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Natural killer (NK) cells have been found to be elevated in mice inoculated with 
vaccinia virus (Welsh et al., 1979; Stitz et al. , 1985) and there is evidence that mouse 
strains resistant to ectromelia have higher NK cell activity than susceptible strains 
(Jacoby et al., 1989). Recent work on a recombinant vaccinia virus expressing IL 2 has 
shown that elevated NK cell activity and corresponding increases in IFN y production 
are responsible for the attenuated growth of this virus (Karupiah et al. , 1990a; Karupiah 
et al., 1990b). NK cells are obviously important in the early response to pox virus 
infection but evidence showing the crucial role of T cells (Hirsch et al. , 1968; Blan den , 
1970; Blanden, 1971) later in infection indicates that the NK cell and other early non-
specific responses do not control the virus. Of the T cell response which occurs later 
in pox virus infection in mice ( day 6 to day 7 post infection) there is a significant 
cytotoxic (CD8+) T cell component which appears to be responsible for in vivo 
protection as increased CTL activity correlates with viral clearance (Hapel & Gardner, 
1974; Blanden & Gardner, 1976). In light of the evidence showing that CTL activity 
is largely responsible for clearance of virus )it is therefore not surprising that antibody 
is not important for the clearance of a primary pox virus infection, although specific 
antibody is apparently important in preventing reinfection (Buller & Palumbo, 199 1). 
In HSV infections ,it is generally agreed that all arms of the immune response 
are at work in the acute phase of primary infection by this virus (Wildy & Gell, 1985). 
Some early interest in immune responses to HSV focused on differences on resistant 
and susceptible mouse strains (Zawatzky et al. , 1981 ; Engler et al. , 198 1). These 
tudies showed no differences in the production of macrophage migration inhibitory 
factor and antibodies between resistant and susceptible mouse trains. A greater 
production of HSY-induced interferon (IFN) was detected in the resistant mouse train 
and this appeared to correlate with increased NK activity. Further work showed very 
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convincingly the necessity of IFN a and IFN y production as primary factors in the 
resistance of mice, particularly C57 /B6 mice, to HSV infection (Zawatzky et al., 1982; 
Stanton et al., 1987). Recent work on the role of T cells in HSV infection have 
demonstrated that in humans CD4+, MHC class II restricted T cells dominate the CTL 
response whereas in the mouse CDS+, MHC class I CTLs are predominant with CD4+ 
cells being a minor component of this response. It has been demonstrated that their 
(CD4+ cells) role in the regulation of the CTL responses may be greater than their 
numbers indicate (Kolaitis et al., 1990). This point is supported by the findings of 
Jennings et al., (1991) who showed that CD4+ T lymphocytes were important for the 
generation of the primary CDS+ CTL response to HSV in C57/B6 mice. CD4+ T 
lymphocytes were, however, not found to be of importance to the secondary CDS+ CTL 
response. 
As discussed above IFN appears to be a crucial factor in the resistance of mice 
to HSV infection. Other cytokines have also been reported as effective in controlling 
HSV growth. These cytokines include TNF (Rossol-Voth et al., 1991), IL 3 (Chan et 
al., 1990), IL la, IL 2 and M-CSF 1 (Berkowitz & Becker, 1992). The work described 
in this thesis also shows TNF to be capable of inhibiting the in vivo growth of HSV-1 . 
The evidence suggests that HSV is sensitive to a range of cytokines, the early 
endogenous action of these factors can, in some cases, significantly lower the viral load. 
This alone, however, cannot control the proliferation of the virus in a normal 
physiological sense, as evidenced by the upregulation of T cell activity later in 
infection. What could be exciting, however, is that the administration of certain 
exogenous cytokines displays potent anti-HSY capabilities in a primary infection, 
although, in the mouse model this potency appears to rely on the genetic background 
of the host. 
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Studies on the host immune response to vaccinia virus in CBA/H mice primed 
with TNF plus enhancing antibody (Ab 301) showed that the enhanced antiviral effect 
of TNF plus Ab 301 (with and without IFN y) was not sensitive to gamma-irradiation. 
Gamma irradiation neutralises proliferative immune cell responses, but not macrophage 
activity (which is of great relevance to future discussion in this chapter). In further 
studies it was discovered that NK cell and CTL responses were reduced in animals that 
had been treated with TNF plus Ab 301 before infection in comparison to animals 
treated with TNF alone. In the NK cell study this reduction in activity was even more 
pronounced if mIFN y had been co-administered with the TNF-Ab 301 complex. For 
both CTL and NK cell studies there was no difference in activities between mock (ie, 
PBS) treated and TNF alone treated mice, which supports the earlier findings that TNF 
alone has almost no effect on the response to vaccinia virus in vivo. The NK cell result 
particularly indicates that the TNF-antibody therapy is inducing or augmenting potent 
antiviral activities earlier than day 2 post infection. Results displayed in table 3.8 
support this, as vaccinia virus growth in TNF plus antibody treated mice was 
considerably lower than in control treated mice at day 1 post infection. These results 
are supported by the findings of Sambhi et al., (1991) who showed that a recombinant 
vaccinia virus encoding the gene for murine TNF a had its growth significantly 
attenuated compared to a control recombinant vaccinia virus. The attenuation of the 
growth of the VV-TNF was also noticeable as early as day 1 post infection and this 
reduction of growth was found not to be due to the enhancement of either cellular or 
antibody responses. The authors concluded that the attenuation of growth seen with 
VV-TNF must be due to the direct antiviral effect of TNF at the foci of infection. 
At day 1 post-vaccinia virus infection no outstanding differences were noted in 
the profile of the resident peritoneal cell population nor was there any evidence of 
108 
increased endogenous IFN activity in the peritoneal washings of mice which had been 
treated with TNF plus Ab 301 24 hours before infection. Also in day 1 post infection 
peritoneal washings no increase was found in reactive nitrogen intermediate (RNI) 
levels in TNF plus Ab 301 pretreated mice. This finding supports past observations on 
the effects of TNF on macrophages. Ding et al., (1988) found that resident m urine 
peritoneal macrophages could not be primed with TNF to produce RNI species upon 
PMA stimulation. TNF could however prime for the increased production of reactive 
oxygen intermediates (ROis) in this model. IFN y could prime resident macrophages 
for RNI as well as ROI production and further to this synergised with TNF to produce 
RNI levels 6 times greater than that induced by IFN y alone. These findings could be 
an attractive explanation for the earlier observations of TNF plus Ab 301 antiviral 
effects and the synergy of this complex with mIFN y to further reduce the in vivo 
growth of vaccinia. Like the Ding et al. model the cytokines were present with 
macrophages (and other peritoneal cells) for a period before stimulation with vaccinia 
virus. If both nitrogen and oxygen radicals were present, as could be envisaged with 
the co-administration of TNF plus Ab 301 and IFN y, additional reactive species such 
as peroxynitrite molecules (Beckman et al., 1990) would be induced which could 
contribute more potency to the inflammatory reaction on viral infection. The induction 
of inflammatory responses involving oxygen/nitrogen radicals is a very early and non-
specific mechanism for the restriction of pathogen growth and could be an important 
factor in explaining the early restriction of virus growth seen after TNF and/or IFN y 
treatment. A more detailed discussion on the possible antiviral action of free-radicals 
will be presented later in this chapter. 
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9.3 The influence of enhancing antibodies on TNF, TNF-receptor interactions. 
An interesting property of Mab 32 and to a lesser extent Ab 301 was their 
ability to enhance the binding of TNF to cells in vitro. The cell lines tested were L929 
(mouse) and HeLa (human). Both of these cell lines also displayed enhanced 
internalisation of TNF if Mab 32 was present. This enhanced binding and 
internalisation correlated with the enhancement of TNF antiviral effects in L929 cells, 
but not in HeLa cells. This raises the notion that while TNF receptors are ubiquitous 
and virtually all cell types tested will bind TNF (Jaattela, 1991) post-receptor binding 
effects depend on the cell type and different intracellular mechanisms. TNF signal 
transduction has been recently reviewed by Kronke et al., ( 1990). Receptor binding and 
internalisation has also been found not to be the significant correlating factor in TNF-
induced in vitro cytotoxicity (Kull et al., 1985; Yoshie et al., 1986; Tsujimoto et al. 
1985). As TNF is a pleiotropic protein it seems likely that the presence of TNF 
receptors on cell lines resistant to TNF cytotoxicity are associated with one or more of 
the other activities of TNF. 
Recent attention has re-focussed on the TNF receptor. It has been discovered 
that there are 2 immunologically distinct murine TNF receptors of approximately 55 kD 
[TNF-Rl] or 75 kD [TNF-R2] (Hohmann et al., 1989; Engelmann et al., 1990a; 
Brockhaus et al., 1990) and now there is evidence implicating each of these classes of 
receptor in different biological functions. The crux of recent investigations on the 
individual receptors was the finding that TNF-R2 will bind murine TNF with high 
affinity but does not bind human TNF at all. TNF-Rl will bind mouse and human TNF 
with equal affinity. It was therefore suggested that human TNF activity in mouse 
tissues or mouse cell lines would be mediated through TNF-Rl and mouse specific 
activities of TNF mediated via TNF-R2 (Lewis et al., 1991). A further study (Tartaglia, 
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et al., 1991) exploited this specificity of murine TNF for TNF-R2 as well as using as 
agonists polyclonal antisera highly specific for the extracellular domain of either TNF-
R l or TNF-R2. The use of these specific antibodies particularly allowed for the 
elucidation of biological activities associated with each receptor. Using this approach 
it was found that the induction of proliferation by TNF on mouse thymocytes and the 
murine cytotoxic T cell line CT-6 mapped to TNF-R2 only. TNF activities mediated 
via TNF-Rl in the cell lines tested were cytotoxicity and the induction of the protective 
enzyme manganese SOD (MnSOD). TNF has been shown previously to induce 
MnSOD in a wide range of cell lines as well as various mouse organs (Wong & 
Goedde!, 1988b). The above findings demonstrate that in the enhancement of human 
TNF antiviral effects in vitro by Mab 32 in L929 cells only TNF-R 1 is important. 
Scatchard analysis of the 1251-hTNF alone binding suggested that only one class of 
receptor was being bound in both HeLa cells and L929 cells, although in the presence 
of Mab 32 1251-hTNF binding kinetics for both cell lines were representative of the 
presence of a second low-affinity class of receptor as well. How this enhanced binding 
occurs is again open to speculation. Mechanisms discussed earlier in relation to 
enhancement of endocrine hormones by antibodies are again relevant. Whatever the 
mechanism in L929 cells there is definitely an antiviral pathway linked to TNF-Rl and 
the presence of Mab 32 with the hTNF enhances this antiviral signal. It is most likely 
that the intracellular pathway responsible for the antiviral effects is very closely related 
to the cytotoxic pathway which emanates from the same receptor. 
With the presence of antibodies in the TNF enhancement model, receptor cross-
linking may be important in the generation of an amplified antiviral signal. Work by 
Engelmann et al., ( 1990b) showed that antibodies to a soluble form of the TNF receptor 
had TNF-like activity. It was concluded from this study that TNF itself is not directly 
111 
involved in intracellular signalling, but rather it is the binding events which initiate the 
stimulation of events such as receptor clustering, which enables more productive TNF-
receptor cross-linking, and hence effective intracellular signalling. The importance of 
cross-linking events was inferred by the observations that univalent fragments of the 
TNF-receptor antibodies had no TNF-like activity and this could be restored by cross-
linking anti-immunoglobulin antibodies. At this point it is useful to note that for TNF 
to be biologically active it must exist in its trimeric form. As a trimer TNF can 
therefore bind to more than one receptor. 
9.3.1 The effect of TNF and/or IFN y pretreatment on normal and HSV-1-infected 
cell TNF receptor expression. 
Further to the above proposed mechanism of enhanced TNF binding with Mab 
32, results in chapter 6 (Fig. 6.5 a) also show that exogenous hTNF can induce 
increased expression of TNF receptors in a dose dependent manner. The presence of 
Mab 32 with TNF results in a non significant enhancement of TNF receptor expression. 
This indicates that TNF with and without Mab 32 can increase proliferation in 
fibroblasts resulting in a higher de nova production of cellular proteins such as TNF-R. 
There is evidence showing that in inflammatory responses cells may shed TNF receptors 
(Van Zee et al., 1992). It appears however that over periods of time, even in the 
presence of TNF, cells can regenerate receptors for TNF. This also suggests that 
autocrine activity by TNF in certain physiological situations might be essential to TNF 
receptor replacement. L929 cells which had been treated with TNF at various doses 
plus or minus Mab 32 and infected 24 hours later with HSV-1 were also examined for 
their TNF receptor expression. The major finding here was that in non-TNF treated 
cells HSV-1 infection itself induced a significant increase in the expression of TNF 
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receptors. This effect of HSV-1 saturated any differences due to TNF treatment alone. 
The upregulation of TNF receptor expression by HSV-1 infection is very interesting 
particularly since this virus is sensitive to TNF both in vitro and in vivo. 
Of interest also was the effect of IFN y alone and with TNF in infected and 
uninfected L929 cells. This interest stems from the early results showing an in vivo 
antiviral synergy when IFN y was co-administered with TNF plus Ab 301. There has 
been conjecture in the past that the modulation of TNF receptors by IFN y is important 
to the TNF:IFN synergy. It has been found that IFN y enhances the specific binding 
of TNF to receptors in a range of cell lines, without significantly effecting receptor 
binding affinity (Aggarwal et al., 1985; Ruggiero et al., 1986; Tsujimoto et al., 1986). 
The increased synthesis of TNF receptors has been found to be the mechanism 
associated with the IFN y induced enhancement of TNF:receptor binding (Tsujimoto & 
Vilcek, 1986). Results shown in figure 6.6a. support this finding since IFN y induced 
the expression of TNF receptors. The presence of TNF alone with IFN did not 
significantly effect this, but there were slight increases in receptor expression if the 
L929 cells were treated with IFN and 100 or 200 ng TNF plus Mab 32. On infection 
of these cells wit~ HSV-1 24 hours after cytokine treatment the profile of TNF receptor 
expression changed. The most dramatic finding was that in IFN pretreated cells HSV-1 
infection resulted in the expression of significantly fewer TNF receptors in comparison 
to both mock-infected cells treated with IFN alone and cells only infected with HSV-1. 
The presence of TNF alone with IFN showed slight TNF-R increases on HSV-1 
infection with the doses of 100 ng and 200 ng TNF being more effective with Mab 32 
and the 10 ng TNF dose not being significantly influenced by Mab 32. Vaccinia virus 
was not tested in this model as it has been found that pox viruses contain regions in 
their genome which are homologous to TNF receptor (Upton et al., 1991; Howard et 
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al., 1991). Therefore there is a possibility that the TNF receptor expression detected 
in this situation would be of viral and not cellular origin. To our knowledge HSY does 
not contain TNF receptor homologs. 
These results show that in vitro IFN y can influence the expression of TNF 
receptors both in non-infected and HSV-1 infected L929 cells. The relative importance 
of IFN y to the observed antiviral synergy with TNF plus Ab 301 is still open to 
speculation. From the results in chapter 3 (Table 3.5), however, it does appear that for 
the best antiviral effect, IFN y should be administered either before TNF plus Ab 301 
or at the same time as this complex. This effect may underlie a more significant role 
for IFN y in TNF receptor modulation in antiviral responses. It has been found 
previously that for the LPS/IFN y-induced production of antimicrobial nitric oxide by 
murine macrophages either LPS and IFN had to be administered simultaneously or 
exposure to IFN was required before LPS. If LPS was given before IFN, little response 
was seen (Lorsbach & Russell, 1992). In the area of TNF tumour cytotoxicity it is felt 
that IFN upregulation of TNF receptors is a contributing factor, although, probably not 
a major one (Tsujimoto et al., 1986). Intracellular events post receptor binding and 
internalisation are almost certainly of equal if not greater importance to the biological 
manifestations of IFN y and TNF plus antibody interactions. 
9.4 The direct in vitro enhancement of TNF antiviral effect by Mab 32 and the 
involvement of a TNF-induced cytotoxic factor. 
The antiviral effects of TNF can be directly enhanced by Mab 32 in vitro for 
both vaccinia and HSV-1. Together with the evidence showing that the in vivo anti viral 
effects of TNF plus Ab 301 occur as early as day 1 post-infection it appears that the 
TNF-induced mechanism responsible for the control of in vivo virus growth is an early-
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acting and non-specific event which occurs directly in the infected tissues. This ha 
been alluded to earlier in the discussion on the role of the host immune response to 
virus infection. Further investigation of the direct in vitro antiviral response uncovered 
an interesting and possibly important mechanism, particularly in regard to HSV-1 
infection. Cells that had been exposed to TNF and infected 24 hours later with a low, 
normally non-cytopathic dose of HSV-1 displayed significant CPE compared to those 
not treated with TNF which showed little or no CPE after infection with the same dose 
of virus. This enhanced CPE effect was most dramatic and severe if the L929 cells had 
been exposed to TNF plus Mab 32 before HSV-1 infection. This effect was definitely 
virus-induced as TNF alone and TNF plus Mab 32 treated, mock-infected controls 
showed no CPE. This enhanced CPE furthermore correlates with the reduced growth 
of HSV-1 in TNF treated cells. 
The dose of virus used would only initially infect 1 m 10 cells (MOI = 0.1), 
therefore it can be hypothesised that a factor is being produced at the foci of HSV-1 
infection which induces severe CPE in the surrounding TNF pre-exposed cells thereby 
restricting the growth of the virus. Further investigation of this phenomenon 
demonstrated that it was unlikely that_ a secreted protein factor was responsible. Also, 
enhanced degradation of cellular DNA was not important to this effect which indicates 
something about the nature of the agent involved in the enhanced CPE. At the 48 hour 
time point the DNA extracted from these cells was largely intact even though significant 
CPE could be observed in the relevant treatments. This could indicate that an external 
factor is operating in this enhanced CPE which potently damages cellular membranes 
before significant nucleic acid damage is observed. The indication therefore is that the 
physical damage to the cells is due to an agent which does not induce damage in the 
target cells via a protein-induced intracellular pathway, but acts from outside of the cell. 
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Free radical involvement in the enhanced CPE was discovered through studies 
with the antioxidant butylated hydroxyanisole (BHA). The addition of BHA after HSV-
1 infection had 2 effects in TNF plus Mab 32 pretreated cells; 1) the considerable CPE 
was reversed and 2) the growth of HSV-1 increased dramatically. In cells which were 
pretreated with PBS (ie, not exposed to TNF) and exposed to BHA a massive increase 
in HSV-1 growth was also seen but there was also CPE, which was not seen in non-
BHA, PBS-treated cells. So in regard to CPE there is an opposite effect between cells 
exposed to TNF before infection and those that were not. The growth of HSY -1 in the 
PBS treated cells exposed to BHA was approximately 1.0-1.5 logs greater than in cells 
pretreated with TNF and exposed to BHA. It may be that the CPE seen in the PBS 
treated cells is a result of the massive growth of the virus in the cells independent of 
free radical damage, or the dose of BHA used was not sufficient to scavenge all the free 
radicals produced due to this enhanced HSV-1 growth. 
It has been shown that BHA can reverse TNF cytotoxicity in L929 cells and 
WEHI-164 cells (Schulze-Osthoff et al., 1992; Brekke et al., 1992). It is important to 
note that the inclusion of BHA with TNF (ie, before infection) showed no effect on 
HSV-1 growth when compared to non-BHA treated cultures. This indicates that there 
was not significant TNF-induced, free radical mediated L929 cell killing before 
infection. This also confirms the previous comment that the factor inhibited by BHA 
is virus-induced. Also pre-exposure of L929 cells to BHA alone had no effect on HSV-
1 growth compared to non-BHA exposed controls. 
BHA, in addition to its antioxidant properties, can inhibit arachidonic acid 
pathways. To test whether arachidonic acid metabolism was important to the BHA-
induced effects, cyclooxygenase/lipoxygenase inhibitors were tested in L929 cell 
infected with HSV-1. None of the 3 inhibitors tested induced an increase in HSV-1 
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growth in vitro. The role of reactive nitrogen intermediates (RNls) was also considered. 
Through studies with a nitric oxide synthetase (NOS) inhibitor, W-ethyl-L-arginine 
acetate (NELA), it was found that RNis were not important to the in vitro growth of 
HSV-1 both in TNF-treated and non-TNF treated cells. It therefore appears most likely 
that free oxygen radicals are responsible for the BRA-induced effects. It appears from 
the experimental evidence that the role of free oxygen radicals in this model is 2 fold. 
Firstly, regardless of whether the cells had been pre-exposed to TNF or not, free oxygen 
radical production is a major component of the direct antiviral response to HSV-1. 
Neutralising free oxygen radicals results in dramatic increases of HSV-1 growth. 
Secondly, prior exposure of cells to TNF sensitises those cells to the cytopathic effects 
of free oxygen radicals and this appears to be a significant factor in the further 
restriction of HSV-1 growth by TNF. 
Although RNis were not important in the in vitro growth of HSV-1 it cannot be 
ruled out as an important effector molecule in vivo, particularly in association with 
cytokines. IFN y and TNF have been found to induce an "L-arginine-dependent 
cytotoxic effector mechanism in murine macrophages" which turned out to be nitrite 
and nitrate (Drapier et al., 1988). There have been several examples in the literature 
of IFNffNF-induced RNis being responsible for increased killing of parasites by 
macrophages (Munoz-Fernandez et al., 1992; Li et al., 1992; Nacy et al., 1991). The 
possible role of TNF, lymphotoxin and IL 1 in the induction of RNis in a malaria 
model have recently been examined also (Rockett et al., 1992). The evidence 
concerning parasite infection seems very convincing in that cytokine induction of RNis 
is an important early effector system. Specific evidence on virus infection to my 
knowledge is not yet available. There will be further discussion on this topic later in 
the chapter regarding the role(s) of down-regulatory cytokines such as TGF ~-
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9.4.1 Free oxygen radicals. 
The in vivo role of oxygen radicals in virus-infection has been considered in the 
past. Studies have highlighted the contribution of oxygen radicals to the pathogenicity 
of influenza virus infection of the mouse lung and maintained that direct free radical 
related cytotoxicity was one aspect of the overall pathology (Akaike et al., 1990; Maeda 
& Akaike, 1991). Whether oxygen radical production was also important to virus-
growth restriction was not made clear. The role of reactive oxygen intermediates (ROI) 
has recently been discussed in HIV infection (Muller, 1992) and this review raised 
another aspect of radicals and virus infection. As well as the possible impairment of 
macrophage and neutrophil ROI production by HIV, it also appears that RO Is can 
activate the intracellular transcription factor NF-KB which stimulates HIV replication. 
The full implications of such findings are as yet unknown. 
There is evidence which supports the relationship of free radical systems and 
antiviral cytokine activity. For example among the range of IFN-inducible proteins two, 
xanthine oxidase and 2,3-dioxygenase, are involved in oxygen metabolism (Samuel, 
1987). It has also been discovered that both IFNs and TNF are capable of inducing 
superoxide generation (Lappegard et al., 1988; Larrick & Wright, 1990). This 
relationship has also been investigated directly in antiviral models. Pottathil et al. 
( 1981) discovered that by inhibition of SOD activity with the copper chelating agent, 
diethyldithiocarbamate (DDC) they reduced the antiviral (VSV) effectiveness of 
exogenous IFN. This was found in a variety of mouse cell lines, including L929 cell , 
and one human cell line. In a more recent study HeLa cells were stably transfected 
with a SOD gene which resulted in CuZn SOD activities ranging from 1.6-7.3 times the 
normal level (Huang et al., 1992). These cells were treated with different 
concentrations of human IFN a and later challenged with VSV. The response to this 
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treatment varied according to the amount of SOD expressed. Cells producing up to a 
3-fold increase displayed an inverse relationship between CuZn SOD activity and 
induction of an IFN-mediated antiviral state, namely, the higher the CuZn SOD activity 
the lower the sensitivity to IFNs antiviral effect (ie, more IFN was needed to produce 
an antiviral state). Clones with SOD activity between 4.0-7.3 times higher showed a 
direct relationship between sensitivity to IFN and SOD activity (ie., the higher SOD 
activities required less IFN to induce an antiviral state). These results are in partial 
conflict with the Pottathil et al. study although it should be noted that the model system 
and cell lines used were different. Both studies taken together however do highlight 
the role of superoxide generation and SOD activity in the modulation of the IFN-
induced antiviral state. It does appear however that SOD is pivotal in determining 
whether the IFN antiviral activity is augmented or diminished. The activity of SOD 
appears not to simply neutralise free oxygen radical production by inhibiting the 
. . 
superoxide radical, but could encourage the production of more deleterious radical 
species such as the hydroxyl radical and this appears from the latest evidence of Huang 
et al. to depend in part on the degree of SOD activity present at the site of virus 
infection. 
There has been a recent examination of the role of SOD and free radical 
production in ischaemia-repetfusion injury (Mao et al., 1993). At higher concentrations 
SOD can enhance injury, and this study found that in such cases the toxicity of free 
SOD could be attributed to hydroxyl radicals resulting from an increased Fenton-type 
reaction. These findings support the argument that SOD activity can result in the 
potentiation of free radical damage. 
The contribution of free radicals and antioxidants in human disease has been 
recently reviewed (Halliwell et al., 1992) and provides insights into how free radical 
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chemistry can apply to biological systems. A point of great relevance to the above 
discussion concerns how from the superoxide radical (02-) which alone under normal 
physiological conditions is not very toxic, more toxic radical species can eventuate via 
Fenton reaction chemistry. To summarise the following equations will be used; 
2) H O ___ Catalase___ Q H Q 2 2 > 2+ 2 
OR 
3) Fe (II) + H20 2 ----> OH- + OH· + Fe (III) 
Which can be summarised by the following equation; 
As described above the product of SOD catalysis of the superoxide radical leads to 
hydrogen peroxide (1) which in the presence of the enzyme catalase is broken down 
into harmless by-products. However, in the presence of transition metals like iron, 
Fenton reactions can occur which ultimately produce toxic hydroxyl radicals which can 
have deleterious biological effects such as lipid peroxidation, nucleic acid oxidation, 
intracellular calcium fluctuation among other things. As can be seen in ( 4) superoxide 
can play a role in the generation of hydroxyl radicals which lends the more accurate 
term Superoxide-Driven Fenton reaction. Therefore, although alone this molecule may 
be harmless, in this situation it can have toxic consequences and this is largely due to 
superoxide 's ability to reduce certain ferric chelates. Of course in mammalian systems 
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iron is normally bound into proteins such as haemoglobin, transferrin and ferritin , 
thereby limiting free iron availability (Halliwell et al., 1992). However in pathological 
conditions where tissue damage occurs it might be that iron and other transition metals 
could be released at the site of injury thereby supplying the catalyst required for such 
free radical-mediated activity. 
9.5 Vaccinia virus infection behaves differently to BHA treatment compared to 
HSV-1 infection. 
It appears from the data that free radical production is not important to the direct 
in vitro restriction of vaccinia virus growth in L929 cells whether with or without TNF 
pretreatment. BRA-reversible CPE was observed in L929 cells which had been TNF 
plus Mab 32 pretreated and vaccinia virus infected but this CPE was not as intense as 
had been observed in similarly treated cells infected with HSV-1. In addition, TNF plus 
Mab 32 pretreated L929 cells did display a small increase in vaccinia virus growth after 
BHA exposure but in general there was no dramatic effect on vaccinia growth in TNF 
pretreated, BHA exposed L929 cells. This was in contrast to the massive increase of 
growth in HSV-1 infected cells after BHA exposure. In L929 cells treated with PBS 
prior to vaccinia virus infection this contrast (with what was found for HSV-1) was 
more pronounced. There was no visible CPE in PBS treated/vaccinia infected cells with 
BHA exposure and the growth of vaccinia in these cells was almost identical to that 
found for similarly treated cells not exposed to BHA after infection. (With HSV-1 
infection CPE was observed in the L929 cells with BHA treatment). These results 
indicate that in L929 cells which have not been exposed to TNF before infection, free 
radical production in infected cells is not an important mechanism in the restriction of 
vaccinia virus growth which is in bold opposition to HSV-1. To highlight this 
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difference further studies on the comparative production of SOD in HSV-1 versus 
vaccinia infected L929 cells showed greater SOD activity in HSV-1 infected cells 
especially if the cells had been TNF plus Mab 32 pretreated. The predominant form 
of SOD produced in both HSV-1 and vaccinia virus infected L929 cells was CuZn SOD 
( cytosolic SOD) which supports the earlier cited work (Pottathil et al., 1981; Huang et 
al., 1992) that showed the involvement of the same SOD species in their virus-infection 
models. Mitochondrial SOD (Manganese SOD) has been shown by Northern analysis 
to be induced in a variety of cells directly by TNF and it is speculated that this SOD 
species is important in the regulation of direct TNF cytotoxicity (Wong & Goedde!, 
1988b ). The biochemical assay system used in the present study is probably not 
sensitive enough to pick up MnSOD activity. No SOD activity was detected in PBS, 
TNF or TNF plus Mab 32 treated and mock-infected L929 cells. This difference does 
emphasise, however, the apparently unique role of CuZn SOD in virus infected cells. 
Of prime importance in the above discussed work is the apparent lack of free radical 
involvement in the inhibition of vaccinia virus infection. In comparison, HSV-1 
infection of the same cell line displayed a very strong free radical component. This 
suggests therefore that the reason(s) for this difference is not of cellular, but of viral 
origin. The ability of viruses, particularly vaccinia virus, to encode for proteins of 
immunological relevance has recently become an area of considerable interest. 
The circumventing of certain aspects host immune response by virus is not 
restricted only to free radical systems as alluded to above. Earlier (pages 113-114) the 
finding that pox viruses can encode proteins with significant homology to cellular TNF 
receptors was discussed. The authors of the work on myxoma virus (Upton et al., 
1991) concluded that this viral TNF-R homolog could be an important secreted 
"virulence factor". More recently it has been discovered that myxoma virus also 
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encodes a homolog of the IFN y receptor which as a protein can bind IFN y and inhibit 
its activity (Upton et al., 1992). It has also been recently found that vaccinia virus 
encodes a secretory glycoprotein that functions as a soluble IL 1 receptor. The authors 
of this work found that this IL 1 receptor homolog had a role in modulating the severity 
of the virus-induced disease, particularly the systemic acute phase responses (Alcami 
& Smith, 1992). An example of virus-encoded immune virulence factors has also been 
found in the herpes virus family. Epstein-Barr virus (EBY) has been found to contain 
a gene very similar to IL 10 (Moore et al., 1990). This molecule is thought to play a 
significant part in the virulence of this virus. As well as down-regulating Th 1-type 
immune function (eg, TNF and IFN y production) it also stimulates the proliferation of 
B cells which is the predominant cell type that EBY infects. It was thought that HSY-1 
could bind and penetrate vascular cells via a fibroblast growth factor (FGF) receptor; 
this was later shown to be possibly due to a HSV-1 associated FGF-like protein (Kaner 
et al., 1990; Baird et al., 1990). However, it has recently been shown by other 
investigative procedures that the FGF receptor is not required for HSY-1 infection 
(Mirda et al., 1992) therefore contradicting the earlier reports. 
Examples. of the resistance of various viruses to interferon antiviral activity exist 
and adds more credence to the ability of viruses, through a range of mechanisms, to 
avoid immune detection and/or effect. For example there have been reports of 
resistance to the IFN-induced 2-5A oligosynthetase antiviral mechanism. Studies by 
Chebath et al. (1987) showed that Chinese hamster ovary (CHO) cells transfected with 
the 40 kD form of 2-5A oligosynthetase were resistant to infection by mengovirus but 
not VSY or HSY-2. Other work showed that similarly 2-5A transfected cells were 
resistant to encephalomyocarditis virus (EMCY) infection (Rysiecki et al., 1989; Coccia 
et al., 1990). Incidentally, both mengovirus and EMCY are picornaviruses. Another 
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study has hown that the resistance of vaccinia virus to interferons may be related to 
virally-induced modifications of the 2-5A synthetase antiviral pathway, for example by 
the vaccinia-mediated inhibition of the activation of the 2-5A dependent RNase (Paez 
& Esteban, 1987). It has also been discovered that another IFN-induced antiviral 
pathway, namely the Pl/eIF-2 protein kinase pathway, can be modified by virus 
infection. Both DNA and RNA viruses are capable of this. There are various ways that 
viruses can modify this mechanism, for example, adenovirus and HIV can induce the 
production of RNA which blocks activation, whereas reoviruses and vaccinia can 
produce a protein which binds the activator RNA needed to initiate this process 
(Samuel, 1991). It therefore appears from the literature that there is overwhelming 
evidence showing that viruses can actively circumvent antiviral mechanisms. The work 
presented in this thesis provides evidence that 1n addition to the above discussed factors, 
viruses like vaccinia are capable of avoiding or neutralising free radicals in early 
antiviral responses. 
9.6 Transforming growth factor-beta (TGF P) in vaccinia virus infection. 
To study the in vivo effects of TGF p on vaccinia virus growth a recombinant 
vaccinia virus was made which encoded this protein. This approach has been used 
previously to study a range of cytokines and their effects on vaccinia virus (Ramshaw 
et al., 1992). The preliminary evidence presented in this thesis showed that TGF ~ 
does not have a significant effect on the growth of vaccinia virus in either athymic nude 
mice or thymic CBNH mice. It can therefore be concluded that TGF ~ is not a 
directly antiviral cytokine. The effect on CTL responses by TGF P in this model was 
also examined and it was found that no significant change was induced in animals 
infected with VV-TGF compared to a control virus. The comparative NK cell activities 
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between VV-TGF P and control infected mice were also found not to be significantly 
different. The NK cell result particularly is in contrast to the results of an earlier study 
using LCMV infection as a model (Su et al., 1991). It was observed initially that TGF 
p was produced at a time that co-incided with the decline of NK cell activity. Closer 
examination revealed that NK cell proliferation was very sensitive to inhibition by TGF 
p both in vitro and in vivo. In contrast to this T cell proliferation was unaffected and 
it was hence suggested that TGF P might be important to the co-ordination of NK cell 
and T cell responses during virus infection. Another study has found however that TGF 
p actually inhibits CTL activity against LCMV (Fontana et al., 1989) which again is 
in contrast to what was found with VV-TGF p. A possible problem in these studies 
could be related to the TGF p sub-type, because while the different types of TGF P 
share many biological properties, there are still differences. For example, it has been 
found that while TGF p 1 expression was high in the spleen, TGF p2 and P3 expression 
was not detected in this organ (Barnard et al., 1990). 
TGF P has been shown to be secreted in vitro as a latent molecule. This 
property is viewed as an important mechanism in the regulation of TGF P as in this 
form TGF is unable to bind its receptor which therefore results in the loss of biological 
activity (Lawrence et al., 1985; Roberts & Sporn, 1988; Barnard et al., 1990). The 
results obtained with VV-TGF p suggest that there might be a problem with the in vivo 
activation of the TGF protein after virus-induced expression. To detect vaccinia virus-
expressed TGF pin a bioassay (Fig. 8.3) heat treatment of the infected cell supematants 
was required to see consistent and full TGF bioactivity. Plasmin has been identified 
as a possible in vivo activator of TGF p (Lyons et al., 1990), but whether this protease 
is activated during a vaccinia virus infection is not known. It has been shown that TGF 
P in serum is also latent. This has been attributed to TGF forming a complex with Ui-
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macroglobulin (CXi-M) which acts as the TGF serum carrier protein and confers to TGF 
all the properties described for latent TGF P (0' Connor-McCourt & Wakefield, 1987; 
Roberts & Sporn, 1988). So as well as TGF P being secreted as a latent form, for in 
vivo studies there is also the problem of TGF complexing to CXi-M. This may not affect 
the bioactivity of TGF that had been expressed via a recombinant vaccinia virus as the 
production of such recombinant cytokines are normally focused to specific sites of 
infection. To properly study the role of TGF P in recombinant vaccinia virus infection 
the latency problems discussed above need to be overcome. Possible approaches 
include the co-expression of TGF P with plasmin, or the construction of a recombinant 
vaccinia virus containing the TGF p 1 gene which by site-directed mutagenesis has been 
manipulated so that it is expressed as the biologically active molecule (Brunner et al., 
1989). 
The past literature on TGF p shows that its antiviral activities are ambiguous. 
A report by Poli et al. (1991) showed that TGF p potently inhibited the production of 
HIV in a chronically infected promonocytic cell line, and this was not due to IFN a 
induction. The HIV suppression by TGF p was also found in primary macrophage 
cultures infected in vitro, but not in either a chronically infected T cell line or primary 
T cell blasts. Another report has appeared which demonstrated that the monocytotropic 
HIV-1 isolate (ADA) had its infection parameters enhanced by TGF p. This enhanced 
effect on HIV production occurs in cells with an established infection or in cells with 
active virus production (Lazdins et al., 1991). Further to this it was shown that TGF 
P was capable overcoming the lymphocytotropic restriction seen in many HIV isolates. 
The presence of TGF with HIV isolates that normally do not grow, due to various viral 
characteristics, in particular macrophages or T lymphocytes resulted in infection 
indicators similar to that found for HIV isolates with a tropism for monocytes (Lazdins 
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et al., 1992). Therefore, inhibition of HIV infectivity in mononuclear blood cells by 
TGF P is still controversial. 
The role of TGF P has also been studied in terms of parasite infections. In this 
context TGF P is quite often discussed along with IL 4 and IL 10 by virtue of these 3 
cytokines having the common ability to down-regulate immune responses to parasite 
infection (reviewed by Sher et al., 1992). Silva et al. (1991) showed that in spleen 
cells, from Trypanosoma cruzi-infected mice, elevated levels of biologically active TGF 
p could be detected. On further investigation it was found that TGF P also blocked the 
IFN y-induced restriction of parasite growth in mouse peritoneal macrophages and 
human macrophages. Treatment of mice with TGF p exacerbated parasitaemia and 
resultant mortality and decreased resistance to Trypanosoma cruzi in certain mouse 
strains. Similar findings were made for Leishmania, which is of considerable interest 
since the exclusive host cell for this parasite is the macrophage (Barral-Netto et al., 
1992). Schistosoma mansoni is another parasite which infects macrophages (at the 
schistosomula stage). Activation of murine peritoneal macrophages with IFN y will kill 
the schistosomula in vitro via an L-arginine dependent mechanism involving RNI 
production. The cytokines IL 4, IL l O and TGF p all inhibit this IFN-induced 
extracellular killing of schistosom ula, and this correlates with the down-regulation of 
RNI production in these activated macrophages (Oswald et al., 1992a). It has been 
found subsequently in regard to Schistosoma mansoni that the pathway responsible for 
the down-regulation of antimicrobial effect is different for IL 10 in comparison to IL 
4 and TGF p (Oswald et al., 1992b ). The above evidence concerning parasite infection 
shows very clearly the crucial role of the macrophage in the early control of infection 
and most importantly the very significant part TGF p, and other cytokines, play in 
down-regulation of macrophage antimicrobial efficacy and associated enhanced disease. 
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In light of this information, plus the earlier discussed ambiguity associated with HIV 
infection and the down-regulation of NK cell responses to LCMV, it would appear that 
TGF P is not a good candidate as an antiviral cytokine. As well as these factors it has 
recently been discovered via the development of TGF P gene-targeted mice that TGF 
P suppresses systemic inflammatory responses (Kulkarni et al., 1993 ). As concluded 
earlier, free radicals, which are important in inflammatory reactions, are potentially of 
great significance in the restriction of virus infection and TGF p may inhibit their 
production. Of additional interest is the possibility that TGF exerts subtle effects on 
other immune cell populations. For example, it has been mooted that TGF p has a 
significant role in the generation of immunological memory by possibly inducing the 
growth of committed memory cells (Swain et al., 1991). 
9.7 Future research. 
As mentioned above there may be subtle effects seen on further study of VV-
TGF p. A second recombinant TGF p virus with a co-expressed influenza 
haemagglutinin gene would prove very useful in the study of processes such as 
immunological memory and antibody isotype switching. 
With the main thrust of the work in this thesis, namely TNF in viral infection, 
of particular importance is the more comprehensive study of early TNF-induced 
antiviral events. Work presented in this thesis has provided evidence for a contribution 
by free radicals to the early restriction of virus growth. However, this work was done 
in a continuous cell line. It would hence be of great use to study the observed in vitro 
effects of free radicals with and without TNF in the context of primary ovary cell 
cultures. Further to this, ultimate interest lies with the study of free radicals in virus 
control in vivo. It is possible to treat mice with substances like BHA and/or to 
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specifically block RNI synthesis with nitric oxide synthetase inhibitors. Although RNI 
production does not seem to be important in terms of a fibroblast cell line it is certain 
to have an important role in a heterogeneous in vivo cell population which includes 
macrophages. Earlier cited literature supports this position. Through the availability 
of recombinant vaccinia virus encoding cytokines like IFN y and TNF it will also be 
possible to examine specifically the contribution of such cytokines to the induction of 
free radical systems against vaccinia virus infection in vivo. As yet the mechanisms of 
TNF and IFN direct antiviral effects in vivo, in the context of recombinant vaccinia, 
have not been fully elucidated and early free radical induction could be a major 
candidate. Regarding the other important issue of the down-regulation of immune 
responses to viruses, the availability of recombinant IL 4 and IL 10 vaccinia viruses, 
along with the recombinant TGF P vaccinia virus described in this thesis) could also 
provide unique opportunities for the examination of such cytokines in the subversion 
of early non-specific antiviral mechanisms like free radical production. 
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